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Medically unexplained symptoms
Experiencing physical symptoms is part of the human condition. In the past two 
weeks, about three out of four people have experienced a physical symptom(1). Most 
people do not visit a doctor for these symptoms. However, some people have reasons 
to present the symptom to a doctor, for example because they feel impaired or due 
to worrying about the symptom. Often, doctors do not have a clear explanation for 
these symptoms. 
Medically unexplained symptoms are symptoms for which no clear medical cause 
has been identified. In other words, no clear biomedical explanation could be given 
to the nature of the symptom. ‘Medically unexplained symptom’ is not a firm 
diagnosis, but is best considered a working hypothesis based on probabilities(2). 
Symptoms which often remain unexplained are: fatigue, headache, bowel symptoms 
and muscular pains(3). 
Medically unexplained symptoms are frequently encountered across all healthcare 
settings.  About one in five patients presenting at the general practitioner’s surgery 
has symptoms which remain medically unexplained(4, 5). Often, these symptoms 
resolve spontaneously. However, in 10-16% of primary care patients the symptoms 
persist for more than six months and result in functional impairment(4, 6). In psychiatric 
terms, these patients fulfill the DSM-IV criteria of a somatoform disorder. In a small 
proportion of patients, approximately 2.5%, medically unexplained symptoms lead to 
frequent attendance of the gP and other health care professionals(7). 
This small proportion of patients suffers from severe, persistent, and disabling 
symptoms. These patients often undergo unnecessary and potentially harmful 
medical procedures(8, 9). Their health care needs lead to considerable costs(10, 11) due 
to high consultation rates in both primary and secondary care(12). These costs, together 
with productivity losses, result in substantial societal costs(13). An intervention 
directed at this specific group of patients has the potential to have large societal and 
individual impact.
Cracks in the biomedical model
In general, doctors have great difficulty dealing with patients with persistent 
medically unexplained symptoms(14, 15). They often refer to these patients as 
‘heartsink’ patients, which has been described as: “the feelings felt in the pit of your 
stomach when their names are seen on the morning’s appointment list”(16). 
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9In the biomedical model, the diagnosis takes a central stage in the delineation of 
treatment and care. The diagnosis as the determinant of the response to patients has 
been the general line of medical education, is at the core of most evidence-based 
guidelines and protocols, and shapes the payment of physicians’ performance(17). 
In the biomedical  model health is regarded as the absence of disease. This 
elucidates why treating patients with medically unexplained symptoms is so diffi  cult 
for doctors: the symptoms do not fi t the model. Doctors seem inadequately 
equipped to deal with symptoms that have no clear biomedical cause. 
A combination of anxiety  about ‘missing something organic’, a lack of training in 
dealing with psychosocial infl uences on health and the continuing stigma 
attached to emotional problems, make it far more acceptable to focus on physical 
factors than on psychosocial factors(10, 12). Hence, physicians focus on three facets: 
the use of diagnostic tests to make sure no pathology is missed, reassurance about 
the absence of disease, and elimination of the unwanted phenomena (i.e. symptom 
treatment). Implicitly, patients are taught not to accept their physical symptom for 
which no medical cause is found. 
Often medical professionals tell patients that ‘nothing is wrong’, which is 
essentially a denial of the symptoms and not experienced as helpful by these 
patients(18). Patients with medically unexplained symptoms therefore often feel 
misunderstood by their doctors. They are searching for empathy and for an 
explanation for their symptoms(19). There is often a disparity between the ideas of 
professionals about unexplained symptoms and the concerns and beliefs of 
patients(20). This situation obviously leads to ineffi  cient management of patients with 
medically unexplained symptoms.
Medically unexplained symptoms seem to confront us with a ‘crack’ in our 
mainstream health care system. The biomedical model limits our understanding of 
illness(21). It enhances the idea that human suff ering is caused by anatomic or 
pathophysiologic abnormalities and seems to introduce a feeling that suff ering not 
caused by these abnormalities is less real(22). Biomedicine is more oriented towards 
disease management than towards caring for suff ering people. The model focuses on 
conservation of health and elimination of disease and symptoms. 
In the tradition of the biomedical health care system there is great confi dence in 
the controllability of health. This does not easily fi t the notion that health is partially 
uncontrollable and that symptoms are part of the human condition. This mismatch 
seems to add to the suff ering of patients with medically unexplained symptoms. 
Disease oriented health care, which has lead to an amazing advance in the treatment 
of many diseases, falls short in treating patients with persistent symptoms. 
1
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Expanding disease oriented care to person centered care
In an attempt to overcome the cracks of biomedicine Engel introduced the bio-
psychosocial model which regards health  as a balance between bio-, psycho- and 
social factors(23). The model implies that treatment of health care problems requires 
that the biological, psychological and social influences upon a patient’s symptoms 
and functioning are addressed. Over time, efforts have been made to apply these 
insights into the care for patients with or without medically unexplained symptoms. 
We will highlight the most important endeavors.
The concept of ‘somatic fixation’ was introduced by Dutch primary care researchers in 
1983. ‘Somatic fixation’ describes a model in which the patient’s problems are 
medicalized both by the patient and by the physician(24). It highlights the continuous 
one-sided emphasis on the somatic aspects of symptoms resulting in patients 
becoming more and more entangled in health care. However, the concept ‘somatic 
fixation’ has not been widely incorporated (25). ‘Somatic fixation’ tells doctors what 
to be cautious about, but does not provide them with clear advice how to care for 
these patients. Truly addressing the patient’s fears and needs and providing guidance 
to the patient with medically unexplained symptoms were not yet included in the 
concept of ‘somatic fixation’. 
The reattribution technique as developed by goldberg, gask and O’Dowd in 1989(26), 
seemed to be a promising technique for doctors to combine physical symptoms 
with psychosocial factors. Doctors were taught to attribute medically unexplained 
symptoms to a psychological cause. However, the technique has been dismissed as 
too simplistic for the treatment of patients with persistent medically unexplained 
symptoms(2). Reattribution was frequently experienced as offensive by the patient. 
Patients felt inadequately cared for when doctors ‘psychologised’ their physical 
symptoms(27). The reattribution technique might have failed due to the dichotomy of 
body and mind: ‘if the cause is not in the body, it must be in the mind’. The complexity 
of the human organism was not fully acknowledged. 
A next step in the care for patients with medically unexplained symptoms was paying 
deliberate attention to the ‘reason for encounter’ of the patient. With the introduction 
of the international classification system for primary care (ICPC), the reason for 
encounter became an important topic in health care(28). The reason for encounter is 
important as it reflects the personal needs and expectations of the patient. Doctors 
are encouraged to investigate why the patient has decided to come for consultation. 
Health care should respond to these specific needs. Often, this leads to discussing 
the social and emotional context of the patient. Specific interventions might come 
up, which one would not have thought of if only working with the disease oriented 
model (e.g. ‘prescribing’ to take care of a pet or to pick up painting again).
10
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In this context, both the terms ‘patient centered care’ and ‘person centered care’ are 
used (29). But person centered care more specifi cally focuses on the whole person. 
Person centered care is  based on accumulated knowledge of people, which provides 
the basis for better recognition of health problems and needs over time and 
facilitates appropriate care for these needs in the context of other needs. Therefore 
we have chosen to use the term ‘person centered care’.
yet, despite the growing international support for person centered care, professional 
performance is still mainly regulated and awarded in relation to the diagnosis, 
disregarding the broader individual and social context of diseases, even in countries 
with a long and strong primary care tradition(17). Although the biopsychosocial model 
has been proposed thirty-fi ve years ago, the persistence of a disease oriented focus 
within the care for people with medically unexplained symptoms is remarkable(21). 
Mindfulness-based cognitive therapy
We searched for an eff ective intervention for patients with persistent medically 
unexplained symptoms and aimed to follow the path of person centered care. 
Cognitive behavioural therapy (CBT) is an intervention which has been proven to be 
eff ective for patients with medically unexplained symptoms(30, 31). It addresses 
dysfunctional emotions, behaviors, and cognitions through a goal-oriented, 
systematic process. However, there were two reasons why we did not further inves-
tigate this intervention and sought for another intervention. First, CBT is not easily 
accepted by patients with medically unexplained symptoms, as the acceptability 
of referral to a psychologist is low(32). Second, in CBT the physical experience of the 
symptom is not truly addressed. CBT focuses on the consequences of the symptoms:  
thought contents are addressed and behaviour changes are suggested. We assumed 
that an intervention which would not only address thoughts and behaviour but also 
the physical experience itself, might be more acceptable and more eff ective. We 
sought for an intervention that would be both eff ective and acceptable(31).
Increasing the acceptance of experiencing symptoms might be a key process in 
improving the care of patients with medically unexplained symptoms. Patients with 
these symptoms have been characterized as patients with a high distress 
intolerance(31). They often perceive symptoms as aversive or threatening, which 
impedes truly paying attention to the body(33). If these patients could learn how to 
accept their symptoms, suff ering might decrease and adaptation might be enhanced. 
Hence, we aimed at developing an intervention that would primarily enhance the 
acceptance of persistent symptoms. An intervention that has emphasis on distress 
tolerance is Mindfulness-based cognitive therapy (MBCT).
11
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MBCT is a group training in which participants are invited to train their attention. 
It was developed for patients with recurrent depression by Segal, Williams and 
Teasdale(34, 35). MBCT combines insights from CBT with the mindfulness-based stress 
reduction program (MBSR) as developed by Jon Kabat-Zinn(36). MBCT consists of a 
course of eight weekly classes and daily home practices. The practices can be divided 
into formal practices, including the body-scan, meditation and yoga, and informal 
practices that increase mindful awareness of everyday experiences(34, 36).  MBCT has 
been called the ‘third wave’ behavioural therapy, with behavioural therapy as the first, 
and CBT as the second wave. What MBCT adds to CBT is the meta-cognitive 
dimension. It primarily addresses the relationship to one’s thoughts and not the 
contents of thoughts. It is a more experiential and less cognitive approach. getting 
to know one’s body, paying attention to physical sensations is a key feature of MBCT. 
MBCT seems to fit well into the Nijmegen tradition of searching for interventions that 
lead towards somatic ‘de-fixation’ or demedicalization.
Previous studies have demonstrated the effectiveness of MBCT for patients with 
depressive and anxiety disorders(37), fibromyalgia(38, 39), chronic pain(40, 41) and chronic 
fatigue syndrome(42). MBCT might also be effective for patients with persistent 
medically unexplained symptoms. MBCT might facilitate participants in developing 
the ability to tolerate symptoms while at the same time not letting the symptoms 
dictate behavior. We hypothesized that MBCT would be acceptable and effective for 
patients with medically unexplained symptoms.
Aim of this thesis 
The aim is to gain a deeper understanding of medically unexplained symptoms 
(MUS). In order to reach this we focus on ways of identifying patients with persistent 
medically unexplained symptoms, explore these patients’ views upon health care and 
examine the effectiveness of diagnostic tests as a way of reassuring patients. In 
addition, we aim to examine a new intervention for patients with medically 
unexplained symptoms: mindfulness-based cognitive therapy (MBCT). We want to 
achieve a deeper understanding of the feasability, effectiveness, cost-effectiveness 
and working mechanisms of mindfulness-based cognitive therapy for patients with 
persistent medically unexplained symptoms.
Inhoud 1.indd   12 13-08-2013   17:57:04
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Main research questions
1.  What is an appropriate screening instrument for the detection of patients with  
 persistent MUS?
2.  What do patients with persistent MUS expect from health care?
3.  Do diagnostic tests intrinsically reassure patients? 
4.  What is the eff ect of MBCT on patients with persistent MUS?
5.  What is the cost-eff ectiveness of MBCT for patients with persistent MUS?
6.  How does MBCT aff ect patients with persistent MUS?
Outline of the thesis
All chapters in this thesis have one main aim in common: increasing the scientifi c 
understanding of medically unexplained symptoms (MUS). 
Both the recognition and the management of patients with persistent MUS are 
experienced as diffi  cult by medical doctors. Hence, a screening questionnaire to 
detect these patients might be helpful. We examined whether the PHQ-15 is a 
suitable questionnaire for the detection of persistent MUS in a high-risk primary care 
population (Chapter 2).
While the doctors’ perspective on persistent MUS has been studied(15, 43), research on 
the patients’ views and experiences with health care is still limited. Current 
knowledge about patient perspectives on MUS originates from patients with an 
initial presentation of unexplained symptoms(8, 44). To reach a deeper understanding 
of the experiences of patients with persistent MUS we interviewed 17 patients with a 
long history of MUS (Chapter 3).
In order to reassure patients with physical symptoms that ‘nothing serious is going 
on’, doctors often use diagnostic tests. Doctors seem to expect that a negative test 
result will be reassuring in itself. We wondered if there was any scientifi c evidence for 
this assumption. To answer the question whether diagnostic tests intrinsically 
reassure patients, we performed a systematic review of randomized controlled trials 
in this fi eld (Chapter 4).
Patients with persistent MUS make intense demands on the health care system. 
Cognitive behavioural therapy (CBT) has been proven to be eff ective(30, 31), but an 
off er for psychological treatment is often declined. The self-perceived need for 
psychological or psychiatric treatment is low, and very few accept it(32). Thus, there is a 
need for acceptable and eff ective treatments for persistent MUS. Mindfulness-based 
cognitive therapy (MBCT) is a relatively new development within the fi eld of 
medicine. MBCT is a group based skills training program intended to enable 
1
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participants to become more aware of their bodily sensations, thoughts, and feelings. 
We wanted to examine the feasibility and effectiveness of MBCT compared to usual 
care in patients with persistent MUS. Hence, we performed a randomized controlled 
trial (RCT) (Chapter 5).
Cost-effectiveness studies are needed to guide investment in new interventions 
for MUS. Knowledge about the cost-effectiveness of MBCT is needed from both the 
societal and the health-care perspective. We therefore performed a cost-effectiveness 
study alongside the RCT to determine the incremental cost-effectiveness of MBCT 
compared to usual care (Chapter 6).
To reach a deeper understanding of the findings of the RCT we performed a 
longitudinal qualitative study examining how MBCT works in patients with persistent 
MUS. We used  several data sources to build a theoretical framework: longitudinal 
interviews with participants, notes from participants written at the end of the MBCT 
and observational reports of two researchers.  We present a process of change 
stimulated by MBCT (Chapter 7).  
Next, a summary of the abovementioned chapters is provided (Chapter 8).
In the general  discussion we discuss methodological and clinical considerations of 
our studies. We will consider why the effects occurred and how the interventions 
could be improved for successful implementation in clinical care (Chapter 9).
 
14
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ABSTRACT
Purpose
Recognition and management of patients with somatoform disorders is difficult. This 
study aims to determine the specificity, sensitivity and the test re-test reliability of the 
PHQ-15 for detection of somatoform disorders in a high-risk primary care population. 
Methods
We studied the performance of the PHQ-15 with the SCID-I interview as a reference 
standard. We approached patients to participate in this study from January through 
September 2006. This study was conducted in primary care settings in the 
Netherlands. Patients between 18 and 70 years old were eligible if they belonged to 
one or more of the following groups: 1) patients with unexplained somatic 
complaints 2) frequent attenders 3) patients with mental health problems. For the 
SCID-I interview we invited all patients with a PHQ-15 score ≥6 and a random sample 
of 40% of patients with a PHQ-15 score <6. The primary study outcomes were the 
sensitivity and specificity for the validity and the kappa-coefficient for the test re-test 
reliability.
Results
Of 2147 eligible patients 906 (42%) participated (mean age  48 years, 62% female). At 
a cut-off  level of 3 or more severe somatic symptoms during the past 4 weeks, 
sensitivity was 78% and specificity 71%. The test re-test reliability was 0.60. 
Conclusions
The PHQ-15 is a valid and moderately reliable questionnaire for the detection of 
patients in a primary care setting at risk for somatoform disorders.
INTRODUCTION
In primary care 20% to 50% of all patients presenting with physical symptoms can be 
categorized as having medically unexplained symptoms(1,2). Earlier research shows 
that the criteria for somatoform disorders are met in 10% to 16% of all primary care 
patients(3-5).  Usually, the medically unexplained symptoms spontaneously resolve 
or improve by effective management. Sometimes the complaints persist, leading to 
functional impairment(6).  
Somatoform disorders are a burden for both patients and family physicians (FPs). 
These patients are at risk for overtesting and unnecessary treatment(7,8). In somatizing 
patients the doctor patient relationship is often difficult and strained(9). It is a 
challenge for physicians to improve their competence in recognizing and managing 
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patients with somatoform disorders. Consequently, a screening questionnaire for 
somatoform disorders might be helpful. 
We wanted to test the instrument in the subgroup of patients for whom FPs will most 
likely use the instrument. Screening in a high-risk population for early detection of 
patients is a key concept in family medicine(10). Therefore, we have opted to screen 
in a high-risk population in the context of regular primary care: frequent attenders 
and patients who were identifi ed by their FPs as presenting either with mental health 
problems or unexplained somatic complaints. 
The PHQ-15 is the physical symptom severity scale of the Patient Health 
Questionnaire (PHQ), a self-administered diagnostic instrument. The PHQ-15 was 
developed for detection of somatoform disorders and consists of a list of 15 somatic 
symptoms(11). Those 15 symptoms constitute the majority of physical complaints in 
primary care(3). 
The test characteristics of the PHQ-15 have been studied by Kroenke et al. Increasing 
scores on the PHQ-15 are strongly associated with functional impairment, disability and 
health care use(12). Kroenke et al. measured a high internal reliability and established 
its construct validity by strong associations with functional status, disability days, and 
symptom related diffi  culty(4). Interian et al. reproduced the high internal reliability and 
established the convergence of the PHQ-15 with the CIDI, a diagnostic interview(13). 
However, data on test-retest reliability of the PHQ-15 are still lacking. 
We address two questions: Is the PHQ-15 a suitable questionnaire for the detection 
of somatoform disorders in a high-risk primary care population? And, what is the test 
re-test reliability of the PHQ-15? 
METHODS
We studied the ability of the PHQ-15 to detect somatoform disorders within a high-
risk population. We compared the performance of the PHQ-15 with our 
reference standard the SCID-I diagnosis, a diagnostic interview for DSM-IV 
diagnoses(14).  Participants completed the PHQ screening questionnaire and were 
rated as cases or non-cases.  Next, we invited all cases and a random selection of 
40% of non-cases for a SCID-I interview. 
Setting
This study was conducted in primary care settings in two regions in the Netherlands. 
We approached patients between 18 and 70 years old from January through 
September 2006 for participation. The institutional ethics review committee of both 
centers approved the study protocol. 
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Study population
We performed this study within a project that was originally designed for screening 
for depression in a primary care population. We predefined 3 groups of patients who 
had a high risk for depression: 
¤ Unexplained somatic complaints (USC): patients with somatic complaints that  
 cannot be explained by a somatic condition. These complaints had to be present  
 for at least 3 months. As it is not possible to code unexplained somatic complaints  
 as such in the International Classification of Primary Care (ICPC) classification  
 system, we asked FPs to identify these patients. Therefore, FPs checked their 
 appointment lists during four weeks preceding study allocation and selected  
 patients fulfilling the criteria: having an unexplained medical complaint for at least 
 3 months. 
¤ Frequent Attenders (FA): patients with attendance rates for primary care in the  
 highest 10%. The method as proposed by Howe(15) was used to define frequently  
 attending patients: the 10% most frequently consulting women and the 10% most  
 frequently attending men in two age groups (18-44 and 45-70 years), in the year 
 preceding study allocation. With this method, differences in gender and age  
 among frequently attending patients are accounted for. We used computerized  
 attendance data from all practice visits, home visits and telephone consultations  
 with doctors, nurses and other team members. The highest 10% was determined  
 separately for each FP because of differences in practice styles.
¤ Mental Health Problems (MHP):  patients presenting to their FP with a new mental  
 health problem up to 3 months prior to the selection date. We selected these 
 patients from electronic patient databases of the participating FPs. Three months  
 were chosen as a timeframe because of the transitory nature of most mental  
 health problems. The participating FPs are accustomed to coding all diagnoses or  
      complaints with the ICPC classification system. Patients with a psychological or  
 social reason for encounter or with a mental health diagnosis can be classified in  
 the P and Z chapters. To identify all patients with possible mental health problems,  
 the electronic patient database was searched with the codes from the P and Z  
 classes and with predefined free text-words: anxiety, worrying, sadness, stress, 
 feeling down, and insomnia. 
Procedure 
FPs received a list of selected patients. They excluded patients suffering from 
schizophrenia, psychosis, bipolar disorder, serious somatic disease, mental 
retardation or having difficulties with Dutch or English language. We also excluded 
patients with a diagnosed depression at baseline. Next, we sent all selected patients a 
letter signed by the FP describing the purpose and content of the study. We also sent 
22
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an informed consent form and the screening instrument, the Patient Health 
Questionnaire (PHQ). If patients did not respond within two weeks, a reminder was sent. 
Patients with 3 or more severe somatic symptoms on the PHQ-15 (scoring 6 or 
higher) are referred to as ‘cases’ and patients with less than 3 severe somatic 
symptoms as ‘non-cases’, which is in accordance with earlier studies(16,17). At the time 
that we decided to take this cut-off  point we had not yet decided to exclude two 
symptoms from the fi nal analysis. To assess the criterion validity of the PHQ-15 we 
invited patients for a SCID-I interview two weeks after receiving the PHQ-15. To 
determine the test re-test reliability of the PHQ-15, we sent the PHQ-15 twice: 
patients were asked to fi ll out the PHQ-15 at baseline and two weeks later, on the 
same day as the SCID-I interview. 
Measurement instruments 
Patient Health Questionnaire (PHQ-15)
The Dutch version of the PHQ  was used, a short self-report version of the Primary 
Care Evaluation of Mental Disorders (PRIME-MD)(11). The PHQ-15 is a somatic 
symptom severity scale for the purpose of diagnosing somatoform disorders. 
It inquires about 15 somatic symptoms or symptom clusters that account for more 
than 90% of the physical complaints (excluding upper respiratory tract symptoms) 
reported in the outpatient setting. Thirteen of the PHQ-15 somatic symptoms are 
included in the PHQ somatic symptom module. Subjects are asked: “During the past 
4 weeks, how much have you been bothered by any of the following problems?” 
For scoring there are three options, which are coded as 0 (“not bothered at all”), 1 
(“bothered a little”), or 2 (“bothered a lot”). A somatic symptom with the score of  2 is 
considered  severe. According to the original algorithm of the PHQ-15, in a primary 
care population, the test is considered positive when three or more severe somatic 
symptoms are present, which is indicated by a test result of 6 or higher(11). Two 
physical symptoms, feeling tired or having little energy and trouble sleeping, are also 
part of the PHQ depression module. Subjects are asked: “Over the past 2 weeks, how 
often have you been bothered by any of the following problems?” For scoring there 
are four options, which are coded as: 0 (“not at all”), 1 (“several days”), or 2 (“more 
than half the days” or “nearly every day”).
Structured Clinical Interview for DSM-IV Disorders (SCID-I)
The SCID-I is a semi-structured interview for diagnosing mental disorders on axis-I 
according to DSM-IV criteria(14). Researchers administered the SCID-I by telephone. 
They  received SCID-I training from an experienced psychiatrist. With the psychiatrist 
they had meetings every two weeks to secure the quality of the interviews. 
Agreement between diagnosis gained from telephone and live administration of the 
SCID-I is excellent(18). A structured set of questions directs the interviewer in 
determining whether the symptoms 1) cannot be fully explained by a general 
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medical condition, another mental disorder, or the effects of a substance; and 
2) cause significant impairment in social, occupational, or other functioning. 
Statistical analysis
Prevalence 
We analyzed the data with SAS 9. For the calculation of the prevalence of 
somatoform disorders in our population, we had to correct for the fact that we did 
not use all PHQ-15 negative patients, but a random sample of 40%. We corrected this 
imbalance with inverse probability weighting(19). All further calculations have been 
performed with these balanced data, except the calculation of the ROC curve, 
optimal cut-off point and test-retest reliability. 
Criterion validity 
We assessed the criterion validity of the first PHQ-15 by calculating sensitivity and 
specificity using different cut-off values. We visualized this in a receiver operating 
characteristic (ROC) curve.  We assessed the utility for everyday practice by 
calculating positive and negative predictive values, using the optimal cut-off value.
Internal consistency 
We performed a factor analysis of the PHQ-15. This analysis showed that two 
symptoms were only weakly associated with the factor: menstrual problems (ITC 
0.26) and sexual pain/problems (ITC 0.18). Kroenke et al. found similar results (20). 
Therefore, we decided to exclude these symptoms from our analysis. Thus, the total 
score of the total thirteen item ‘PHQ-15’ in our analysis ranges from 0 to 26, compared 
to the 0 to 30 range when all 15 items of the PHQ-15 are scored. 
Test-retest reliability 
For the assessment of the test re-test consistency of the PHQ-15 we calculated the 
intraclass correlation coefficient (ICC). With the paired Student T-test we calculated 
the p-value for the difference between the first and second PHQ-15 outcomes. Next, 
we dichotomized the PHQ-15 outcome into cases and non-cases and compared the 
first and the second PHQ-15 with kappa, a measure of agreement that takes into 
account the influence of chance. We measured the influence of time on the scores 
on the first PHQ-15 and the second PHQ-15 with a logistic regression analysis.
RESULTS 
Thirty five FPs participated. In total 2659 patients fulfilled the criteria for mental 
health problems (MHP n=1039), for frequently attending their FP (FA n=1745) and for 
unexplained somatic complaints (USC n=183). There was overlap among the groups. 
The mean age was 45 years and sixty percent were female (Figure 1). FPs excluded 
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345 patients from the study for the following reasons: death of the patient (7), being 
too old (13), schizophrenia or bipolar disease (43),  inability to understand the Dutch 
or English language (49), terminal illness or mental retardation (71) and serious illness 
(162). Additionally we excluded 167 patients who were already known by their FP 
with major depressive disorder.
Of the remaining 2147 patients eligible for PHQ screening, 906 (42%) patients 
returned the PHQ-15 and gave informed consent. In total 68 patients in the USC 
group, 344 in the MHP group and 586 patients in the FA group consented (Figure 2). 
Consenting patients were slightly older (mean age 48 years).
Figure 1. Patient ﬂ owchart
2.147 Patients eligible for screening
1.243 Patients declined
did not return full PHQ-15 or 
did not sign informed consent
904 Patients with informed consent
344 MPH, mean age 47 years, 67% female
586 FA, mean age 49 years, 57% female
68 USC, mean age 47 years, 82% female
602 Patients with PHQ-15≥6
262 invited for SCID-I
340 not invited for SCID-I
6 Patients SDIC-I positive
201 Patients SDIC-I negative
55 Declined or were not reached
45 Patients SDIC-I positive
174 Patients SDIC-I negative
83 Declined or were not reached
302 Patients with PHQ-15≥6
302 invited for SCID-I
FA = frequent attenders; MHP = mental health problems; PHQ-15 = 15-symptom Patient 
Health Questionnaire; SCID-I = Structured Clinical Interview for the Diagnostic and Statisti-
cal Manual of Mental Disorders-IV Axis I disorders; USC = unexplained somatic complaints.
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Prevalence
Three hundred and two 
(33%) out of 904 patients had 
three or more severe somatic 
symptoms (score of 6 or 
higher). The other 602 
patients had less than 3 
severe somatic symptoms. 
Patients with MHP had the 
lowest prevalence of a 
positive PHQ-15 with 31%, 
FA’s had a positive PHQ-15 in 
35% and USC patients had the 
highest prevalence with 63%. 
We diagnosed a somatoform 
disorder in 51 of 426 patients 
who had the SCID-I interview. 
The prevalence was lowest in 
the MHP group with 8.7%, in 
the FA group 11% and highest 
 in the USC group with 32%.  
 Those 426 patients are a 
subgroup sample of our original population with a preplanned overrepresentation of 
patients with a positive outcome on the PHQ-15. After correction for the 40% 
sample of PHQ-15 negatives, by inverse probability weighting, the prevalence of 
somatoform disorders in our study population was 8.6%.
Sensitivity and specificity
We assessed the optimal physical symptom threshold for somatoform disorders with 
an ROC curve for the non-weighted sample (Figure 3).The optimal sum of sensitivity 
and specificity of the PHQ-15 is found at 3 or more severe somatic symptoms 
(Table 1). The accuracy of the PHQ-15 is fair  with an area under the ROC curve of 0.76. 
After correction with inverse probability weighting, sensitivity of the PHQ-15 (at 
cut-off level of 3 or more severe somatic symptoms) was 78% and specificity 71%. 
This yields a LR+ of 2.70 and LR- of 0.31. The PPV shows that 21% of patients who 
have 3 or more ‘severe’ physical symptoms on the PHQ-15 (score  6) will have a 
somatoform disorder. The NPV of 97% indicates that only 3% of patients who have 
less than 3 severe physical symptoms will have a somatoform disorder. 
Figure 2. Overview of the research population
FA = frequent attenders; MHP = mental health problems; 
USC = unexplained somatic complaints.
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Table 1. Using symptom thresholds to predict somatoform disorders
Sensitivity
Specifi city
Negative predictive value
Positive predictive value
These data are calculated without inverse propability weighting
A)  Optimal sum of sensitivity and specivicity.
number of severe  somatic symptoms ≥
1 2 3 4 5 6 7
97.7 95.8 87.5 66.7 52.1 41.7 25.0
20.3 37.7 54.5 71.5 79.7 86.5 90.1
98.7 98.6 97.1 94.3 92.7 91.9 90.2
13.8 16.7 20.0 23.4 25.0 28.6 24.5
Test characterestics
Figure 3. Receiver operating characteristics curve of the PHQ-15
False-Positive Rate (1-Specifi city)
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PHQ-15 = 15-symptom Patient Health Questionnaire.
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Reliability
We assessed test-retest reliability with the data of 355 patients who completed the 
second PHQ-15 within 14 days from the first PHQ-15. This sample contains 63% of the 
patients invited for the SCID-I (n= 564) and the second PHQ-15. The remaining 37% 
did not succeed to perform the SCID and the second PHQ-15 within 2 weeks.
By counting only the ‘2’ scores indicating severe somatic symptoms, the mean score 
of the first PHQ-15 was 6.1 points (SD 5.3), of the second PHQ-15 it was 5.5 points 
(SD 5.3), which is a decrease of 0.6 points (p<0.0001). The ICC is 0.83. Next, we 
dichotomized the outcome. This means that patients with three or more severe 
somatic symptoms were considered positive and patients with less than 3 severe 
somatic symptoms were considered negative. On the dichotomized outcome the 
percentage agreement between the first and second score was 80%. The score 
changed from negative to positive in 6%, from positive to negative in 14%. The 
kappa-coefficient is 0.60. A logistic regression analysis with time as the independent 
variable revealed the following p-values:  p = 0.38 for negative PHQ-15 outcomes 
changing to positive and p = 0.79 for positive PHQ-15 outcomes changing to 
negative. So, there is no significant influence of time on the difference in results of 
the first and second PHQ-15. The internal consistency (Cronbach’s alpha) of the PHQ- 
15 is 0.80. 
DISCUSSION
The sensitivity and specificity of the PHQ-15, as measured by the concordance with 
the SCID-I diagnosis of somatoform disorders, have been established in our primary 
care population as 78% and 71%, respectively, with a low positive predictive value 
and a high negative predictive value. The test re-test reliability is moderate with a 
kappa-coefficient of 0.60(21). The prevalence of somatoform disorders differed 
significantly between the three high risk groups. The patients identified by their FPs 
as having USC had by far the highest prevalence of severe somatic symptoms. 
Diagnosis of somatoform disorders was three times more likely in this group than in 
the MHP and FA group.
Strengths and limitations
Patients who were known to have a depression at baseline were excluded from 
our PHQ-15 study. We did this for both research and clinical reasons. Patients with 
a depression often have many somatic complaints that could fit the diagnosis of a 
somatoform disorder, but those complaints are usually better accounted for by the 
diagnosis of a depression. The PHQ-15 measures symptoms, without taking into 
account if those symptoms are produced by a depression or not. In contrast, the 
SCID-I will only lead to a diagnosis of somatoform disorders if complaints are not 
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accounted for by another mental disorder. Therefore, the relatively low prevalence of 
somatoform disorders in our study population (8.6%) might be due to the fact that 
we excluded the patients with a known depression at baseline. 
The suitability of the SCID-I to diagnose somatoform disorders has been criticized. 
The ‘best estimate diagnosis’ is considered to be more accurate in this respect(22). 
The ‘best estimate diagnosis’ consists of longitudinal assessment, done by expert 
diagnosticians, using all data that are available about the patients, such as family 
informants, review of medical records, and observations of clinical staff . Although this 
standard is appealing, it is often not used due to problems when used in research 
practice. So, for practical reasons, we have chosen to use the SCID-I. 
We found a high internal consistency (α = 0.80) which is a replication of the fi ndings 
of  Kroenke et al. (α = 0.80) and Interian et al.( α = 0.79)(4,13). Interian et al. measured 
the convergent validity of the PHQ-15 with the CIDI symptom count in patients with 
moderate to severe somatization. They found a signifi cantly lower validity in the 
Hispanic population. Their results are diffi  cult to compare with ours because we used 
a diff erent validation instrument and we used it in a mainly Dutch population.
For the diagnosis of a somatoform disorder the complaints are necessarily medically 
unexplained. This requires a clinical judgment, which a questionnaire cannot provide. 
One might expect that patients with known physical disorders have many somatic 
symptoms and therefore high scores on the PHQ-15. However, in earlier research only 
a weak correlation has been found between the number of physical disorders and 
the number of somatic symptoms(4). Total symptom counts, including unexplained 
and explained, have been proven to be prognostic for somatoform disorders(20,23)
As we excluded patients with mental retardation and patients having diffi  culties with 
Dutch or English language, all included patients were well able to read and 
understand the questions. We performed our research in clinically relevant 
subgroups in family practice during routine practice. Patients who frequently attend, 
patients presenting with mental health problems and patients with unexplained 
symptoms are at risk for somatization and thus for unnecessary medical procedures 
and problematic doctor-patient relationships. With this procedure we increased the 
chance of detecting a meaningful result. Moreover, we tested the instrument in the 
subgroup of patients for whom the instrument is likely to be used by FPs. 
The response to our fi rst PHQ-15 measurement was low with 42%. Usually around 
50% of subjects respond to questionnaires. However, in our study we did not only 
ask to return the questionnaire but also asked for their participation within the whole 
project, including treatment in a trial setting. We assume that patients, especially 
patients with mental health problems, might have been less willing to return the 
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PHQ-15 because they did not want to take part in the trial. This is the first study to 
examine the test re-test validity of the PHQ-15, which is moderate. We expected time 
between tests to affect the outcome, but we could not find an influence of time on 
test re-test reliability. The decrease in PHQ-15 scores between the test and the re-test 
could be explained by both natural course of symptoms as by regression toward the 
mean. 
Implications for research and clinical practice
For recognition of somatoform disorders the PHQ-15 has proven to be a valid and 
moderately reliable instrument in our primary care study population. For 
implementation into clinical practice one should realize that we excluded patients 
with a depression. The negative predictive value of the PHQ-15 (97%) is a 
considerable advantage in family medicine where incidences are usually low. With a 
short questionnaire the diagnosis of a somatoform disorder can be excluded in the 
majority of patients. In a small group of patients further discussion of the patients 
symptoms will be necessary to draw firm conclusions. This fits well into the primary 
care process. Taken into consideration the complex nature of somatization, the 
PHQ-15 might bring us the closest we can get to objectifying patients at high risk for 
somatoform disorders. 
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Abstract
Background: The interaction between gPs and patients with persistent medically 
unexplained symptoms (MUS) is complicated. Research on the perspectives of 
patients with persistent MUS regarding the care they receive from their gP is lacking. 
Insight in patients’ experiences and expectations will guide interventions to improve 
the care for patients with persistent MUS in primary care.
Methods: A qualitative approach. 17 Interviews were conducted with patients with 
persistent MUS. Data were analyzed by an iterative process according to the 
principles of constant comparative analysis.
Results: Patients with persistent MUS in our interview study want to be taken 
seriously by their gP and fear not receiving high quality care for their symptoms. 
Feelings of not being taken seriously result in postponing consultations and 
impairment of a discussion about all aspects of the symptoms. These patients with 
persistent MUS want prompt treatment to prevent unnecessary suffering. 
Furthermore they want to be partners in the decision making process. A clear 
explanation and sufficient consultation time could help. Proactive care by the gP, for 
example by proposing follow up appointments is highly appreciated.
Conclusions: These patients ask for person centered care in which not only the 
patient as a person is taken seriously, but also the patient’s symptoms. Ongoing 
guidance within a personal continuing doctor-patient relationship and a patient 
centered orientation of care might contribute to improve the care for these patients.
36
Inhoud 1.indd   36 13-08-2013   17:57:07
37
3
Introduction
Physical symptoms such as headache, back pain, dizziness and fatigue are common 
in the general population and most people do not contact professional medical care 
for these symptoms.(1-3) In those who do present these symptoms, physicians often 
do not fi nd an organic cause (i.e. medically unexplained symptoms).(4, 5) Fortunately, 
medically unexplained symptoms (MUS) have a benefi cial course.(6) In a minority of 
patients the symptoms do not disappear, they have persistent MUS. Exactly these 
patients represent a serious problem in health care as they suff er from their 
symptoms, are functionally impaired, and are at risk for potentially harmful additional 
testing and treatment.(5, 7)
 The interaction between gPs and patients with persistent MUS is described as 
complicated. Encounters between gPs and these patients often leave both with 
frustration and confusion.(8-10) According to Epstein et al. gPs treat patients with MUS 
quite diff erently from patients with medically ‘explained’ symptoms.(11) In his study 
two unannounced covert standardized patients visited gPs with either MUS or with 
symptoms which could be explained by biomedical pathology. Physicians’ inquiry 
into and validation of symptoms in patients with MUS was less common compared to 
their approach in patients with symptoms with a clear medical explanation.
While the GP perspective on persistent MUS has been studied,(12, 13) research on 
patients’ views and experiences regarding the care they receive from their gP, is still 
limited. Knowledge in this area is necessary to improve the care for these patients. 
Current knowledge about patient perspectives on MUS originates from patients 
with an initial presentation of unexplained symptoms.(12,14-16)  Analysis of videotaped 
consultations in primary care revealed a mismatch between what patients with initial 
MUS want and what they actually receive from their gP.(14,15) Patients often feel 
stigmatized and not taken seriously,(17) they want to have a convincing, legitimating 
and empowering explanation for their symptoms,(11, 18-20) and they want emotional 
support from their gP.(21) As the majority of patients with persistent MUS is 
dissatisfi ed with the health care they receive, exploration of the experiences and  
expectations of patients with persistent MUS in primary care might contribute to 
improve the care for these patients.
Method 
Study sample
We conducted 17 semi-structured interviews with patients with persistent MUS  
who recently attended the gP. Patients were selected for our interview study on  
basis of persistent consultation of the gP with symptoms that could not be 
attributed to a clear organic cause. We selected 5 patients from practices related to 
the Radboud University Nijmegen in the neighbourhood of Nijmegen, to test the 
interview guide and to train the interview technique, and 12 patients from the  
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Continuous Morbidity Registration (CMR) project. The CMR is a project in which four 
general practices in the surroundings of Nijmegen continuously registered the  
morbidity of their approximately 13500 patients since 1971. Patients who attend  
a CMR practice are aware of the fact that their data are used for medical research.  
In the CMR project every episode of illness seen by,  or reported to, the gP is
registered as soon as it is established using an adapted version of the E-list.(22-25) 
As far as we are aware, the CMR project is the only morbidity registration system with 
a structural possibility to classify patients with persistent MUS.(26, 27) From the CMR  
database, we selected patients who were diagnosed with persistent MUS for the  
first time between 2006 and 2008. We invited patients aged  > 18 years, who were  
registered in practice for at least one year and without language barriers or 
cognitive disabilities. We excluded patients with severe psychiatric disorders 
(psychosis, PTSS, anxiety disorder, depressive disorder and drug or alcohol abuse).  
They were excluded because these patients often have MUS as a result of the   
underlying psychiatric disorder. We were interested in MUS without clear underlying 
Table 1. Patient characteristics
Age in years (mean (range))  50.4 (27 – 76)
Sex
	 •	Women	 	 	 	 15
	 •	Men		 	 	 	 	 		2
Level of education1)
	 •	Low	 	 	 	 	 		5
	 •	Middle	 	 	 	 		6
	 •	High	 	 	 	 	 		6
Situation of living
	 •	With	partner	 	 	 	 		9
	 •	With	partner	and	children	 	 		4
	 •	Single	 	 	 	 		4
 
Time on practice list
	 •	<	1	year	 	 	 	 		0
	 •	1-3	years	 	 	 	 		2
	 •	3-5	years	 	 	 	 		2
	 •	>5	years	 	 	 	 13
1) Education level was classified as low (primary and lower secondary 
education), middle (upper secondary education, until age 17-18), and high 
(pre-university, higher vocational training, and university) 
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disorder. Patients who fulfi lled the inclusion criteria and not  the exclusion criteria 
(n = 59) were sent a letter, and if necessary a reminder, in which we asked them to 
participate in an interview study regarding the quality of care received from their gP. 
A total of 31 patients responded to this letter, 12 patients volunteered to participate 
and 19  refused. Socio-demographic details (age, sex, level of education, marital 
status and time on the practice list) were obtained from the participants (Table 1). 
Patients gave informed consent to participate in this study.
Semi-structured interviews
The semi-structured interviews were conducted at the patient’s  home by one of the 
researchers (JN). These interviews were recorded, transcribed verbatim, and entered 
into Atlas.ti, a software program for the analysis of qualitative data. The interviewer 
was guided by a list of topics, based on important topics highlighted in the literature 
regarding patients’ views on MUS (Table 2). Open questions were used to encourage 
patients to communicate their views on important aspects of the care they receive 
for their persistent MUS. As the collection of data and the analysis in qualitative 
research is an iterative process, two researchers (ToH, PL) added relevant topics to 
the interview topic list after a preliminary analysis of the fi rst fi ve interviews. Ideas 
and thoughts that emerged in primary stages of the analysis were brought back to 
subsequent interviews as the study proceeded. 
Table 2. Interview guidebook
Experiences with and expectations about gP care
	 •	Discussion	of	symptoms	and	problems	
	 •	Discussion	of	own	thoughts	and	concerns	
	 •	Talking	about	feelings	and	emotions	
	 •	Talking	about	infl	uence	of	symptoms	on	daily	life
	 •	Receiving	an	explanation	for	the	symptoms
	 •	Satisfaction	with	the	explanation
	 •	Receiving	additional	diagnostic	tests
	 •	Receiving	a	diagnosis		and	prognosis	for	the	symptoms
	 •	Receiving	advice	on	handling	the	symptoms
	 •	Discussing	the	treatment	plan
	 •	Decision	making
	 •	Characterizing	the	patient-doctor	relationship
	 •	Attention	for	personal	circumstances
	 •	Feeling	understood	
	 •	Being	taken	seriously	
3
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Analysis
The interviews were analysed independently by two researchers (ToH, HvR). They 
read  the transcripts several times to familiarize themselves with the data. The two 
researchers coded the transcripts and compared and discussed these codes with 
each other. Codes in each interview were compared with those in other interviews. 
Additional codes, which emerged from discussions were also  applied to the 
transcripts. Concepts and categories emerged through this iterative process of 
coding, analysis and discussion (constant comparative qualitative analysis).(28, 29) 
The results of the analysis were discussed with a third researcher (PL). After 15 
interviews no new themes emerged and saturation was reached.(30) 
RESULTS
In the interviews with patients with persistent MUS about experiences in primary 
care we could distinguish four themes which were highly important to these 
patients: 1) being taken seriously, 2) care for symptoms, 3) symptom explanations 
and 4) consultation time. The participants gave examples of both barriers and 
positive factors which they had experienced. 
Being taken seriously
Most patients with persistent MUS who participated in our study stated being afraid 
of not being taken seriously. Often, they had had such experiences with doctor visits 
in the past. When they noticed that the gP did not take them seriously, they hesitated 
or even postponed visiting the gP. 
 I’m always reluctant to go to my GP because I don’t feel like I am taken seriously. (…)  
 It’s really humiliating and it makes you really feel sad because you have pain and you  
 can’t explain it. (P5: female, age 76) 
Furthermore, participants feared that if they had frequent consultations with their gP, 
this would have a negative influence on the gP’s attitude. 
 When you consult the GP regularly you get that feeling (…) Will he take me seriously?  
 Or will he think: there she is again? (P6: female, age 60)
Participants stated that it is of utmost importance to have the feeling of being taken 
seriously by their gP. Some participants stated that having a gP who takes them 
seriously, was reassuring in itself. These patients mentioned that the fact that they did 
not feel judged by their gP, made it easier to consult their gP and to tell their story. 
These participants stated that their gP paid attention to the whole person, not only 
to the symptoms themselves.
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 He listens. (…) he lets me tell my story fi rst (…) I can say whatever I want to say. 
 So, that’s nice. (P4: female, age 29) 
 She doesn’t only pay attention to what is going on in my body, but she also pays 
 attention to what else is going on. (P3: female, age 33)
Participants appreciated when the gP paid attention to their emotions, especially 
fears regarding the cause of the symptoms. This contributed to the feeling of being 
taken seriously. 
 Interviewer: And were you able to then discuss that fear with your GP? Patient: Yes, I  
 did do that. I said, I am scared. And he dealt with that well. He said, What are you 
 scared of? I am scared that I have some kind of cancer in my bowels. Then he examined  
 my belly and he started to talk about stress. (P6: female, age 60) 
A continuing and ongoing doctor-patient relationship also facilitates the feeling of 
being taken seriously according to the patients. 
 I have the sense that we have a connection. I feel good and safe there. I don’t feel like  
 there are certain things I would be reluctant to say. (P13: female, age 28)
Participants stated that the quality of care improved by jointly searching for 
solutions. Furthermore, they stated that such a search should be initiated by the gP. 
Patients wanted to understand why a certain solution would be preferable for them. 
However, some of the participants wanted to make their own choice based on the 
provided information and expected the gP to respect their decision. 
 We think about things together. It’s not one-way like that I have to think about things  
 on my own. Together, we come up with the best approach and determine what’s 
 possible. (P10;104-153)
Some participants mentioned that their gP did not listen to their view upon possible 
solutions for their problems. One participant mentioned how she raised the topic of 
visiting a homeopath for her problems. The gP was not open to that, so the patient 
did not feel free to discuss the topic any further.
 When I said: maybe this is something for a homeopath? He said: ‘Yeah, that’s up to  
 you. I don’t really have a lot of faith in that’. So, obviously, I’m not really encouraged to  
 explore those options. I don’t think that’s very good. (P11: female, age 52) 
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Care for symptoms
In general, the participants with persistent MUS were afraid that their symptoms 
would not be treated appropriately and that their symptoms would persist even 
longer. Participants mentioned their need for a competent gP. Someone who, from 
the first presentation, takes a close look at the symptoms to find out what is wrong 
and who gives a comprehensible explanation and good advice. 
 That it’s properly examined to determine if something is wrong or if it‘s serious or if it  
 just requires some rest. That someone just takes a look to find out what’s going on and  
 just gives you good advice. (P13: female, age 28) 
Participants expected the gP to react quickly and adequately to the symptoms 
presented during consultations. They state that they fear their symptoms will become 
chronic. One patient stressed the importance of a quick treatment of the symptoms 
to prevent unnecessary suffering. 
 My GP treated the symptoms directly, otherwise they would become chronic. 
 (P1: female, age 59) 
 She gave me something to relieve my symptoms. You don’t have to suffer to let it be  
 healed by itself. (P12: female, age 40)
If the gP planned follow-up appointments to check the course of the symptoms, this 
was highly appreciated by participants. They stated that this ongoing guidance made 
them feel supported, they felt that the gP really cared about them. Moreover, with 
follow-up appointments they were sure that their symptoms would be observed over 
a longer period of time.
 I had to come back on regular intervals – every three or four weeks or so. Not that they  
 send you out on your own to figure it out. No, it’s nice that they keep tabs on you. (P4:  
 female, age 29)
Participants mentioned that they have often experienced a lot of  resistance for 
referral. They indicated that they expect gP resistance in advance and therefore they 
even prepare themselves for this. In this regard, the importance of the opportunity to 
clarify their own ideas to the gP was stressed by the patients. When the gP 
immediately agreed with the requested referral or additional test, patients 
mentioned to be surprised. At the same time, they stated that a positive response to 
a request for referral is not always necessary, provided that the gP has a proposal for 
further inquiry.
42
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 At home, I said to my husband, I am going to demand a bowel examination. I was  
 incredibly surprised that he [the GP] was okay with that. I expected that he would say  
 that that wouldn’t be necessary. (P6: female, age 60)
According to these patients with persistent MUS referrals and additional 
investigations are part of the possibilities and solutions for their symptoms. 
Some participants stressed that referral to specialty care is necessary when the gP 
and the patient get stuck with the symptoms. 
 Sometimes, I think, send someone to the specialist earlier. All too often, it’s: we’ll try this  
 medication fi rst. If it doesn’t work, we’ll try another kind of medication. Then you can  
 keep coming back and only after a really long time do you get a referral. (P5: female,  
 age 76)
Interviewed patients did not mention any expectation about receiving information 
about the prognosis of the symptoms. None of the participants made remarks about 
discussing the duration of symptoms. In conclusion, these patients with persistent 
MUS are afraid that symptoms will not be treated appropriately. Furthermore, they 
seem to be afraid to develop a chronic condition and not receiving a referral for 
diagnostic testing.
Symptom explanation
Participants stated that they need a clear explanation of their symptoms. A clear 
explanation often reassured the patients about the severity of their symptoms and 
increased the trust in the gP. 
 Then she explains it to me in a really simple fashion. She says, this and that… and  
 that’s why your body reacts diff erently and that’s why you have those complaints. (…)  
 Now she is the fi rst that has given me that kind of clear information (P8: female, 
 age 27)
Although these patients were aware of the diffi  culties gPs have when searching for 
a diagnosis for their complaints, they pointed out that getting a diagnosis for their 
symptoms is important. According to the participants, such a diagnosis helps to 
search for a solution. 
 On the one hand, it changes absolutely nothing. On the other, it allows me to label  
 it and then I can look for a solution more eff ectively. And I think that it is also important
  for my GP. Then he can also be more focused and eff ective in  looking for a solution  
 together with me. (P3: female, age 33)
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Consultation time
Participants indicated that they had often experienced a lack of consultation time. 
This limited consultation time sometimes had a negative influence on the contact 
with the gP. Many patients considered the routine of 10 minutes consultation time 
too short with regard to their symptoms. The lack of consultation time seemed to 
influence patients’ symptom presentation. Some patients stated that their 
feeling of hurry resulted in the decision just to talk about the physical aspects of their 
symptoms and not about other aspects.
 It is actually too short if you have something which you can’t get rid of. And you have 
 to deal with it every day, every hour, then it is not so nice. I have once told him: I would 
 want you to have it for a week.  (P9: male, age 75)
 When you  notice that he is delayed (…) you won’t mention all your complaints,
  because you know, you only have 10 minutes. And then you can’t tell all you want to 
 tell. Then you will go for the pain that you have, but  nothing else.  (P5: female, age 76) 
DISCUSSION
Summary of main findings
Being taken seriously was of high importance to these patients with persistent MUS. 
gP’s attention to fears regarding the cause of the symptoms, gP’s attention to the 
whole person, a continuing doctor-patient relationship and shared decision making 
all seem to facilitate the feeling of being taken seriously. Experiences with doctor 
visits in the past promoted the patients’ fear of not been taken seriously. If these 
patients did not feel taken seriously by their gP, this impaired them to openly discuss 
what was on their mind and for some it was even a major barrier to visiting the gP. 
Patients in this study feared not receiving high quality care for their symptoms. 
They wanted prompt medical care as they fear suffering from and chronicity of the 
symptoms. Furthermore, participants indicated they want a comprehensible 
explanation for their symptoms. A lack of consultation time was experienced as a 
barrier to discuss all aspects of the symptoms. A feeling of hurry sometimes led to 
only focussing on physical aspects of their symptoms. If the gP proposed for follow 
up appointments to monitor the course of the symptoms, this was highly 
appreciated. Implicitly, these patients ask for person centred care in which not only 
the patient as a person, but also the patient’s symptoms are taken seriously. Patients 
want to be regarded as partners in decision making and hope for high quality care for 
their symptoms. Ongoing guidance by the gP, even though no physical disease can 
be diagnosed is highly appreciated.
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Comparison with existing literature 
Studies on opinions of  persistent MUS patients in primary care regarding the gP’s 
management are scarce. Studies on expectations of patients during the initial 
presentation of MUS suggest that physician attitude and medical competence are 
important at the beginning of an episode of unexplained symptoms. The patients 
with persistent MUS in our study considered these topics as highly important too.
But they also stressed receiving suffi  cient consultation time and receiving a clear 
explanation for their symptoms. In addition, in their opinion, an ongoing doctor-
patient relationship contributed to the quality of care. This is probably due to the 
fact that during the course of persistent MUS continuity of care with the gP becomes 
more and more important. 
Partly, these fi ndings are similar to reports by patients with (chronic) pain, chronic 
fatigue syndrome and irritable bowel syndrome. These studies concluded that 
patients often feel dissatisfi ed because of the attitude of the doctor, delay of or 
confusion over the diagnosis, and because of inadequate and often confl icting 
information given by their doctors.(31,32) In these studies patients indicated that 
interpersonal skills and support are more important than the ability of doctors to 
treat the disease.(31,32) In our study too, patients focused more on the relationship with 
and communication by the gP than on actual medical treatments.
The fear of not being taken seriously is related to the fear of not being regarded as a 
partner in decision making. Patients in our study felt a strong need for partnership. 
Partnership refl ects the patients’ expectations concerning their gP to listen to their 
treatment proposals and to go through a process of shared decision making. This 
process was highly valued by the patients in our study. If patients are not
considered as partners in the decision making process this adds to a feeling of 
powerlessness. Our fi ndings are supported by two qualitative studies. The fi rst, 
conducted by Churchill at al., interviewed fi fty practitioners, who were identifi ed as 
“healers” by their peers. Sharing authority appeared to be one of the eight healing 
skills. This skill is described as sharing the responsibility for healing at the very 
beginning of the consultation,  recognizing the patient as a ‘fellow expert’, with a 
particular level of expertise, and  having and showing confi dence in the relationship 
with the patient.(33) 
The second study, by Scott et al., shows results from in-depth interviews about 
healing relationships with gPs, who were selected as exemplar healers, and their 
patients.(34) One of the three key processes which emerged as fostering healing 
relationships was ‘appreciating power’. Engaging patients as partners in decisions 
about diagnosis and treatment was seen as quintessential. The other two key 
processes which were described by Scott et al. as fostering healing relationships are: 
creating a nonjudgmental emotional bond and showing commitment to caring for 
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patients over time. In our study these two aspects of care were clearly mentioned by 
the patients with persistent MUS. They wanted to be taken seriously and were afraid 
of being judged. Also, they highly appreciated it if their gP showed commitment for 
caring over time, for example by making follow-up appointments.
However, the patients interviewed by Scott et al. were not patients with persistent 
MUS, they suffered from different chronic diseases. It is striking that the perspective 
of patients with persistent MUS upon the relationship with their gP does not seem 
to differ from patients with other chronic conditions. Patients with persistent MUS 
might be highly comparable to any other patient. A subtle difference might be that 
these patients with persistent MUS show a higher level of health anxiety and less 
trust in the health care system. Furthermore, they seem to need more guidance than 
other patients. Patients with persistent MUS are patients who usually have had many 
health care contacts. Consequently, they may be regarded as experts in valuing the 
health care system. As they have often encountered significant barriers, they are 
probably well able to appoint what is truly important in health care. 
Strengths and limitations
This is the first study examining opinions of patients with persistent MUS about 
primary care. Most of the interviewed patients have known their gP for at least 5 
years, they were given the diagnosis ‘persistent MUS’ and were currently received care 
for persistent MUS from their gP. Therefore, our results reflect the opinions of the 
interviewed patients who have had recent and probably relatively many contacts 
with the health care system and their gP. These patients have built their opinions 
about gP care on a broad experience with medical services. 
Qualitative research has been recommended as the best method to explore and 
clarify patients’ opinions.(35) By using a cyclical and interactive way of collecting and 
analyzing data, we were able to perform an in depth exploration of patients’ 
opinions.(36) Transcribing the interviews verbatim, entering the full texts into Atlas.ti, 
and coding and re-organizing data by two independent researchers, strengthens our 
findings. The  number and characteristics of participants included in our study are 
considered adequate for the purpose of this qualitative study.(37) The findings 
presented here, however, reflect the perceptions of a small group of patients and may 
not represent the views of patients in general. The validity of our analysis is enhanced 
by the diversity of training and experience of the analysis team (experienced gP and 
a psychiatrist in training) and reflexivity (reflecting on our own experiences).(38)
A weakness of our study is that patients were recruited by sending them a letter and 
a reminder to ask for participation in a study regarding the quality of care they 
receive from their gP. Only 12 of the 31 patients (39%) agreed to participate. This 
might have caused response bias as patients who are satisfied with their gP are 
46
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possibly more inclined to participate in such a study. Furthermore, our sample might 
have been more homogeneous than a purposive sample of patients with persistent 
MUS. Therefore, certain specifi c viewpoints could have been left out of sight in this 
study. 
  
Implications for further research and clinical practice
Like patients presenting initial MUS to their gP, patients with persistent MUS want to 
be taken seriously, they want a clear explanation for their symptoms and they want 
emotional support. However, patients with persistent MUS also want an ongoing 
personal relationship with their gP who is proactive in the care for the symptoms.(39) 
Patients with persistent MUS want to be regarded as partners in the decision 
making process. In short, a patient-centred orientation to care is highly valued by 
these patients. It should be a key focus for gPs when dealing with patients with 
persistent MUS to build a strong relationship and to deliver proactive care.
Patients in this study showed a relatively high level of health anxiety, they had 
diffi  culty with proposals of  ‘watchful waiting’ by their gP and were afraid of 
developing a chronic condition. They expected their gP to react quickly to their 
symptoms, both for symptom reduction and for reassurance. These patients seem 
to have a relatively low level of acceptance of  symptoms, or otherwise stated: a 
high level of distress intolerance. This specifi c group of patients with persistent MUS 
might have particular diffi  culty to deal with uncertainty about symptoms. Therefore 
new interventions for patients with persistent MUS should focus on acceptance 
of symptoms. Mindfulness-based cognitive therapy (MBCT) and acceptance and 
commitment therapy (ACT) might be eff ective for increasing acceptance of bodily 
suff ering.(40, 41)
The doctor-patient relationship largely depends on the communication style of the 
gP. Further research should focus on studying and maximizing the therapeutic eff ects 
of gPs’ communication to achieve better health outcomes in patients with 
persistent MUS. As patients appreciate and seem to benefi t from a non-judgmental 
and attentive listening style, educational programs in health communication 
focussing on exploration of the reason for encounter and interventions such as 
mindful communication might be of help.(42-44) Furthermore, the eff ects of the quality 
of the gP-patient relationship on symptoms, impairment and satisfaction of patients 
should be studied to further understand how gP-patient relationships contribute to 
healing and well-being of patients with persistent MUS.
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ABSTRACT 
Objective: This review is a narrative synthesis of the RCTs which studied the efficacy 
of using diagnostic tests to reassure patients.
Methods: We searched for RCTs that examined the level of reassurance after 
diagnostic testing in outpatients. We used PubMed, Psychinfo, Cochrane Central, 
Ongoing Trials Database and Scopus. 
Results: We found 5 randomized controlled trials that included 1544 patients. The 
trials used different diagnostic tests (ECg, radiography of lumbar spine, MR brain 
scan, laboratory tests, MR of lumbar spine) for different complaints (e.g. chest pain, 
low back pain and  headache). Four out of 5 RCTs did not find a significant reassuring 
value of the diagnostic tests. One study reported a reassuring effect  at 3 months 
which had disappeared after one year. 
Conclusion: Despite the sparse and heterogeneous studies, the results point in the 
direction of diagnostic tests making hardly any contribution to the level of reas-
surance. We recommend further studies on the use of diagnostic tests and other 
strategies to reassurance the patient.
Practice implications: A clear explanation and watchful waiting can make additional 
diagnostic tests unnecessary. If diagnostic tests are used, it is important to provide 
adequate pre-test information about normal test results.
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INTRODUCTION 
According to the Oxford Dictionary of English, reassurance is ‘the action of 
removing someone’s doubts or fears’. Providing reassurance is one of the most 
important tasks of gPs(1). Patients often fear that something serious is wrong and 
expect to be reassured by their physician(2). Physicians have several strategies for 
reassuring their patients. Examples are: paying sincere attention by listening well and 
‘laying hands’ during physical examination(3). Another way of reassuring the patient is 
making use of diagnostic tests. 
The use of diagnostic tests for reassurance of the patient is considerable in family 
practice. In a Dutch cohort study in primary care (n=31000) the reasons for 
requesting diagnostic tests were recorded over a one year period. Of all requested 
diagnostic tests, reassurance of the patient was the fourth reason for ordering tests, 
in 11% of the requests it was the main reason for testing(4). This percentage might be 
lower than in other countries, regarding the fact that Dutch family practitioners are 
not paid for ordering tests. 
Despite the apparent confi dence of physicians in the reassuring value of diagnostic 
tests, the eff ects remain doubtful.  For example, in 40 replicated single case studies 
McDonald et al.(5) examined whether normal test results reduce patients’ fears. 
Patients were referred for echocardiography, in 10 cases because of symptoms and in 
30 cases because of a heart murmur. All but one had normal test results. The patients 
presenting with symptoms were all left with worries despite a normal test result. Of 
the patients with a heart murmur, 20 became anxious after the detection of the 
murmur; 11 had residual worries despite the normal test result. Thus, negative test 
results are not always eff ective in reassuring patients. 
We performed a systematic review of randomized controlled trials assessing the 
reassuring value of diagnostic tests, both in primary care and outpatient secondary 
care settings. As there is no generally accepted instrument to measure the level of 
reassurance, we accepted diff erent instrument for the measurement of reassurance. 
We included various diagnostic tests, therefore we did not expect that we would be 
able to perform a meta-analysis. Our goal was to give a narrative synthesis of the 
current evidence. The eff ect of diagnostic tests on the level of reassurance is our 
primary outcome. Furthermore, we assessed whether diagnostic testing infl uenced 
symptom and disability levels and patient satisfaction.
4
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METHODS
Selection criteria
In October 2009 we systematically searched for RCTs assessing the reassuring 
properties of diagnostic tests. Our inclusion criteria were: 1) type of study: RCT, 2) any 
diagnostic test, 3) subjects: outpatients, 4) control condition: patients not receiving 
results of a diagnostic test,  5) outcome: level of reassurance.
Search methods
We searched in PubMed, Psychinfo, Cochrane Central, Ongoing trials database and 
Scopus, which includes the Embase database.  For Pubmed, our search consisted of 
three parts, combined with the Boolean operator AND: the text word ‘reassur*’, the 
string ‘Diagnostic Techniques and Procedures’ OR ‘Laboratory Techniques and 
Procedures’ (MeSH terms) and an established search string for controlled trials(5). 
Repeating this search with other words (‘consola*’, ‘relie*’, ‘comfor*’, ‘alleviat*’) instead 
of reassur* did not reveal additional publications. We adapted the searches for the 
other databases as required. There was no language restriction.
Data collection
Three investigators (DD, PL, HvR) independently included publications from the 
list of retrieved publications by reading title and abstract. When title and abstract 
did not reveal sufficient information for inclusion, the investigators read the whole 
publication. After inclusion we checked the references for additional publications. 
Subsequently, three investigators (DD, HvR, IvD) extracted and registered the data 
on standard forms. Disagreements about in- or exclusion or data extraction were 
resolved by consulting a fourth investigator (FvdL). Inter-investigator agreement on 
in- and exclusion was calculated as kappa; we considered kappa 0.6-0.8 as good, and 
kappa 0.8-1.0 as excellent agreement(6).  Our primary outcome measure is the level of 
reassurance. Secondary outcome measures are symptom levels, disability levels and 
patient satisfaction. 
Data analysis
Outcomes are described per study. We assessed whether there was a difference in the 
level of reassurance between the test group and the control group. For the evaluation 
of the risk of bias we (HvR, PL, IvD) assessed the randomisation procedure, allocation 
concealment, the drop-out rate and blinding of the outcome assessor. Two reviewers 
assessed each trial independently. Patient and physician blinding was not a part of 
the assessment, because in this type of studies blinding is practically impossible. 
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RESULTS
The searches yielded 4602 diff erent publications to be judged for in- and exclusion. 
We included 6 journal articles that described 4 diff erent randomized controlled 
trials(7-12). The kappa for in- and exclusion was 0.80 (CI 0.77 - 0.83). One additional 
study resulted from checking references(13). In sum, we present the results of 5 RCTs 
of in total 7 articles on the reassuring eff ect of diagnostic tests (Figure 1). In Table 1 
study details are provided. The trials were published between 1981 and 2009. 
The included trials
measured the 
reassuring eff ect of fi ve 
diff erent diagnostic tests, 
or combinations of tests: 
ECg and laboratory 
blood tests for chest 
pain, radiography of the 
lumbar spine for low 
back pain, MR brain scan 
for headache, laboratory 
blood tests for 5 
specifi ed unexplained 
complaints and one trial 
studied the reassuring 
eff ects of MR for low 
back pain. Most trials 
compared the reassuring 
eff ects of a diagnostic 
test with a control group 
without diagnostic 
tests(7, 10, 12, 13). In the study by Ash et al. (11) all patients were provided with a diagnostic 
test, both patients in the intervention group and in the control group received an MR 
scan. However, the patients and physicians in the control group did not receive the 
results of the MR scan until six months after the scan. The total number of patients that 
have been studied in the included trials is 1544. Two trials have been performed in the 
United States of America(11, 13), two trials in the United Kingdom(7, 10) and one trial in the 
Netherlands(12).  Three trials use a similar defi nition of reassurance: taking away the 
concern that something serious is wrong(7, 10, 13). Ash et al. and Van Bokhoven et al. 
defi ned reassurance by the absence of anxiety. They asked for the current anxiety 
level(12) and the anxiety level concerning the current and future physical situation(11). 
Figure 1. Flowchart of study inclusion
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Table 1: Characteristics of RCTs which measure the reassuring value of diagnostic tests
Source  Type of Inclusion criteria Diagnostic Control group Setting  
Patients
 Measure for Baseline level of  Follow up level of   Direction of effects
 complaint  test group   
intervention/
 reassurance reassurance or worry reassurance or worry 
      
control (n=)
Sox et al.  Chest pain  Chief symptom is ECg and  Care as usual Outpatient 74/72 5-point scale:  67% of patients in the 20% of patients in No significant difference
1981 (13)  chest pain, with laboratory  clinic  worry that the test group and 70% of both groups worried   between groups at 2
  low risk  of having tests    pain was due to patients in the control (2 months); 16% of and 4 months (p>0.02)
  ischemic pain     serious disease group worried patients receiving tests     
         and 22% in the control     
         group worried (4 months)
Miller et al. Low back Pain for at least 6 Radiography Care as usual Primary care 195/199 5-point scale:  44% of patients in the 58% of patients in the test No significant difference
(7) pain weeks, or at ran- of lumbar  practices  reassurance that test group and 47% of group were reassured,  between groups at
  domization and   spine    there is no serious patients in the control 48% of patients in the 9 months (p=0.37)
   > 6weeks in past     condition causing group felt reassured control group were
  6 months     the pain  reassured
Howard et Headache Headache at least MRI brain Care as usual Outpatient 71/71 VAS: level of worry Mean score on VAS in Mean score on VAS 43 in Significant difference at
al. 2005 (10)  15 days a month scan  clinic  about health +  test group 60 (SD 32) both groups at one year; 3 months, patients in
  for  > 6 months     5-point scale:  and in control group 69 on 5-point scale: patients test group have less fear
        something seriously (SD 25); No information in test group less worried for something serious
       wrong causing the available about scores about serious cause at (p=0.004); no significant
       pain, (0 – 100 on 5-point scale 3 months (no exact data),  difference at one year in
       maximal worry)  no difference at 1 year 5-point scale, nor in VAS
          scores
Ash et al.  Low back Low back pain  MRI of lumbar MRI of lumbar Primary care 115/131 Fear avoidance  Mean score in test Mean score in test group  No significant differences
2008 (11) pain and/or and/or radiculo- spine spine, patient and  questionnaire(24):  group 17.0 (SD 5.8) and 13.8 (SD 6.4) and in control  between groups at 6
 radiculopathy pathy for spine  and physician secondary  4 items on beliefs in control group 17.4 group 13.4 (SD 6.3)  at 6 weeks (p=0.70), nor at
  < 3 weeks; age  blinded to care (with  about physical (SD 5.5) weeks; mean score in test 1 year (p=0.59)
  18-65 years  results until 6 outpatients)  activity, (0 - 24  group 13.3 (SD 7.0) and in
    months after   maximal avoidance)  control group 13.9 (SD 6.5) 
    scan     at one year
Bokhoven Fatigue,  Complaint Laboratory Watchful waiting Primary care  229/269 10-point scale: level No baseline measures Mean score in test group No significant difference
et al. 2009  abdominal  remained unex- blood tests (with or without practices  of anxiety, (0- 10 were taken 3.1 (SD 2.5), mean score in  between groups after the
(12) complaints,   plained after  quality improve-   maximal anxiety)  control group 3.0 (SD 2.8) consultation
 musculo- history taking   ment education)
 skeletal  and physical
 complaints,   examination; 
 weight- blood test might
 change,  add to the diag-
 or pruritus nosis; age  
  18 years or older
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Source  Type of Inclusion criteria Diagnostic Control group Setting  
Patients
 Measure for Baseline level of  Follow up level of   Direction of eff ects
 complaint  test group   
intervention/
 reassurance reassurance or worry reassurance or worry 
      
control (n=)
Sox et al.  Chest pain  Chief symptom is ECg and  Care as usual Outpatient 74/72 5-point scale:  67% of patients in the 20% of patients in No signifi cant diff erence
1981 (13)  chest pain, with laboratory  clinic  worry that the test group and 70% of both groups worried   between groups at 2
  low risk  of having tests    pain was due to patients in the control (2 months); 16% of and 4 months (p>0.02)
  ischemic pain     serious disease group worried patients receiving tests     
         and 22% in the control     
         group worried (4 months)
Miller et al. Low back Pain for at least 6 Radiography Care as usual Primary care 195/199 5-point scale:  44% of patients in the 58% of patients in the test No signifi cant diff erence
(7) pain weeks, or at ran- of lumbar  practices  reassurance that test group and 47% of group were reassured,  between groups at
  domization and   spine    there is no serious patients in the control 48% of patients in the 9 months (p=0.37)
   > 6weeks in past     condition causing group felt reassured control group were
  6 months     the pain  reassured
Howard et Headache Headache at least MRI brain Care as usual Outpatient 71/71 VAS: level of worry Mean score on VAS in Mean score on VAS 43 in Signifi cant diff erence at
al. 2005 (10)  15 days a month scan  clinic  about health +  test group 60 (SD 32) both groups at one year; 3 months, patients in
  for  > 6 months     5-point scale:  and in control group 69 on 5-point scale: patients test group have less fear
        something seriously (SD 25); No information in test group less worried for something serious
       wrong causing the available about scores about serious cause at (p=0.004); no signifi cant
       pain, (0 – 100 on 5-point scale 3 months (no exact data),  diff erence at one year in
       maximal worry)  no diff erence at 1 year 5-point scale, nor in VAS
          scores
Ash et al.  Low back Low back pain  MRI of lumbar MRI of lumbar Primary care 115/131 Fear avoidance  Mean score in test Mean score in test group  No signifi cant diff erences
2008 (11) pain and/or and/or radiculo- spine spine, patient and  questionnaire(24):  group 17.0 (SD 5.8) and 13.8 (SD 6.4) and in control  between groups at 6
 radiculopathy pathy for spine  and physician secondary  4 items on beliefs in control group 17.4 group 13.4 (SD 6.3)  at 6 weeks (p=0.70), nor at
  < 3 weeks; age  blinded to care (with  about physical (SD 5.5) weeks; mean score in test 1 year (p=0.59)
  18-65 years  results until 6 outpatients)  activity, (0 - 24  group 13.3 (SD 7.0) and in
    months after   maximal avoidance)  control group 13.9 (SD 6.5) 
    scan     at one year
Bokhoven Fatigue,  Complaint Laboratory Watchful waiting Primary care  229/269 10-point scale: level No baseline measures Mean score in test group No signifi cant diff erence
et al. 2009  abdominal  remained unex- blood tests (with or without practices  of anxiety, (0- 10 were taken 3.1 (SD 2.5), mean score in  between groups after the
(12) complaints,   plained after  quality improve-   maximal anxiety)  control group 3.0 (SD 2.8) consultation
 musculo- history taking   ment education)
 skeletal  and physical
 complaints,   examination; 
 weight- blood test might
 change,  add to the diag-
 or pruritus nosis; age  
  18 years or older
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Reassurance levels
None of the trials found a significant difference in reassurance levels between  
intervention and control group at the end of the follow up. One trial, the study by 
Howard et al., did find a significantly higher reassurance level in the intervention 
group at 3 months (p= 0.004), but not at 12 months.  Trials which measured the level 
of reassurance (or worry) both at baseline and at follow up , all show that with the 
passing time the level of worry decreases(7, 10, 11, 13). 
Quality assessment details are provided in Table 2.  Four out of five studies had 
adequate randomization and allocation concealment procedures. In the study by Sox 
et al. the procedures are not mentioned. All studies, except for the study by Van 
Bokhoven et al., have high dropout rates: between 16 and 77%. Blinding during 
outcome assessment was described in only one trial, the trial by Howard et al. 
Study  Adequate  Adequate Adequate drop out  Blinding during
 randomization  allocation handling: description outcome
  concealment of drop outs and  assessment
   dropout rate (<15%)
Sox et al. No: procedure No: not No: insufficient Not mentioned
1981 not mentioned mentioned description and drop
   out 16%
Miller et yes: computer yes: sealed No: clear description,  No: outcome
al. 2002 generated opaque but  total dropout rate assessor was not
 scheme envelope 77% (at reassurance blinded for the
   level measurement) intervention
Howard et yes: computer yes: sealed No: clear description,  yes: outcome
al. 2005 generated envelope but dropout rate 36% assessor was blind
 scheme   to intervention
Ash et al. yes: stratified yes: concealed No: insufficient Not mentioned
2008 block design envelope description and drop-
   out rate at 3 months
   28%
Bokhoven yes: computer Not applicable,  yes: clear description No: outcome et al. 
2009 generated list practices were and total dropout assessor was not 
  randomized as rate 3% blinded for the
  a whole  intervention
Table 2: Quality assessment of RCTs on the reassuring value of diagnostic tests
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Symptom levels 
Symptom levels have been measured in four trials(7, 10, 11, 13). Two trials did not fi nd 
a signifi cant diff erence in symptom levels between the intervention and control 
group(11, 13). One study shows that 3 months after randomization the percentage of 
patients that still experienced back pain was higher in the radiography group than in 
the control group, 74% versus 65%, (P=0.04). At nine months there was no signifi cant 
diff erence between intervention and control group(7). In another trial the subgroup of 
patients with high scores on anxiety and depression at baseline had signifi cantly less 
headaches after receiving an MR scan, than the patients who had not received an MR 
scan at one year follow up. Patients without anxiety and depression at baseline did 
not show a diff erence in symptom levels between intervention and control 
condition(7, 10, 11, 13). 
Disability levels
In three trials the disability levels have been measured (7, 11, 13). The study by Ash et al. 
measured self-rated disability due to back pain, no signifi cant diff erences between 
the groups were found. Another trial found a signifi cant diff erence in disability levels 
at three months follow-up; patients that were assigned to diagnostic testing, 
reported higher disability scores compared to the control group(7). However, there 
was no signifi cant diff erence at the end of follow up, at 9 months. The only study 
which found lower disability levels in the intervention group is the study by Sox et 
al. Disability was measured by asking whether the activity level was unchanged or 
less than at the index visit. At 3 weeks follow up 46% of the control group reported 
disability, whereas in the intervention group 20% of the patients reported disability 
(p<0.01). At four months follow up the diff erence had disappeared.
 
Patient satisfaction
Patient satisfaction was measured in three trials(7, 12, 13). One did not fi nd any 
diff erence between the groups(12). In the trial by Miller et al. at nine months follow 
up the patients who received a radiography were more satisfi ed with care than the 
controls (p<0.01). Sox et al. found a short term diff erence:  at 3 weeks follow up 57% 
of the patients in the intervention group were satisfi ed with care versus 31% in the 
control group (p<0.0001). At 4 months there was no diff erence between the groups. 
DISCUSSION 
Although the use of diagnostic tests to reassure patients is common(4), we identifi ed 
only fi ve randomized controlled trials which could be included in our systematic 
review. None of these trials found a signifi cant diff erence in reassurance levels 
between intervention and control group at the end of the follow up. We did fi nd an 
increase in reassurance over time, but this was irrespective of whether participants 
had the diagnostic test (intervention group) or not (control group).
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Strengths and limitations
Strengths
Our extensive and thorough search in all relevant databases without language 
restriction and the selection of studies by two independent researchers make it 
unlikely that we missed relevant studies. Moreover, we had excellent interrater 
agreement (kappa 0.80) for in- and exclusion. Finally, two independent researchers 
extracted the data and assessed the quality of included studies with a validated 
checklist. In scientific literature the concept ‘reassurance’ has not yet been clearly 
articulated, therefore we used the definition of the Oxford dictionary of English. Our 
conceptualization of ‘reassurance’ as ‘the action of removing someone’s doubts or 
fears’ was similar to the definitions which were used in the included RCTs.
Limitations
The small number of trials and the relatively low methodological quality of the 
included trials do not permit us to draw firm conclusions about the reassuring value 
of diagnostic tests. We found a high heterogeneity of instruments used to measure 
reassurance levels. Moreover, most trials used non-validated questionnaires. Due to 
the diversity among the measurement instruments, the diversity among medical 
conditions in the trials and the consequent diversity in diagnostic tests, we cannot 
make any statement about the reassuring properties of a specific diagnostic test. For 
the same reasons we could not perform a meta-analysis.
Considerations for clinical practice
There is a widely shared belief in clinical practice that patients will be reassured after 
additional testing. Physicians might heavily rely on the supposed reassuring effect of 
a normal test result, whereas patients might not share the implications of this. In this
review we could not confirm this supposed reassuring effect of diagnostic testing. On 
the contrary, the application of diagnostic testing could also increase worrying as it 
might unintentionally confirm the patient’s conviction that the symptoms are serious
(14,15). For example, in a qualitative study by Donovan and Blake (16) the investigators 
concluded that the typical methods of providing reassurance – allaying fears and 
anxieties by emphasizing the minor seriousness or early stage of a disease – are not
necessarily interpreted as reassuring by patients. For patients who previously did not 
worry about their health ordering a diagnostic test can be a cause of anxiety itself (5). 
However, we did not find an increase of worrying after diagnostic testing in our 
systematic review.
The diagnostic tests in the trials in this review have been targeted to the medical 
conditions to be studied and not to associated individual fears and worries. 
Concerning the quality and amount of information given by the physician before 
ordering thetest, Petrie et al. found out that patients who received good pre-test 
information were significantly more likely to be reassured after the test than patients 
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who did not receive this information(17). It is not diffi  cult to imagine that a good 
doctor–patient relationship increases the sense of reassurance of the patient: the
patient fi nds a good listener, a person who gives a clear explanation and who is 
committed to caring over time(18). van Bokhoven et al.(12) found that reassurance and 
patient satisfaction had a stronger association with the quality of the doctor–patient 
relationship in general, than with ordering of diagnostic tests. The reassuring value of 
diagnostic testing depends on how well the diagnostic test matches with disclosed 
worries and fears of the patient, on the information provided by the physician about 
the consequences of a positive or negative test result, and on the quality of the 
doctor-patientrelationship. Therefore, no fi rm conclusions about a reassuring value of 
diagnostic testing can be made when the individual fears, the pre-test information 
and the doctor–patient relation are not taken into account. Future research about the 
reassuring value of diagnostic testing should deal with these factors.
Conclusion
There is a lack of sound methodological studies about the reassuring value of
diagnostic tests. More trials are needed to judge the effi  cacy of specifi c diagnostic 
tests in providing reassurance. It would be wise to use validated questionnaires for 
the measurement of reassurance. There is very limited evidence for the assumption 
that diagnostic tests intrinsically reassure patients.
Practice implications
In clinical practice we advice an early exploration of the patient’s fears. By making 
them explicit, they can be discussed and an explanation about the symptom can be 
given. Watchful waiting can sometimes make diagnostic testing unnecessary. 
If diagnostic tests are used, it is important to provide adequate pre-test information 
about normal test results. Diagnostic tests are easily available and might seem to be a 
good instrument to reassure patients, but this review shows that the reassuring eff ect 
of diagnostic tests is limited.
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ABSTRACT 
Background: Patients with medically unexplained symptoms make heavy demands 
on the health care system. An offer for psychological treatment is often declined. 
There is a need for acceptable and effective treatments. We assessed the acceptability 
and effectiveness of mindfulness-based cognitive therapy (MBCT) for patients with 
persistent medically unexplained symptoms. 
Method: A randomized controlled trial comparing MBCT (n = 64) to enhanced usual 
care (EUC; n = 61). Participants were the 10% most frequently attending patients in 
primary care. The primary outcome measure was general health status at the end of 
treatment. Secondary outcome measures were mental and physical functioning.
Assessments took place at the end of treatment and at the 9-month follow-up. 
Results: Health status and physical functioning did not significantly differ between 
groups. However, participants in the MBCT group reported a significantly greater 
improvement in mental functioning at the end of treatment (adjusted mean 
difference, 3.9; 95% CI, 0.24–7.6), in particular with regard to vitality and social 
functioning. In addition, at 9 months of follow-up, the mindfulness skills ‘observing’ 
and ‘ describing’ were significantly higher in the MBCT group. Within the MBCT group, 
almost half of the outcome measures had significantly improved at the end of 
treatment, whereas in the EUC group none had.
Conclusions: MBCT was feasible for frequently attending patients with persistent 
medically unexplained symptoms in primary care. Although MBCT did not lead to a 
significant difference in general health status between the two groups, it did result in 
a significant improvement in mental functioning.
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INTRODUCTION 
Patients with medically unexplained symptoms are common. About one in fi ve 
patients presenting  at the general practitioner (gP)’s offi  ce has medically 
unexplained symptoms(1, 2). Often, these symptoms resolve spontaneously(3). 
However, in 10-16% of primary care patients the symptoms persist and result in 
functional impairment (1, 4). Uncertainty regarding the diagnosis often leads to 
unnecessary and unproductive investigations, resulting  in high health care costs(5, 
6). Thus, eff ective interventions for patients with persistent medically unexplained 
symptoms are needed.
At present, cognitive behavioural therapy (CBT) is the intervention of choice for 
persistent medically unexplained symptoms. Several studies have shown modest  
improvements of somatic symptoms, psychological distress and functional 
impairment(7-9). However, many patients with medically unexplained symptoms do 
not easily accept psychological treatment(10). Consequently, there is still a need for 
more acceptable treatment options. 
Mindfulness-based cognitive therapy (MBCT) is a relatively recent development in 
the fi eld of medicine. It consists of meditation, yoga exercises and psychoeducation(11). 
MBCT is a group based skills training program intended to enable participants to 
become more aware of their bodily sensations, thoughts, and feelings. It has a body 
focused and experiential approach, which is diff erent from the more cognitive 
approaches which are used in CBT and in the reattribution model(12). Mindfulness 
training is a promising line of research as it facilitates participants in developing the 
ability to tolerate symptoms while at the same time not letting the symptoms dictate 
behaviour(8).
MBCT might be acceptable to patients with medically unexplained symptoms 
because it is off ered as a skills training rather than as a psychological treatment. 
Positive eff ects of MBCT have been demonstrated  in patients with anxiety and mood 
disorders(13),  sleep disorders(14), fi bromyalgia(15), chronic pain(16), hypochondriasis(17) 
and chronic fatigue syndrome(18).The aim of this study was to examine the 
acceptability and eff ectiveness of MBCT in patients who frequently attend their 
general practitioner with medically unexplained symptoms. We hypothesized that 
MBCT would lead to an improvement of the general health status.
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METHOD
Design
We used a randomized controlled design comparing MBCT in addition to enhanced 
usual care (EUC), with EUC only. Inclusion was carried out by a three-step procedure. 
First, a selection was made of the 10% most frequently attending male and female 
patients of the participating gPs. Second, the gPs were asked to  exclude patients on 
the basis of the exclusion criteria for the study and we invited the remaining patients 
to participate in the trial. Third,  the researchers determined whether patients fulfilled 
the inclusion criteria in a research interview. Assessments took place at baseline, end 
of treatment and at the 9 months follow-up.
Participants
We invited gPs  in the area of Nijmegen, a medium-sized city in the Netherlands, to 
participate in the trial. Nineteen gPs agreed to participate, their practices located in 
neighbourhoods with both low and higher socio-economic  standards. Patients aged 
18-70 and belonging to the 10% most frequently attending male and female patients 
of their gP were eligible for the study. Frequent attendance was calculated over a 
period of one year. Exclusion criteria were: frequent attendance for other reasons 
than physical symptoms, physical symptoms fully explained by somatic diseases, no 
significant distress or functional impairment due to the symptoms, psychosis or 
bipolar disorder in medical history, current alcohol or drug abuse, cognitive 
impairment, problems with Dutch language, and previous MBCT. Inclusion criteria 
were: having physical symptoms for at least 6 months which were not (fully) 
explained by a physical disease or by substance abuse, and experiencing functional 
impairment due to these physical symptoms.
Procedure 
At first, we provided the gPs with a list of their 10% most frequently attending male 
and female patients, which we retrieved from the computerized database of the gP’s 
practice. To control for gender and age differences, we selected the 10% most 
frequently consulting women, and the 10% most frequently consulting men in two 
age groups (18-44 and 45-70 years)(19). Secondly, the gPs applied the exclusion 
criteria to the list of frequently attending patients. The remaining patients were sent 
an invitation letter which described the study, signed by their own gP. Thirdly, if 
interested, patients were invited by phone for a research interview. The researcher 
and trainee psychiatrist (HR) conducted the research interviews under the 
supervision of an experienced psychiatrist (AS) to assess eligibility and to gain 
informed consent. Patients were asked about the main physical complaint and 
current physical diseases. The interview included the Mini-International 
Neuropsychiatric Interview (MINI)(20) and the section on somatoform disorders of the 
Structural Clinical Interview for DSM IV axis I disorders (SCID-I)(21). All gPs were 
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informed about the assessment by a letter including the results of the psychiatric 
assessment. If patients were randomized to the EUC group, they were off ered to 
participate in the MBCT after completion of the study and requested to refrain from 
attending an MBCT course during the study period. All patients seen for the research  
interview were given a unique patient identifi cation number. After the interview, this 
number was given to the research assistant who was blinded for the interview data. 
For randomization the assistant used a computer generated permuted block 
randomization table with block size 20. The patient identifi cation number was 
matched with the corresponding name to inform each participant about the 
allocation. Assessments were done at baseline (2 weeks before start of the MBCT), at 
the end of treatment (within 3 months from baseline assessment) and 9 months after 
the end of treatment (12 months after baseline). We described the study using the 
CONSORT guidelines(22).
Mindfulness-Based Cognitive Therapy
Participants in the MBCT group received (enhanced) usual care and eight weekly 
sessions of 2.5 hours plus a 6 hours silent day. In addition to the group sessions, 
participants were instructed to practice 6 days a week for approximately 45 minutes a 
day. Our training protocol was based on the MBCT format for patients with recurrent 
depression(11). We made minor adaptations to the MBCT training protocol to make it 
more suitable for patients with physical symptoms. The program consisted of formal 
meditation exercises such as the body scan, sitting meditation, walking meditation 
and mindful movement. Participants are also encouraged to cultivate awareness 
of everyday activities, such as eating or taking a shower. In addition, the program 
includes cognitive techniques such as psychoeducation, monitoring and scheduling 
of activities, identifi cation of negative automatic thoughts and devising a relapse 
prevention plan. In the section on psychoeducation, we included information about 
respecting physical and mental boundaries and dealing with impairments. In line 
with the original Mindfulness-Based Stress Reduction format(23), we incorporated a 
silent day to give participants the opportunity to deepen their mindfulness 
practice(24). To support home practice, patients received a folder with information 
about the individual sessions, homework assignments and forms to keep a record of 
their practice, together with CDs with guided meditations and movement exercises. 
group size varied between 7 to 14 participants. The MBCT groups were instructed 
by two experienced mindfulness trainers, who both had participated in an intensive 
two-year teacher training course for mindfulness teachers and have many years of 
ongoing personal meditation practice. They have both taught more than 30 MBCT or 
MBSR courses to patients with psychiatric disorders and/or physical conditions. 
In line with previous MBCT trials, an adequate dose of MBCT for the participants (i.e. 
the treated “per protocol” cases) was defi ned as participation in at least four MBCT 
group sessions(11, 25).  
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Outcome Measures
Our primary outcome was the general health status assessed with the visual 
analogue scale (VAS) of the EuroQol 5D (EQ-5D), which ranges  from 0 (worst 
imaginable) to 100 (best imaginable)(26). Mental and physical functioning were 
measured with the summary measures (mental component summary, MCS; physical 
component summary, PCS) of the Medical Outcomes Study 36 Item Short-Form 
(SF-36). MCS and PCS scores range from 0 to 100, higher scores corresponding to 
better health status(27). We used the eight subscales of the SF-36 to measure specific 
health domains: physical functioning, role physical, bodily pain, general health, 
vitality, social functioning, role emotional and mental health(27). To assess physical and 
mental symptoms, we used the Patient Health Questionnaire (PHQ) scales for 
somatization (PHQ-15, Scale 0 to 30, higher indicating more and/or more severe 
symptoms) and depressive disorder (PHQ-9, scale 0-27, higher indicating more and 
or more severe symptoms)(28). We used the 14 item Whitely Index to assess health 
anxiety (scale 0-56, higher indicating more anxiety)(29). For the assessment of 
mindfulness skills we used the Five Facet Mindfulness Questionnaire (FFMQ), 
consisting of: observing, describing, acting with awareness, non-judging of inner 
experience and non-reactivity to inner experience (scales 8-40, non-reactivity to inner 
experience 7-35, higher scores indicating higher levels of mindfulness skills) (30). 
To assess healthcare use, we requested all patients to fill in monthly diaries 
concerning all healthcare contacts during the year of the study (e.g. gP visits, 
physiotherapy, homeopathist, cardiologist). The research interview and the MBCT 
sessions were not included in the counts of health care contacts.
Sample Size 
The power calculation is based on an estimate of the treatment effect on the general 
health status as measured with the VAS of the EQ-5D (range 0-100). We considered 
10 units on the VAS as the minimum clinically relevant difference using a standard 
deviation of 20 points. We based this on  the results of an RCT by Blankenstein with 
a similar study population as our population(31) and a cross-sectional study in cancer 
patients(32). Using an alpha of 0.05 and a power of 0.80, the sample size needed for an 
analysis of covariance, controlling for baseline measurement and assuming a 
correlation of 0.7 (R-square = 0.5), would be 64 patients in total and 32 patients per 
arm(33). We also took account of the multilevel character of the data (estimated ICC of 
0,05)(34). As a consequence, with a mean group size of 12, we needed 55% as many 
patients: 100 patients, 50 in each arm.
Statistical analysis
The analysis was performed according to the principle of intention to treat, i.e. special 
care was taken to gather follow-up data on all patients regardless of whether they 
complied to the intervention they were randomized to or not(35). A sensitivity analysis 
was performed with the multiple imputation technique to estimate missing values(36). 
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Only if patients were unable or unwilling to fi ll out the remaining questionnaires, we 
did not include these patients in the further analysis. A secondary per protocol 
analysis (PP) was done with all participants who attended four or more sessions in the 
MBCT group and all of those not attending a mindfulness course in the EUC group. 
We assessed the heterogeneity across MBCT groups on the primary outcome 
measures by calculating the intra-class correlation coeffi  cient (ICC). Post-treatment 
and follow-up scores were compared  between the two groups, controlling for 
baseline measurements. We used an analysis of covariance (ANCOVA) to compare the 
groups with respect to changes in primary and secondary outcomes at the end of 
treatment and 9 months follow-up. The ANCOVA model also included age, gender 
and level of education as covariate, as these might infl uence the eff ectiveness of 
MBCT. In addition, in each group we tested the diff erence between baseline 
measurements and the post treatment and 9 months follow-up measurements using 
paired T-tests. Eff ect sizes were calculated with the adjusted diff erences between 
the groups using Cohen’s d formula. For the analysis of predicting factors we have 
examined the eff ects of: age, gender, level of education and the presence of physical 
diseases and additional psychiatric disorders on the primary outcome measures. 
These analyses were restricted to the patients who adhered to the study protocol. 
RESULTS
gPs in the region of Nijmegen were readily willing to off er MBCT to their frequently 
attending patients with persistent medically unexplained symptoms.  Participants 
were recruited from December 2009 to August 2010. Of the 2231 frequently 
attending patients, 1546 (69%) were excluded by their gP, most often because they 
had symptoms which were fully explained by physical diseases or did not have 
physical symptoms (anymore) (Figure 1). gPs excluded signifi cantly more men 
(n=859, 77%) than women (n=692, 62%; p <0.05). Of the 685 eligible patients, 500 
(73%) were not interested in participation or did not answer the invitation letter. 
More than a quarter (n=185; 27%) of the invited patients was interested in 
participation. From the 153 patients interviewed, 18 (12%) were excluded because 
they did not meet the inclusion criteria (Figure 2). Ten patients (7%) declined to 
participate, mostly because of a lack of time. As a result, 125 patients were included 
in the trial, 94 women and 31 men. The inclusion of participants ended at the 
scheduled date of closure. About half of the participants were unemployed (Table 1). 
Education levels were evenly divided among low, middle and high. In addition to the 
persistent medically unexplained symptoms, 95 patients (81%) had at least one 
physical diseases and 34 (29%) had three or more physical diseases. The most 
frequent physical complaint was fatigue (n=31, 26%). According to the psychiatric 
interview, somatization disorder was diagnosed in 15 (13%) and pain disorder in 23 
(20%) patients. One third of the patients (n= 41, 35%) had a co-morbid anxiety 
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Excluded  by GP (n=1546)
 physical disease explained symptoms (n= 813),  no physical  
 symptoms (n=173), psychosis or bipolar disorder in medical  
 history (n=94), problems with Dutch language (n=92), no 
 impairment due to symptoms (n=60), cognitive impairment  
 (n=58), current alcohol or drug abuse (n= 53), previously 
 attended mindfulness training (n=11), other reasons (i.e. 
 deceased,  moved, frequent attendance due to mourning)   
 (n=192), no reason given by gP (n=48)
gP assessment of medical 
records of top 10% frequent 
attenders (n=2231)
Invitation letter signed by the 
gP (n=685) 
Telephone screening (n=185)
Research interview (n=153)
Declined to participate (n=32)
    lack of time (n=16),  not interested (n=5) ,  symptoms which  
 impede participation (n=2), unable to make an appointment  
 (n=6), no impairment due to symptoms (n=1), 
 no reason given (n=2)
Figure 1. GP assessment of the medical records of the 10% most frequently 
       attending patients
Enrollment
Not willing to participate (n=500)
   no response to invitation (n= 300)
   declined to participate (n= 200)
 not interested (n=93), lack of time (n=69), no physical   
 symptoms (n=13), symptoms which impede participation  
 (n=12), receiving treatment for symptoms (n=6), previously  
 attended mindfulness training (n=2), no reason given (n=5)
disorder, depressive disorder, or both. More than half of the patients (n=71, 61%) 
used three or more medicines, including both prescribed and over the counter 
medication.  In the year preceding participation in this study, the average number of 
visits to their gP was 9.8 (SD 4.8) (n=117). Female patients had an average of 10.4 
(SD 4.9) visits, males 8.1 (SD 4.0) visits, a non-significant difference. Patients who 
withdrew before baseline assessment (n=8) or were lost to follow-up (n=10) did not 
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Figure 2. Patient assessment for eligibility
Enrollment
9 Months 
Follow- up
End of 
Treatment
Adherence 
to Protocol
Allocation
Excluded (n=28)
  not meeting inclusion criteria (n=18)
 no impairment due to symptoms (n=12), 
 physical disease explained symptoms (n=5), 
 psychosis in medical history (n=1)
  declined to participate (n=10)
 lack of time (n=5), not interested (n=3), 
 practical reasons impede participation (n=1), 
 withdrew and requested removal of all data (n=1)
Received care according to protocol 
(n =55)
  Deviation from protocol (n=1)
 Received mindfulness training due to strong   
 preference (n=1)
Allocated to enhanced usual care (n=61)
Completed baseline measurement (n=56)
  Withdrawal (n=5)
 diffi  culty with questionnaires (n=2), disappointed  
 with allocation (n=2), psychological symptoms   
 (n=1)
Allocated to mindfulness training (n=64)
Completed baseline measurement (n=61)
 Withdrawal (n=3)
 diffi  culty with questionnaires (n=1), 
 physical disease (n=1), work situation (n=1)
Completed 2nd follow up measurement 
(n=50)
 Lost to second follow-up (n=3)
 diffi  culty with questionnaires (n=1), home 
    environment (n=1), physical symptoms (n=1)
Intention to Treat analysis (n=50)
Per Protocol analysis (n=49)
Completed fi rst follow up measurement 
(n=53)
  Lost to follow up (n=3)
 disappointed with allocation  (n=1), migration   
 (n=1), diffi  culty with questionnaires (n=1)  
 
Received mindfulness training according 
to protocol (n=49) 
 Dropped out from treatment (n=12)
 did not start (n=8): lack of time (n=4),  
 physical symptoms (n=3), preferred other   
 treatment (n=1) attended < 4 sessions 
 (n=4): expectations not met (n=2), physical   
 symptoms (n=1), family situation (n=1)
Completed fi rst follow up measurement 
(n=58)
  Lost to follow-up (n=3)
 diffi  culty with questionnaires (n=1), physical   
 symptoms (n=1), family situation (n=1)
Completed 2nd follow up measurement 
(n=57)
 Lost to second follow-up (n=1) 
 diffi  culty with questionnaires (n=1)
Intention to Treat analysis (n=57)
Per Protocol analysis (n=49)
Assessed for eligibility (n=153)
Randomized (n=125)
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Table 1. Sociodemographic and baseline clinical characteristics
Demographic characteristics
Female gender
Age, mean (SD) years 
Marital state
 Married
 Single/unmarried
 Divorced
 Widowed
Employed
Level of education 1)
 Low
 Middle
 High
Born in the Netherlands
Clinical characteristics
Main physical symptom
 Fatigue
 Joint problems
 Back pain
 Other musculoskeletal 
 symptom
 gastrointestinal symptom
 Neurological symptom
Impairment in daily functioning
 Moderate
 Severe
Physical diseases
 Hypertension
 Arthrosis
 Asthma/bronchitis
 Diabetes mellitus type II
Psychiatric disorders
 Somatization disorder
 Pain disorder
 Hypochondriasis
 Depressive disorder
 Anxiety disorder
1) Education level was classified as low (primary and lower secondary 
education), middle (upper secondary education) and high (higher vocational 
training and university).
MBCT
(n = 61)
n(%) 
EUC
(n = 56)
n(%) 
49 (80) 
47.6 (11)
30 (49)
20 (33)
11 (18)
0 
29 (48)
18 (30)
28 (46)
15 (25)
53 (87)
17 (28)
12 (20)
7 (12)
13 (21)
6 (10)
3 (5)
29 (48)
32 (52)
18 (30)
11 (18)
11 (18)
6 (10)
8 (13)
11 (18)
2 (3)
9 (15)
15 (25)
38 (68)
46.5 (12)
22 (39)
20 (36)
11 (20)
3 (5)
30 (54)
20 (36)
20 (36)
16 (29)
48 (86)
14 (25)
6 (11)
9 (16)
10 (18)
7 (13)
8 (14)
27 (48)
29 (52)
11 (20)
8 (14)
6 (11)
5 (9)
7 (13)
12 (21)
1 (2)
13 (23)
14 (25)
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Table 2. Eff ects of MBCT and EUC at the end of treatment and at 9-month follow up
Health status
general health status 
Physical functioning
PCS
Physical functioning
Physical role
Bodily pain
general health
Mental functioning
MCS
Vitality
Social functioning
Emotional role
Mental health 
Symptoms
Physical symptoms
Depressive symptoms
Health anxiety
Mindfulness skills
Observing
Describing
Acting with awareness
Non-judging of 
inner experience
Non-reactivity to 
inner experience
Figures are means with SD in parenthesis.
A = p<0.05 for diff erence between MBCT and EUC group (ANCOVA, function score adjusted  
 for baseline, age, gender, level of education)
B = p<0.05 for diff erence within MBCT or EUC group (Paired samples T-test)
PCS =  Physical Component Summary
MCS =  Mental Component Summary
MBCT EUC MBCT EUC MBCT EUC
(n = 61) (n = 56) (n = 58) (n = 53) (n = 57) (n = 50)
58.2 (17.4) 62.9 (14.4) 63.8 (17.1)B 64.2 (16.7) 63.5 (18.3)B 66.7 (16.9)
36.3 (9.62) 40.7 (9.60) 38.2 (11.0) 41.4 (11.5) 39.6 (12.1)B 42.7 (10.2)
65.2 (22.9) 70.3 (23.0) 68.4 (24.8) 71.3 (24.9) 69.1 (27.8) 73.4 (22.6)
27.1 (33.9) 35.7 (38.4) 36.6 (39.8)B 38.9 (37.8) 43.9 (42.9)B 56.0 (41.2)B
48.8 (18.5) 54.2 (19.5) 53.1 (18.6) 57.8 (20.5) 56.2 (23.6)B 59.3 (22.1)
46.3 (16.4) 50.0 (20.2) 50.6 (21.5) 51.0 (20.0) 51.7 (21.6)B 54.3 (19.9)
44.3 (11.5) 41.5 (11.7) 47.4 (11.6)AB 42.2 (12.3) 47.0 (12.3)B 46.3 (10.5)B
40.0 (21.3) 45.2 (21.7) 47.7 (24.3)AB 45.4 (21.6) 48.3 (25.8)B 52.5 (22.0)B
59.4 (27.7) 64.7 (21.6) 69.6 (23.7)AB 63.9 (24.5) 68.2 (28.3)B 72.5 (23.4)B
56.3 (41.5) 47.0 (42.5) 67.2 (40.2)B 52.6 (43.0) 70.2 (39.7)B 66.0 (39.5)B
66.0 (19.1) 59.7 (20.5) 67.9 (19.6) 61.2 (18.2) 66.9 (20.1) 66.6 (17.9)B
12.6 (4.68) 12.7 (5.15) 10.9 (4.90)B 12.6 (6.10) 11.0 (5.44)B 11.8 (5.46)B
8.50 (5.11) 8.77 (5.44) 7.61 (5.92) 7.87 (5.35) 7.26 (5.61) 7.66 (5.33)B
23.1 (8.61) 23.3 (10.3) 20.6 (9.16)B 21.9 (9.26) 20.6 (9.19)B 22.6 (10.1)
25.7 (6.53) 24.8 (5.08) 26.5 (5.68) 24.5 (5.22) 26.7 (5.34)A 24.4 (5.53)
27.1 (6.52) 26.8 (6.00) 26.9 (7.13) 26.9 (6.20) 28.5 (6.52)AB 26.3 (6.93)
25.6 (6.36) 24.4 (5.44) 26.1 (6.83) 25.3 (6.37) 26.3 (6.00) 25.1 (6.19)
27.8 (6.59) 26.2 (5.47) 28.8 (6.82) 27.1 (6.53) 28.8 (5.96) 27.4 (6.25)
20.3 (5.33) 20.2 (4.03) 21.7 (4.53 )B 20.5 (4.68) 21.5 (4.98)B 21.0 (4.80)
Nine month 
follow-up
Baseline End of treatment 
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Table 3. Differences between and within MBCT and EUC groups at the end of treatment and        the 9-month follow-up
Health status
general health status 
Physical functioning
(PCS)
Physical functioning
Physical role
Bodily pain
general health
Mental functioning
(MCS)
Vitality
Social functioning
Emotional role
Mental health 
Symptoms
Physical symptoms
Depressive symptoms
Health anxiety
Mindfulness skills
Observing
Describing
Acting with awareness
Non-judging of 
inner experience
Non-reactivity to 
inner experience
*p<0.05
A = ANCOVA, function score adjusted for baseline, age, gender, level of education
B = Paired samples T-test
PCS =  Physical Component Summary
MCS =  Mental Component Summary
MBCT EUC MBCT EUC 
1.53 (-4.74 to 7.79) 6.04 (1.25 to 10.8)* 1.48 (-3.78 to 6.74) 0.68 (-6.54 to 6.68) 5.84 (1.13 to 10.3)* 2.00 (-3.22 to 7.22)
0.59 (-2.39 to 3.57) 2.00 (-0.10 to 4.09) 0.75 (-1.63 to 3.13) -0.14 (-3.44 to 3.17) 3.20 (0.61 to 5.80)* 1.74 (-0.57 to 4.04)
1.89 (-4.10 to 7.88) 3.53 (-1.07 to 8.14)  1.83 (-2.52 to 6.18) -0.02 (-5.75 to 5.72) 3.86 (-0.69 to 8.41) 2.80 (-1.50 to 7.10)
4.01 (-8.70 to 16.7) 9.91 (0.87 to 19.0)* 3.37 (-8.41 to 15.1) -8.54 (-23.3 to 6.19) 16.7 (4.95 to 28.4)* 19.5 (7.21 to 31.8)*
-0.73 (-6.52 to 5.07) 4.57 (-0.01 to 9.15) 3.25 (-1.39 to 7.89) 0.08 (-7.28 to 7.43) 7.54 (1.67 to 13.4)* 5.02 (-0.76 to 10.8
3.05 (-3.48 to 9.58) 5.02 (0.33 to 9.71) 0.87 (-4.23 to 5.96) 0.01 (-5.95 to 5.96) 5.86 (1.33 to 10.4)* 3.90 (-0.19 to 7.99)
3.91 (0.24 to 7.59)* 3.66 (1.00 to 6.33)* 0.69 (-2.21 to 3.59) -0.94 (-4.66 to 2.78) 3.24 (0.27 to 6.20)* 5.28 (2.27 to 8.30)*
7.38 (1.08 to 13.7)* 8.71 (4.06 to 13.4)* 0.7 (-3.82 to 5.36) -1.15 (-8.42 to 6.12) 9.30 (3.88 to 14.72)* 8.90 (2.89 to 14.9)*
9.45 (1.37 to 17.5)* 11.4 (4.64 to 18.2)* 0.48 (-7.09 to 6.13) -0.19 (-8.64 to 8.27) 9.21 (1.94 to 16.5)* 7.50 (0.65 to 14.4)*
9.41 (-4.83 to 23.6) 11.5 (1.04 to 22.0)* 5.77 (-6.38 to 17.9) -0.25 (-13.1 to 12.6) 15.2 (5.17 to 25.2)* 18.0 (6.48 to 29.5)*
4.15 (-1.29 to 9.58) 2.76 (-1.33 to 6.84) 1.31 (-3.18 to 5.80) 4.05 (-9.82 to 1.73) 1.61 (-2.63 to 5.86) 8.32 (3.05 to 13.6)*
-1.17 (-2.57 to 0.23) -1.61 (-2.50 to -0.71)* -0.54 (-1.63 to 0.56) -0.40 (-1.99 to 1.20) -1.44 (-2.60 to -0.28)* -1.24 (-2.37 to -0.11)*
-0.031 (-1.70 to 1.64) -1.23 (-2.52 to 0.06 -1.10 (-2.25 to 0.06) 0.22 (-1.19 to 1.63) -0.05 (-0.16 to 0.05) -0.16 (-0.27 to -0.05)* 
-1.62 (-4.00 to 0.77) -2.36 (-4.09 to -0.63)* 0.81 (-2.71 to 1.10) -2.04 (-4.18 to 0.10) -2.33 (-3.95 to -0.72)* -0.54 (-2.07 to 0.99)
0.92 (-0.55 to 2.39) 0.57 (-0.72 to 1.86) -0.15 (-1.18 to 0.87) 1.40 (0.038 to 2.76)* 0.70 (-0.45 to 1.86) -0.44 (-1.30 to 0.42)
0.05 (-1.31 to 1.41) 0.04 (-1.00 to 0.93) -0.02 (-0.95 to 0.91) 1.80 (0.107 to 3.50)* 1.54 (0.35 to 2.74)* -0.32 (-1.59 to 0.95)
-0.18 (-1.83 to 1.48) 0.79 (-0.57 to 2.14) 0.90 (-0.07 to 1.88) 0.43 (-1.47 to 2.34) 0.93 (-0.50 to 2.36) 0.98 (-0.57 to 2.53)
0.89 (-0.92 to 2.71) 0.98 (-0.47 to 2.43) 0.63 (-0.60 to 1.87) 0.40 (-1.27 to 2.07) 1.11 (-0.09 to 2.30) 1.08 (-0.26 to 2.41)
1.36 (-0.18 to 2.90) 1.55 (0.22 to 2.88)* 0.25 (-0.92 to 1.42) 0.30 (-1.29 to 1.87) 1.25 (0.09 to 2.40)* 1.14 (-0.11 to 2.39)
Difference 
between 
groups, end of 
treatment 
(95% CI)A
Difference within groups, 
end of treatment (95% CI)B
Difference within 
groups, nine 
months follow-up 
(95% CI)A
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signifi cantly diff er on baseline characteristics from the 
others. One patient withdrew due to a severe physical 
condition (newly diagnosed cancer).
Regarding possible diff erences between the MBCT and 
EUC, there were no important diff erences in socio-
demographic characteristics. With regard to somatic 
morbidity patients in the MBCT group more often 
suff ered from hypertension and joint problems, those in 
the EUC group reported more neurological symptoms as 
their main physical symptom. Of all patients randomized 
to MBCT, three (5%) withdrew after the research 
interview and before the baseline questionnaire, eight 
(13%) completed the questionnaire but did not start 
MBCT and four (8%) did start but did not complete 4 or 
more treatment sessions. Those who did not start or did 
not complete the training were slightly older than the 
completers, although this diff erence was not statistically 
signifi cant. One patient in the EUC group received MBCT 
within the follow-up period. We assessed the 
heterogeneity across training groups on the primary 
outcome measures by calculating the intra-class 
correlation coeffi  cient (ICC). The highest ICC was found 
to be 0.031, so adjustments for clustering were not 
deemed necessary. A sensitivity analysis was done 
by using multiple imputation technique(36) to assess 
whether missing data aff ected the outcomes, no 
diff erences were revealed. 
End of Treatment 
With regard to the primary outcome measure, the general 
health status as measured with the EQ-5D VAS at end of 
treatment, the MBCT and EUC groups did not signifi cantly 
diff er (see Table 2). However, mental functioning as 
assessed with the SF-36 MCS was signifi cantly better in 
the MBCT than in the EUC group (adjusted diff erence 3.91, 
95% CI 0.24 to 7.59).  This also applied to two subscales 
the SF-36: vitality (adjusted diff erence 7.38, 95% CI 1.08 
to 13.7) and social functioning (adjusted diff erence 9.45, 
95% CI 1.37 to 17.5). These were all small to moderate 
eff ects, with eff ect sizes d = 0.34 for mental functioning, 
d = 0.34 for vitality and d = 0.38 for social functioning. 
Table 3. Diff erences between and within MBCT and EUC groups at the end of treatment and        the 9-month follow-up
Health status
general health status 
Physical functioning
(PCS)
Physical functioning
Physical role
Bodily pain
general health
Mental functioning
(MCS)
Vitality
Social functioning
Emotional role
Mental health 
Symptoms
Physical symptoms
Depressive symptoms
Health anxiety
Mindfulness skills
Observing
Describing
Acting with awareness
Non-judging of 
inner experience
Non-reactivity to 
inner experience
*p<0.05
A = ANCOVA, function score adjusted for baseline, age, gender, level of education
B = Paired samples T-test
PCS =  Physical Component Summary
MCS =  Mental Component Summary
MBCT EUC MBCT EUC 
1.53 (-4.74 to 7.79) 6.04 (1.25 to 10.8)* 1.48 (-3.78 to 6.74) 0.68 (-6.54 to 6.68) 5.84 (1.13 to 10.3)* 2.00 (-3.22 to 7.22)
0.59 (-2.39 to 3.57) 2.00 (-0.10 to 4.09) 0.75 (-1.63 to 3.13) -0.14 (-3.44 to 3.17) 3.20 (0.61 to 5.80)* 1.74 (-0.57 to 4.04)
1.89 (-4.10 to 7.88) 3.53 (-1.07 to 8.14)  1.83 (-2.52 to 6.18) -0.02 (-5.75 to 5.72) 3.86 (-0.69 to 8.41) 2.80 (-1.50 to 7.10)
4.01 (-8.70 to 16.7) 9.91 (0.87 to 19.0)* 3.37 (-8.41 to 15.1) -8.54 (-23.3 to 6.19) 16.7 (4.95 to 28.4)* 19.5 (7.21 to 31.8)*
-0.73 (-6.52 to 5.07) 4.57 (-0.01 to 9.15) 3.25 (-1.39 to 7.89) 0.08 (-7.28 to 7.43) 7.54 (1.67 to 13.4)* 5.02 (-0.76 to 10.8
3.05 (-3.48 to 9.58) 5.02 (0.33 to 9.71) 0.87 (-4.23 to 5.96) 0.01 (-5.95 to 5.96) 5.86 (1.33 to 10.4)* 3.90 (-0.19 to 7.99)
3.91 (0.24 to 7.59)* 3.66 (1.00 to 6.33)* 0.69 (-2.21 to 3.59) -0.94 (-4.66 to 2.78) 3.24 (0.27 to 6.20)* 5.28 (2.27 to 8.30)*
7.38 (1.08 to 13.7)* 8.71 (4.06 to 13.4)* 0.7 (-3.82 to 5.36) -1.15 (-8.42 to 6.12) 9.30 (3.88 to 14.72)* 8.90 (2.89 to 14.9)*
9.45 (1.37 to 17.5)* 11.4 (4.64 to 18.2)* 0.48 (-7.09 to 6.13) -0.19 (-8.64 to 8.27) 9.21 (1.94 to 16.5)* 7.50 (0.65 to 14.4)*
9.41 (-4.83 to 23.6) 11.5 (1.04 to 22.0)* 5.77 (-6.38 to 17.9) -0.25 (-13.1 to 12.6) 15.2 (5.17 to 25.2)* 18.0 (6.48 to 29.5)*
4.15 (-1.29 to 9.58) 2.76 (-1.33 to 6.84) 1.31 (-3.18 to 5.80) 4.05 (-9.82 to 1.73) 1.61 (-2.63 to 5.86) 8.32 (3.05 to 13.6)*
-1.17 (-2.57 to 0.23) -1.61 (-2.50 to -0.71)* -0.54 (-1.63 to 0.56) -0.40 (-1.99 to 1.20) -1.44 (-2.60 to -0.28)* -1.24 (-2.37 to -0.11)*
-0.031 (-1.70 to 1.64) -1.23 (-2.52 to 0.06 -1.10 (-2.25 to 0.06) 0.22 (-1.19 to 1.63) -0.05 (-0.16 to 0.05) -0.16 (-0.27 to -0.05)* 
-1.62 (-4.00 to 0.77) -2.36 (-4.09 to -0.63)* 0.81 (-2.71 to 1.10) -2.04 (-4.18 to 0.10) -2.33 (-3.95 to -0.72)* -0.54 (-2.07 to 0.99)
0.92 (-0.55 to 2.39) 0.57 (-0.72 to 1.86) -0.15 (-1.18 to 0.87) 1.40 (0.038 to 2.76)* 0.70 (-0.45 to 1.86) -0.44 (-1.30 to 0.42)
0.05 (-1.31 to 1.41) 0.04 (-1.00 to 0.93) -0.02 (-0.95 to 0.91) 1.80 (0.107 to 3.50)* 1.54 (0.35 to 2.74)* -0.32 (-1.59 to 0.95)
-0.18 (-1.83 to 1.48) 0.79 (-0.57 to 2.14) 0.90 (-0.07 to 1.88) 0.43 (-1.47 to 2.34) 0.93 (-0.50 to 2.36) 0.98 (-0.57 to 2.53)
0.89 (-0.92 to 2.71) 0.98 (-0.47 to 2.43) 0.63 (-0.60 to 1.87) 0.40 (-1.27 to 2.07) 1.11 (-0.09 to 2.30) 1.08 (-0.26 to 2.41)
1.36 (-0.18 to 2.90) 1.55 (0.22 to 2.88)* 0.25 (-0.92 to 1.42) 0.30 (-1.29 to 1.87) 1.25 (0.09 to 2.40)* 1.14 (-0.11 to 2.39)
Diff erence within groups, nine 
months follow-up (95% CI)B
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Additional information concerning the adjusted differences between the groups 
(ANCOVA, adjusted for baseline, gender and level of education; 95% CI) and the 
difference within the groups (paired samples T-test; 95% CI) is provided in Table 3. 
Looking at within group differences, however, a broader picture arises.  In the MBCT 
group, general health status significantly improved over the course of treatment, as 
did physical symptoms and the subscale physical role of the SF-36.  Mental 
functioning according to the SF-36 improved, alongside the subscales vitality, social 
functioning and emotional role.  In addition, both health anxiety and the 
mindfulness skill non-reactivity to inner experience (e.g. ‘When I have distressing 
thoughts or images, I just notice them and let them go’) improved. In contrast, in 
the EUC group none of the outcome measures showed any significant improvement 
over the course of this three months period.  The per protocol analysis did not reveal 
relevant differences on the primary outcome. In the per protocol analysis (n=98), 
the level of health anxiety showed statistically significant differences between the 
MBCT and EUC group in terms of health anxiety (p=0.05) and non-reactivity to inner 
experience (p=0.04).
Nine Months Follow-up
At 9 months follow-up (Table 2), the MBCT and EUC groups showed some significant 
differences in terms of mindfulness skills: the MBCT group reported more observing 
skills (adjusted difference 1.40, 95% CI 0.038 to 2.76) (e.g. ‘I pay attention to physical 
experiences, such as the wind in my hair or sun on my face’) and describing skills 
(adjusted difference 1.80, 95% CI 0.107 to 3.50) (e.g. ‘I’m good at finding words to 
describe my feelings’) than the EUC group.   
Again, the within group differences give a fuller picture of the changes over time.  In 
comparison with the start of treatment, the MBCT group reported significant 
improvements with regard to general health status, physical and mental 
functioning according to the SF-36 and six out of eight subscales of the SF-36: 
physical role, bodily pain, general health, vitality, social functioning and mental 
health. In addition, they reported lower levels of physical symptoms and health 
anxiety, alongside higher levels of the mindfulness skills describing and non-
reactivity. This time, the EUC group also showed  some improvements, particularly 
with regard to their mental functioning. They reported improvements in the mental 
component summary of the SF-36, the subscales vitality, social functioning, 
emotional role and mental health, and depression. They also experienced less 
physical symptoms and had lower scores on the physical role subscale of the SF-36.  
Health Care Use
Health care use during the year of the study was recorded each month by 55 (90%) 
patients in the MBCT group and 41 (73%) patients in the EUC group. Overall, health 
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care use did not diff er signifi cantly between the two groups. In the MBCT group, the 
median of health care contacts was 26 (range 0-129, mean 38, SD 35) and in the EUC 
group 22 (range 0-166, mean 39, SD 41). 
Predicting Factors
A subgroup analysis was performed on a per protocol basis to check for relevant 
interactions. gender, level of education, the presence of physical diseases and the 
presence of psychiatric disorders did not show signifi cant interactions with any of 
the three main outcome measures (VAS EQ-5D, MCS and PCS). The only interaction 
that proved signifi cant was that between age and physical functioning at 9 months 
follow-up (estimated diff erence per year -0.40, 95% CI -0.69 to -0.10). This indicates 
that higher age had a stronger negative infl uence on physical functioning in the 
MBCT than in the EUC group.
DISCUSSION 
This is the fi rst RCT about MBCT in patients with persistent medically unexplained 
symptoms in primary care. The intervention seemed to be feasible for patients with 
unexplained symptoms, but MBCT did not result in an improvement of general 
health status. However, mental functioning had signifi cantly improved after the 
MBCT training, in particular vitality and social functioning had improved.  Although 
the diff erences between the two groups were modest, the within group comparisons 
were more revealing. After completing the MBCT course, participants reported 
improvements in 9 out of 19 outcome measures: general health status, physical 
symptoms, physical role, mental functioning, vitality, social functioning, emotional 
role, health anxiety and non-reactivity. In contrast, at end of treatment no signifi cant 
changes in any of these outcome measures were demonstrated in the EUC group.  
Although the validity of existing mindfulness measures such as the FFMQ, has been 
under scrutiny recently(40),  we did demonstrate changes in mindfulness skills such 
as observing, describing and non-reactivity to inner experience. This is particularly 
interesting in the light of the fact that patients with persistent medically unexplained 
symptoms are sometimes described as ‘alexithymic’, i.e. having diffi  culty with 
recognizing and describing emotions(41, 42). In addition, although only 3 out of 117 
patients had a diagnosis of hypochondriasis, there were signifi cant decreases in 
health anxiety within the MBCT group both at end of treatment and at follow-up. 
So, cognitive processes such as mindfulness skills and health anxiety might be more 
addressed by MBCT than the physical symptoms themselves and their resulting 
impairment.  
The eff ect size of MBCT on mental functioning at post treatment was similar to that  
in studies of MBCT for chronic somatic conditions. In a recent review by Bohlmeijer et 
5
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al.(37),  MBCT  appeared to have small effects on depression (d = 0.26) and on anxiety 
(d = 0.24). In our study the effect size of MBCT on mental functioning at the post 
treatment measurement was d = 0.34. In Denmark, Fjorback recently completed 
an  RCT on the effectiveness of mindfulness training for patients with somatization 
disorder and functional somatic syndromes in secondary care(38, 39). In their severely 
affected population mindfulness training was acceptable and feasible, 88% 
completed treatment. At the end of treatment, the mindfulness group showed more 
improvement in physical functioning (SF-36) than the control group. However, at 15 
months follow-up the control group had improved as well. Although our population 
seemed to be less severe, our results are comparable. Our results concerning mental 
functioning, health anxiety and mindfulness skills show a greater improvement than 
the results in Fjorback’s study.  
With regard to the intervention itself, we did not systematically assess the treatment 
integrity and therapist competency. Instruments which have recently been 
developed to assess therapist competency in mindfulness based interventions(43) 
were not available when we started the study.  However, the trial therapists were 
both adequately trained and had a longstanding professional experience and 
personal meditation practice.  They were both mindfulness trainers on an earlier trial 
of MBCT for recurrent depression(44), which demonstrated the effectiveness of MBCT 
with an effect size of d>0.5.  Their ratings based on videotaped therapy sessions of 
a current trial of MBCT(44) were competent or above. Another factor that might have 
influenced the effectiveness of the training is the compliance of the patients.  
Unfortunately, we did not keep a record of their compliance with the homework 
exercises.  
The fact that both groups showed improvements over time might be attributable 
to selection of patients in a period when their symptoms were most severe, after 
which the symptoms generally gradually diminished. This phenomenon is known 
as ‘regression to the mean’.  In addition, in both groups a proportion of the patients 
might have improved naturally, whether or not due to the unrestricted utilization of 
‘usual care’(45). Health care use was similar in both groups, with a median of about 25 
contacts (e.g. with physiotherapist, gP, specialist) per person per year. 
In addition, it is not unlikely that the participation in the study itself led to an 
additional improvement in the control group. To begin with, these participants were 
willing to participate in this study, so they showed ‘readiness for change’. A thorough 
research interview was done, which might have led to new insights in some patients. 
Also, gPs received a letter about the diagnostic assessment, which included a new 
psychiatric diagnosis in 30% of the patients. This might have led to a more effective 
treatment of psychiatric symptoms which could also affect their physical well being. 
Moreover, the patients in the EUC group just like those in the MBCT group, filled out 
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many questionnaires over the year which might have made them more aware of their 
coping style. 
It is encouraging that more than a quarter of the invited patients was interested in 
MBCT and that it was feasible for the participants to take part in MBCT, especially 
when taking into account the high level of patient involvement required in MBCT. 
given the many improvements in the patients participating in the MBCT group over 
the course of treatment and at 9-months follow-up, mindfulness has the potential to 
become a valuable contribution to the scarce therapeutic arsenal for persistent 
medically unexplained symptoms. Further research is needed to tailor the 
intervention to the particular needs of these patients and to select or develop more 
suitable outcome measures. It might be interesting to compare the MBCT to other in-
terventions like CBT(46), acceptance and commitment therapy (ACT) or other specifi c 
group interventions for medically unexplained syptoms(47).  
5
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ABSTRACT 
Objective: Our aim was to assess cost-effectiveness of mindfulness-based cognitive 
therapy (MBCT) compared to enhanced usual care (EUC) in treating patients with 
persistent medically unexplained symptoms (MUS). 
Methods: A full economic evaluation with a one year time horizon was performed 
from a societal perspective. Costs were assessed by prospective cost diaries. 
Health-related Quality of Life was measured using SF-6D. Outcomes were costs per 
Quality Adjusted Life year (QALy). Bootstrap simulations were performed to obtain 
mean costs, QALy scores and incremental cost-effectiveness ratios (ICERs).
Results: MBCT participants (n=55) had lower hospital costs and higher mental 
health care costs than patients who received EUC (n=41). Mean bootstrapped costs 
for MBCT were €6,269, and €5,617 for EUC (95% uncertainty interval for difference: 
-€1,576; €2,955). QALys were 0.674 for MBCT and 0.663 for EUC. MBCT was on average 
more effective and more costly than EUC, resulting in an ICER of €56,637 per QALy 
gained. At a willingness to pay of € 80,000 per QALy, the probability that MBCT is 
cost-effective is 57%.
Conclusion: Total costs were not statistically significantly different between MBCT 
and EUC. However, MBCT seemed to cause a shift in the use of health care resources 
as mental health care costs were higher and hospital care costs lower in the MBCT 
condition. Due to the higher drop-out in the EUC condition the cost-effectiveness 
of MBCT might have been underestimated. The shift in health care use might lead 
to more effective care for patients with persistent MUS. The longer-term impact of 
MBCT for patients with persistent MUS needs to be further studied.
Inhoud 1.indd   88 13-08-2013   17:57:12
89
6
INTRODUCTION 
Medically unexplained symptoms (MUS) are commonly encountered across all 
healthcare settings.  About one in fi ve patients presenting  at the general practitioner 
(gP)’s offi  ce has medically unexplained symptoms(1, 2). Often, these symptoms resolve 
spontaneously. However, in 10-16% of primary care patients the symptoms persist 
and result in functional impairment(1, 3). Frequent attendance because of persistent 
medically unexplained symptoms is seen in 2.5% of primary care patients. This group 
mainly consists of women with a lower socioeconomic status(4).
Societal costs associated with persistent MUS are substantial(5, 6), they mainly consist 
of health care costs and costs of lost productivity. Health care costs of patients with 
persistent MUS are high due to high consultation rates in both primary and 
secondary care(7, 8) and due to often unnecessary medical procedures with the 
potential for iatrogenic harm(5, 9, 10). In the United Kingdom the incremental annual 
health care cost incurred by patients with MUS was estimated at approximately 10% 
of the total health care expenditure for the working-age population(11). In the United 
States 16% of the total medical care costs are attributable to the incremental costs 
of MUS(7).  In addition, disabilities caused by MUS lead to diminished employment 
participation: patients with persistent MUS are more on sick leave and have higher 
rates of unemployment(12). 
Clearly, eff ective interventions for MUS are needed in order to diminish functional 
impairment and societal costs. Mindfulness-based cognitive therapy (MBCT) is a 
promising treatment in the fi eld of MUS as it appears to be eff ective(13) and provides 
us with a new approach: MBCT stimulates acceptance of symptoms(14). An economic 
evaluation of MBCT for patients with somatisation disorder has been performed 
within a recent Danish trial. MBCT was compared to a specialized treatment 
consisting of a two-hour individual consultation by a psychiatrist(15). Total health care 
costs did not diff er between the conditions, but the percentage of patients on 
disability pension had decreased signifi cantly more in the MBCT condition.  
In a recently conducted randomized controlled trial the eff ectiveness of MBCT was 
compared to enhanced usual care (EUC) for frequently attending patients with 
persistent MUS(13). Both MBCT and EUC succeeded in improving current health status 
and mental and physical functioning. However, MBCT led to an earlier improvement 
of mental functioning, especially with regard to vitality and social functioning. In the 
context of health care budget constraints, an economic evaluation of this eff ect can 
inform decisions which health care services to off er to these patients. Therefore, we 
performed a cost-eff ectiveness analysis comparing MBCT versus EUC for patients 
with persistent MUS.
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METHODS
Design of RCT 
This study was embedded in a randomized controlled trial examining the effects of 
MBCT on frequently attending patients in primary care with persistent MUS. 125 
Patients were randomly allocated to either MBCT (n=64) or EUC (n=61)(13). All patients 
belonged to the 10% most frequently attending patients of the participating gPs 
(n=19), and they fulfilled the DSM-IV criteria of an undifferentiated somatoform 
disorder, which means that they had at least one physical symptom which was not 
(fully) explained by a physical disorder or by substance abuse, lasted for at least 6 
months, led to functional impairment and could not be put down to another 
psychiatric disorder. All patients received a psychiatric interview at the pre-
randomization assessment which included the Mini-International Neuropsychiatric 
Interview (MINI)(16) and the section on somatoform disorders of the Structural Clinical 
Interview for DSM IV axis I disorders (SCID-I)(17). Primary outcomes were current health 
status and mental and physical functioning (SF-36 PCS and MCS)(18). Assessments 
took place at baseline, end of treatment and 9 months follow-up by filling out postal 
or online questionnaires. Patients randomized to the EUC condition were requested 
to refrain from attending mindfulness training during the study period and they 
had the possibility to participate in the mindfulness training after completion of the 
study.
Interventions
Participants randomized to MBCT received eight 2.5 hour sessions of MBCT from 
experienced mindfulness trainers.  Both trainers had participated in an intensive 
two-year teacher training course for mindfulness teachers, had many years of 
ongoing meditation practice, and both trainers taught more than 30 MBCT or MBSR 
courses to patients with psychiatric disorders and/or physical conditions. Participants 
were instructed to practice at home 6 days a week for approximately 45 minutes a 
day. To support home practice, patients received a folder with information about the 
individual sessions, homework assignments and forms to keep a record of their 
practice, together with CDs with guided meditations and movement exercises. group 
size varied between 7 to 14 participants.  Our training protocol was based on the 
MBCT format for patients with recurrent depression(19). We made minor adaptations 
to the MBCT training protocol to make it more suitable for patients with physical 
symptoms. The program consisted of formal meditation exercises such as the body 
scan, sitting meditation, walking meditation and mindful movement. Participants 
were encouraged to cultivate awareness of everyday activities, such as eating or 
taking a shower. In line with the original Mindfulness-Based Stress Reduction 
format(20), we incorporated a silent day to give participants the opportunity to 
deepen their mindfulness practice(21). Patients in the EUC condition received usual 
care provided by their gP and other health care professionals. The term ‘enhanced 
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usual care’ was considered appropriate as all patients received a psychiatric interview. 
The gP was explicitly informed about the psychiatric diagnoses resulting from the 
interview(22).
Main results RCT
 In the randomized controlled trial, current health status and physical functioning 
did not signifi cantly diff er between groups. However, participants in the MBCT group 
reported a signifi cantly greater improvement in mental functioning at the end of 
treatment (adjusted mean diff erence 3.9, 95%CI 0.24 to 7.6), in particular with regard 
to vitality and social functioning. Within the MBCT group, almost half of the 
secondary outcome measures had signifi cantly improved at end of treatment, 
whereas in the EUC group none had. 
Assessments cost-eff ectiveness study
A face-to-face pre-randomization assessment was performed in which we assessed 
socio-demographic and clinical characteristics, the current employment status and 
medication use in the past month. Further assessments were performed with online 
or postal questionnaires at baseline, 3 months and 12 months after randomization. 
To assess health care use and employment participation we used a prospective cost 
diary in which patients were asked to note their health care use and their 
employment participation per calendar day. given a societal perspective, the 
prospective cost diaries covered employment participation and health care use per 
day. The prospective diaries were mailed to the patients before the start of each 
month during the whole year of the trial. Patients were requested to send the diary 
back at the end of each month. If the patient did not send in the diary in time, our 
research team made a phone call to the patient. We kindly requested patients to 
keep fi lling out the diaries. A fi nal follow-up assessment was made by telephone at 
12 months after baseline in which we assessed again the current employment status 
and medication use in the past month. The number of attended MBCT sessions was 
registered by the mindfulness trainer. 
Unit prices
We used Standardized Dutch unit prices(23). When a standardized unit price was not 
available, prices were based on tariff s. Medication costs were obtained from the 
Dutch ‘Pharmacotherapeutic Compass’ (the most used drug reference in the 
Netherlands)(24). Medication costs which were not retrieved from these resources (e.g. 
vitamin pills), were derived from suppliers on the Internet. If these medication costs 
varied, we used the lowest price. Productivity costs (i.e. when patients are unable to 
perform paid work) were calculated according to the Friction Cost (FC) method(25), 
implying that the number of hours patients were absent from their job is multiplied 
with the actual gross wage per hour. The cause for absence is not taken into account. 
Absence could  for example be due to illness, being fi red or resigning from a job. 
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In FC, productivity costs are only counted as long as it takes to replace someone. The 
friction period is defined as the time needed to restore the initial production level. 
After this friction period, costs to society fall back to zero. For FC, standardized FC 
tariffs as well as the friction period of 160 days were obtained from the Dutch Manual 
for Costing studies(23). The tariffs are calculated based on the average value added per 
working person. FC was calculated according to the standards, implying that when a 
patient was continuously absent for more than 160 days, it was assumed that this 
patients’ place in the production process was filled again and productivity returned 
to its original level. Therefore, after these 160 days had passed, productivity costs 
were considered zero. Price indices were used to convert costs to the 2010 price level.
Outcome measures
Effectiveness was expressed as Quality Adjusted Life years (QALy). A QALy is a 
measure of life expectancy, weighted by the health-related quality of life (HRQoL) 
represented by utility scores. HRQoL was measured with the SF-6D(26) which is based 
on the SF-36(18). The SF-6D revised the SF-36 into a six-dimensional health state 
classifications system. This classification systems allows the calculation of a utility 
score, which is a component of the QALy. It contains 6 dimensions: physical 
functioning, role participation (combined role-physical and role-emotional), social 
functioning, pain, mental health and vitality(26). Each dimension has four to six levels. 
The specific areas or activities contributing to the SF-6D index include current ability 
to engage in both moderate and vigorous activities and current ability to bath and 
dress one’s self. From the SF-36 Health Survey data, individual respondents can be 
classified on any of four to six levels of functioning or limitations, on each of six 
domains. These SF-6D health states can be converted into utility scores by assigning 
preference weights. The preference weights are derived from valuations of a sample 
of 249 SF-6D health states using the standard gamble in a representative sample of 
the UK population and range from 0.29 to 1.00(27), with 1 representing perfect health. 
From these utility scores, Quality-Adjusted Life years (QALys) were derived using the 
area under the curve method by using the SF-36 measurements at baseline, three 
months and 12 months after baseline(28).
Data analysis
Patients who had filled out six or more prospective diaries and whose data on the 
SF-6D were available from all three assessments were included in the analysis. Costs 
were divided by the total number of days filled out in the diaries and multiplied with 
365 to reach an estimation of the costs per year. We used the independent samples 
Mann-Whitney U test to determine whether the costs differed between the two 
conditions at a significance level of p=0.05. Since cost data are generally highly 
skewed, and not distributed normally, bootstrap simulations with 1000 replications 
were performed(29, 30) to estimate uncertainty intervals around the mean costs. For the 
same reasons, QALy scores were bootstrapped with 1000 replications. The uncertainty 
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interval is represented by the 2.5th and 97.5th percentiles. Results of Incremental 
Cost-Eff ectiveness Ratios (ICER) bootstraps are presented in cost-eff ectiveness planes. 
Cost-eff ectiveness planes show diff erences in costs on the vertical axis and diff erences
in eff ect on the horizontal axis. Bootstrapped cost-eff ectiveness pairs located in the 
north-west quadrant indicate MBCT to be inferior to EUC (more costly and less 
eff ective than EUC). Cost-eff ectiveness pairs located in the south-east quadrant 
show MBCT to be dominant over EUC (more eff ective and less costly than EUC). With 
respect to the other two quadrants (higher costs for better eff ectiveness and lower 
costs for lower eff ectiveness), the choice of an intervention depends on the threshold 
value, i.e. what society is prepared to pay for an eff ectiveness gain, or willing to 
accept as savings for eff ectiveness loss. In these cases, an ICER is determined. An ICER 
is calculated by dividing the diff erence in costs between the treatments by the 
diff erence in eff ectiveness between the treatments. An ICER represents the extra 
amount of money that has to be invested or will be saved to gain or lose one extra 
unit of eff ect. In our study, the unit of eff ect was a QALy. Cost-eff ectiveness 
acceptability curves (CEACs)(31) were constructed. They represent the probability that, 
given a certain threshold for the willingness to pay for a QALy, the intervention is 
cost-eff ective.
Secondary analyses
Secondary analyses were performed to assess robustness of the results.
1.  An analysis with a healthcare perspective, meaning that only direct healthcare  
 costs, including costs of MBCT and medication use, were considered. For this 
 analysis we excluded the productivity losses from our analysis. 
2.  A per protocol analysis: analyzing only those patients who adhered to the study  
 protocol. In line with previous MBCT trials, an adequate dose of MBCT (i.e. the  
 treated “per protocol” cases) was defi ned as participation in at least four MBCT  
 group sessions(19, 32). Data are presented from the societal perspective. 
3.  An analysis without extreme cost outliers due to physical disease. Data are 
 presented from the societal perspective. 
The results of all three secondary analyses are represented in a CEAC.
RESULTS
Patients
Although 125 patients participated in the randomized controlled trial, we obtained 
data for the cost-eff ectiveness analysis of only 96 patients, 55 in the MBCT condition 
and 41 in the EUC condition (Figure 1). Filling out prospective monthly diaries was 
experienced as burdensome by many patients, for 15 patients this was the main 
reason to stop fi lling out these diaries. Of the 29 patients who were excluded from 
the cost-eff ectiveness analysis, twenty-seven patients fi lled out less than six monthly 
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diaries. Two patients did hand in the monthly diaries, but not the questionnaires. 
Patients who withdrew or dropped-out (n=29) seemed more severely impaired in 
their daily functioning at baseline. They were less often employed (41% v. 52%), had 
a lower level of education (17% only attended primary education v. 9%)  and more 
often these patients had a depressive or anxiety disorder (48% v. 28%) than those 
included in the cost-effectiveness analysis. We present the cost-effectiveness data of 
the 96 patients for whom sufficient data were available. Table 1 shows baseline 
Allocated to usual care (n=61)
  Withdrawal (n=5)
 difficulty with questionnaires (n=2), 
 disappointed with allocation (n=2), 
 psychological symptoms (n=1)
  Lost to follow up (n=15)
 difficulty with questionnaires and monthly 
 diaries (n=11), disappointed with allocation    
 (n=1), migration (n=1), home environment   
 (n=1), physical symptoms (n=1)
Excluded  (n=28)
  not meeting inclusion criteria (n=18)
 no impairment due to symptoms (n=12), 
 physical disease explained symptoms (n=5),   
 psychosis in medical history (n=1)
   declined to participate (n=10)
 lack of time (n=5), not interested (n=3), 
 practical reasons impede participation (n=1), 
 withdrew and requested removal of all data   
 (n=1)
Enrollment
Allocated to MBCT (n=64)
  Withdrawal (n=3)
 difficulty with questionnaires (n=1), 
 physical disease (n=1), work situation (n=1)
  Lost to follow-up (n=6)
 difficulty with questionnaires and monthly  
 diaries (n=4), physical symptoms (n=1),  
 family situation (n=1)
Figure 1. Patient enrollment
Assessed for egilibility (n=153)
Cost-effectiveness analysis (n= 41)
Randomized (n=125)
Cost-effectiveness analysis (n= 55)
  Not adhering to protocol (n=8)
 Did not start MBCT (n=4), attended less than   
 four sessions MBCT (n=4)
 
Per protocol analysis (n=47)
  Not adhering to protocol (n=1)
 Attended MBCT (n=1)
 
Per protocol analysis (n=40)
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characteristics of these patients. There were no signifi cant diff erences in baseline 
characteristics between patients in het MBCT condition and patients in the EUC 
condition. Costs, QALy results, and cost per QALy ratios are based on all 96 patients.
Employment status
At baseline 53% in the MBCT condition had a paid job, and 51% in the control condition. 
At the end of follow up 44% in the MBCT condition and 51% in the control condition 
had a paid job. Unemployment rates were 11% in the MBCT condition and 15% in the 
control condition at baseline.  The unemployment rates increased in both conditions to 
20%. The percentage of patients on disability pensions was 13% in the MBCT condition 
and 12% in the EUC condition at baseline. The percentage of patients on disability 
pensions slightly increased in both conditions: at the end of follow up disability 
pensions were provided to 16% in the MBCT condition and to 15% in the control 
condition.
Table 1. Baseline characteristics of 96 study participants
Age (years (SD)) 
Women 
Civil class
 Married
 Single/unmarried
 Divorced
 Widowed
Level of education*
 Low
 Middle
 High
Employment status
 Labor
 Sick leave
 Disability pension
 Unemployment benefi t
 Social welfare
 Elderly pension
 Student
 No income
A)  Based on Pearson Chi-square test, if no other test is indicated
B) Based on Independent samples T-test
*  Education level was classifi ed as low (primary and lower secondary education), middle  
 (upper secondary education) and high (higher vocational training and university)
47.0 (11.3) 
43 (80.3)
27 (49.1)
20 (36.4)
8 (14.5)
0 (0.0)
14 (25.5)
26 (47.3)
15 (27.3)
29 (52.7)
3 (5.5)
7 (12.7)
2 (3.6)
2 (3.6)
7 (12.7)
3 (5.5)
2 (3.6)
48.1 (12.3)
31 (67.9)
18 (43.9)
12 (29.3)
8 (19.5)
3 (7.3)
17 (41.5)
13 (31.7)
11 (26.8)
21 (51.2)
3 (7.3)
5 (12.2)
1 (2.4)
4 (9.8)
5 (12.2)
1 (2.4)
1 (2.4)
MBCT
(n = 55)
EUC
(n = 41) P-Value
 A)
0.66B)
0.78
0.18
0.20
0.94
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Costs
Bootstrapped societal costs over one year were €6,269 for MBCT and €5,617 for EUC 
which is a non-signifi cant diff erence (Table 2). With respect to health care costs, 
treatment costs (including costs of the attended MBCT sessions and, if attended, the 
6 hour silence retreat) were € 450 per person randomized to MBCT. Apart from the 
costs for the MBCT training, patients in the MBCT condition had lower hospital care 
related costs than the patients in the EUC condition (€636 versus €861, p=0.18) and 
higher mental health care costs (€431 versus €224, p=0.98). The majority of patients 
(63%) did not make use of mental health care. Mean costs of participants who did use 
mental health care were €1185 in the MBCT condition and €574 in the EUC condition 
(p=0.29). In both conditions about one in fi ve patients made use of alternative 
healers. Mean costs for all patients were €100 per patient in this study, which makes 
the mean costs per patient who used alternative healers approximately €500. 
Medication costs were higher in the MBCT condition (€673 versus €386, p=0.27 
Mann-Whitney test). This was partially due to a single very high cost outlier in the 
MBCT condition who used antiretroviral HIV medication and had annual medication 
costs of €9.513. His medication costs accounted for 60% of the diff erence between 
MBCT and EUC medication costs.
Eff ectiveness
Table 3 presents mean societal costs and SF-6D utility scores. Baseline utility scores 
were 0.632 (SD 0.11) for MBCT and 0.639 (SD 0.10) for EUC, (p=0.983) (Figure 2). 
Figure 2. Utility scores on the SF-6D
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0,6
0,55
0,5
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MBCT
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Utility scores increased in both conditions; from 0.63 to 0.69 in MBCT patients, and 
from 0.64 to 0.68 in EUC patients, an improvement of 0.06 and 0.04, respectively. As a 
result, total QALys over the 1-year period were 0.674 for MBCT and 0.663 for EUC. The 
bootstrapped difference in QALys between MBCT and EUC of 0.012 (95% CI –0.019 to 
0.041) was not statistically significant.
Cost-effectiveness
In comparison to the EUC condition, bootstrapped total societal costs were €652 
higher and QALys were 0.012 higher in the MBCT condition. The ICER based on the 
QALy shows that for one QALy gained the costs are €56,637, as MBCT was more costly 
and more effective than EUC (Table 3). The bootstrapped results (Figure 3) show that 
52% of the cost-effectiveness pairs are in the north-east quadrant, where MBCT is 
more costly and more effective. Twenty percent are located in the north-west 
quadrant, which is the inferiority quadrant. The south-east quadrant, i.e. the 
dominance quadrant, contains 25% of the replications. And the final 4% of the 
cost-effectiveness pairs are in the south-west quadrant, where MBCT is less costly 
and less effective. The CEAC (Figure 4) indicates that the probability of MBCT being 
cost-effective increases with an increasing threshold value. If society’s maximum 
willingness to pay would be €0 for a QALy gain, the probability of MBCT being cost 
effective is 28%. And at a threshold of €40,000 this is 48%. Assuming that society’s 
maximum willingness to pay is €80,000 for a QALy gain(33) the probability that MBCT 
is cost-effective is 57%.
Societal 
perspective 
(n=96)
Health care 
perspective  
(n=96)
Per protocol 
analysis (n=87)
Analysis 
without 
extreme cost 
outliers (n=95)
6,269 0.674 5,617 0.663 +652 0.012 56,637
3,107 0.674 2,351 0.663 +756 0.011 66,450
6,249 0.670 5,686 0.660 +562 0.011 53,198
6,263 0.679 5,617 0.663 +647 0.016 41,167
MBCT EUC Differences
Table 3. Results of main and secondary analysis (mean bootstrapped costs and QALY’s in Euros)
ICER
QALY’s Costs per QALY (n=96)
Costs 
per year
Costs 
per year
Incre-
mental 
costs
QALY’s
Incre-
mental 
QALY’s
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6Secondary analysesHealth care perspective
Costs per QALy gained when regarded from the health care perspective did not 
signifi cantly diff er from the costs per QALy gained when regarded from the societal 
perspective (Table 3). In the MBCT condition bootstrapped costs were €756 higher 
and QALys 0.011 higher than in the EUC condition. Leaving out productivity losses 
led to an ICER of €66,450 per QALy gained. Analysis from the health care perspective 
resulted in higher costs per gained QALy than analysis from the societal perspective 
(ICER of €56,637 per QALy gained). Assuming that society’s maximum willingness to 
pay is €80,000 for a QALy gain(33) the probability that MBCT is cost-eff ective is 55%.
Per protocol analysis
In the MBCT condition 8 patients (of patients included in the cost-eff ectiveness 
analysis) did not follow the protocol, they attended less than four sessions of MBCT. 
In the EUC one patient did not follow the protocol, she attended MBCT during the 
year of study. Therefore the per protocol analysis consists of 87 patients (MBCT n=47, 
EUC n=40). In the MBCT condition bootstrapped costs were €562 higher and QALys 
Figure 3. Bootstrapped costs and eff ects for cost per QALY  
Extra costs
Extra eff ects 
(QALY)
This fi gure shows 1000 bootstrap replications for incremental cost-eff ectiveness of MBCT 
compared to EUC from a societal perspective. Costs are on the y-axis, and eff ects on the x-axis, 
so a replication in the north-east quadrant means that MBCT is more eff ective but also more 
costly than EUC for that replication.
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Figure 4. Cost-effectiveness acceptability curves for costs per QALY 
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0.011 higher than in the EUC condition. With respect to costs per QALy, costs dropped 
from €56,637 in the main analysis to €53,198 in the per protocol analysis. Assuming 
that society’s maximum willingness to pay is €80,000 for a QALy gain(33) the 
probability that MBCT is cost-effective is 56%.
Analysis without extreme cost outliers due to physical disease
There was one extreme cost outlier, this was a patient in the MBCT condition. This 
patient had exceptionally high medication costs due to antiretroviral drugs, which 
were prescribed for HIV. Medication costs exceeded €9,500 per year, whereas all other 
patients had medication costs between €0 and €2,600, with mean €453 and median 
€230. After exclusion of this patient cost data of 95 patients were analyzed using the 
societal perspective (MBCT n=54, EUC n=41). In the MBCT condition bootstrapped 
costs were €647 higher and QALys 0.016 higher than in the EUC condition. With 
respect to costs per QALy, costs dropped to €41,167. Assuming that society’s 
maximum willingness to pay is € 80,000 for a QALy gain(33) the probability that MBCT 
is cost-effective is 62%.
The curves indicate the probability (y-axis) of MBCT being cost-effective compared with EUC, given the 
threshold value (x-axis) for a QALy.
Inhoud 1.indd   100 13-08-2013   17:57:13
101
6
DISCUSSION
General results
Total societal costs did not signifi cantly diff er between treatments, costs per patient 
were approximately €650 higher for MBCT than for EUC in the one year follow-up. 
The costs of lost productivity did not signifi cantly diff er between groups. There were 
notable diff erences in the distribution of health care resources. Patients in the MBCT 
condition used less hospital care and more mental health care than those in the 
EUC condition. Mean medication costs were higher (p=0.27) in the MBCT condition, 
however this was mainly caused by one extreme cost-outlier. In addition, we had less 
patients in the EUC condition (n=41) than in the MBCT condition (n=55), this was due 
to higher drop-out in the EUC condition. Patients who dropped out seemed more 
severely impaired, therefore our results might underestimate the costs of the EUC 
condition.
Utility scores increased from 0.63 to 0.69 in MBCT patients, and from 0.64 to 0.68 in 
EUC patients, an improvement of 0.06 and 0.04, respectively. The minimally 
important diff erence for SF-6D utility scores is considered to be 0.04 points(34). So, in 
both conditions there was a clinically relevant eff ect on HRQoL. QALys based on the 
1-year period were slightly higher for MBCT, resulting in an ICER indicating a costing 
€56,637 for a QALy gain. In the per protocol analysis the societal costs for a QALy gain 
were €53,198. There was one extreme cost outlier due to the use of antiretroviral 
drugs for HIV in the MBCT condition, leaving out the extreme outlier led to an ICER of 
€41,167 per QALy gained.
To date, there is no consensus about a reasonable threshold value for cost-
eff ectiveness. Most studies with the explicit goal to determine a threshold resulted 
in values ranging from €10,000 to €27,000(35-37). However, in practice, thresholds used 
for appraisal of new interventions may be higher, around €40,000(38) for the UK and 
€80,000 for the Netherlands(33). The CEACs (Figure 4) show a range of thresholds, 
varying from €0 to €150,000. In the present study, when applying a €80,000 per 
QALy threshold, the chance that MBCT was cost-eff ective within the year of study lies 
between 56% and 62%.
Comparison to literature
Another intervention for MUS,  cognitive behavioral therapy (CBT), has been 
economically evaluated(39). CBT was combined with drug management and compared 
to usual care. The cost-minimization study showed non-signifi cant diff erences in total 
costs. Costs due to lost productivity were slightly lower in the intervention group, but 
this diff erence was not signifi cant. Although the study reports an increase in mental 
health outcomes on the SF-36, no cost-eff ectiveness analysis was reported. Therefore 
we cannot compare our cost eff ectiveness analysis to their study.
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Fjorback et al. performed an economic evaluation of MBCT for patients with a 
somatisation disorder(15). The study showed a stronger decrease in hospital costs after 
MBCT. Mental health care costs were significantly higher in the MBCT condition, this 
was attributable to the extra costs incurred by the intervention. This partially 
corresponds with our results. We found a difference in the distribution of health care 
use between patients who attended MBCT and those who did not. During the year 
of study, there was a trend for patients in the MBCT condition to have lower costs 
for hospital care and higher costs for mental health care compared to patients in the 
control condition. In our study, the higher mental health care costs were not caused 
by the MBCT training itself, because these costs were reported separately. It can be 
speculated that somatising patients who attend MBCT become more willing to seek 
help for psychological problems. They might have reached a deeper understanding 
of the nature of their problems, or at least a different view upon which health care 
services could be helpful to them. It would be interesting to examine whether the 
different distribution of health care use persists over the following years. One could 
expect that mental health care workers are better equipped to deal with patients 
with MUS than the more physically oriented specialists in the hospital. 
The cost-effectiveness of MBCT has also been studied for patients with recurrent 
depressions, Kuyken et al. compared MBCT to treatment with antidepressant 
medication(32). Similar to our study, the total costs of the MBCT were slightly higher 
than the costs in the control condition. Exploration of costs over time revealed that 
MBCT was consistently more expensive than treatment with antidepressant 
medication over the first 12 months. MBCT for patients with recurrent depression 
seems to be cost-effective. given the assumption that society’s willingness to pay 
for MBCT is zero, the probability of MBCT being more cost-effective than the control 
treatment, was 42% in the study by Kuyken et al. The results are not fully comparable 
to our study, because in the study by Kuyken et al the outcome was prevention of 
relapse, whereas our outcome was more comprehensive: the increase of a full QALy. 
In our study the probability of MBCT being more cost-effective than the control 
treatment, would be 28% (societal perspective) at society’s willingness to pay of zero. 
It is important to realize that society is probably willing to pay for a gain in quality of 
life. 
Strengths
This study has several strengths. We examined a group of patients causing relevant 
excess costs for society(6). For the measurement of costs we used a broad perspective: 
we included in- and outpatient care, medication costs and productivity losses due to 
sickness absence. In addition, we did not solely focus on costs, but also on the 
effectiveness of the intervention. Although several  economic evaluations of 
interventions have been performed (cost minimization studies), studies examining 
the cost-effectiveness of interventions for medically unexplained symptoms are 
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scarce(60). This is the fi rst full economic evaluation presenting the cost-eff ectiveness 
ratios of MBCT for patients with persistent MUS.
Limitations
A number of limitations should be addressed. Firstly, data upon health care use and 
employment participation combined with eff ectiveness data were available for only 
96 patients out of 125 patients who were randomized for the trial[13]. Filling out 
prospective monthly diaries was experienced as very burdensome by many patients. 
During reminder telephone calls, the reason for not wanting to fi ll out the diary was 
often severe physical or mental illness. Patients who decided to stop fi lling out the 
monthly diaries were less often employed and had higher rates of depressive or 
anxiety disorders at baseline than those who continued. In the EUC condition more 
participants (n=19) decided to stop fi lling out the monthly diaries than in the MBCT 
condition (n=8). These patients might have been disappointed because they had to 
wait a year before they could receive mindfulness training. Another possible reason 
for lower drop-out in the MBCT condition is that ‘a mindful attitude’ reduced the 
aversion towards fi lling in the monthly diary. The higher drop-out in the EUC 
condition might have led to an underestimation of health care costs, underestimation 
of productivity loss and overestimation of HRQoL. Multiple imputation could be 
used to increase the number of patients included in the analysis(40). However, the 
high number of missing values would probably lead to the estimates resulting from 
the multiple imputation tending towards extreme (and even impossible) values. We 
therefore decided not to use multiple imputation results in this paper. Due to the 
higher drop-out in the EUC condition the total costs in the EUC condition might be 
an underestimation of the true costs and the HRQol might be overestimated in the 
EUC condition. This underestimates the cost-eff ectiveness of MBCT and is therefore 
conservative toward the strategy under evaluation, which is the recommended 
approach in cost-eff ectiveness research. 
Second, the time horizon of the analysis was 1 year. This was probably too short to 
capture the long-term eff ects of MBCT and EUC on societal costs. Within the health 
care use we see a shift in the MBCT condition from hospital care towards mental 
health care. It remains unknown whether the health care use distribution continues 
to be diff erent between patients with persistent MUS who participated in MBCT and 
those who received EUC. The follow-up of one year might have been too short to 
measure the total eff ects of on HRQoL. A qualitative longitudinal interview study was 
performed alongside the randomized controlled trial(41).  This study described how 
MBCT stimulated patients to change their behavioral patterns. A year after 
participation in MBCT these changes were ongoing in about half of the interviewed 
patients. One might speculate that MBCT may show further cost savings and HRQoL 
improvements after this time point. Also, the societal costs in the year before 
participation in the trial would have provided us further information about the 
6
Inhoud 1.indd   103 13-08-2013   17:57:13
MINDINg THE BODy
104
cost-effectiveness of our intervention, unfortunately this was not part of the study 
design. In future trials more long-term information should be collected to confirm or 
refute the results now presented.
Third, because the FC method was used to calculate productivity losses, we took into 
account only the productivity losses of patients who had a paid job during the year 
of study and who were absent from work. This may have underestimated the actual 
productivity losses(42). The reason for absence is not taken into account in this 
method. It can be expected that the time to replace an employee is shorter if the 
employee loses his or her job, than when he/she is absent due to illness. In this study 
we have not examined the reason why participants lost their job, however, in the 
MBCT condition we had more participants losing their job, this may have 
overestimated the productivity losses in the MBCT condition. Next to the FC 
method, the Human Capital (HC) approach can be used to estimate productivity 
losses. This approach estimates the value of all potentially lost production, whereas 
the FC method attempts to quantify actual production losses. The FC is therefore 
considered to be more realistic, and recommended in the Dutch guideline for costing 
research(23). generally, the HC approach results in higher productivity losses than the 
FC method(43). As the productivity losses were very similar between the groups in the 
present study, it is not expected that the use of the HC method would have 
significantly changed our results. Also, we did not incorporate losses due to 
diminished efficiency at work (presenteeism) and losses of unpaid work and 
domestic tasks. For these costs it is to date unclear how they should be measured and 
valued(23, 42, 44).  We also left out direct costs for the patients such as travel expenses. 
For the societal perspective this has probably led to an underestimation of costs in 
both conditions. 
At last, the economic evaluation is limited to the comparison of only two possible 
alternatives. Other alternatives, such as cognitive behavioural therapy have not been 
considered. The use of a single RCT as a vehicle for economic evaluation is often a 
non-sufficient basis for decision making, because decision-makers need to be 
informed about costs and effects for the full range of alternative  interventions(45). 
In that respect, the present study has contributed evidence to the broader case of 
cost-effectiveness of treatment for MUS.
Implications
MBCT is a relatively cheap intervention for MUS because it is a group intervention. 
Individual therapies are generally more expensive due to therapist costs. Although 
total costs were higher in the MBCT condition in the year of follow up, the provided 
health care might have been more efficient in the MBCT condition as these patients 
had less hospital related costs and higher mental health care costs. Patients might 
have learnt that hospital care is probably not the most effective care for their 
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problems on the long term. 
We have several recommendations for future studies. Careful attention should be 
given to the methods of measuring costs. We lost many patients due to the 
diffi  culties which they experienced with fi lling out the prospective cost-diaries. One 
could consider providing patients with a reimbursement per returned diary. As this 
is the fi rst cost-eff ectiveness study of MBCT for patients with persistent MUS, the 
cost-eff ectiveness should be re-examined in studies that follow patients for a longer 
period of time. MBCT can lead to behavioral change on the long term, studies with 
only a short term scope might lead to low levels of implementation of MBCT due to 
the relatively small short term eff ects. Therefore it is of great importance to examine 
the costs and eff ects of MBCT over several years. Also, the cost-eff ectiveness of MBCT 
should be compared to the cost-eff ectiveness of other interventions for MUS, such as 
cognitive behavioural therapy. 
Conclusions & Recommendations
Our study shows that MBCT had a clinically relevant eff ect on HRQoL of patients with 
persistent MUS. Although it still remains uncertain whether MBCT is cost-eff ective, it 
is encouraging that MBCT was acceptable and eff ective for these patients with 
persistent MUS. Due to the higher drop-out in the EUC condition the cost-
eff ectiveness of MBCT might have been underestimated. MBCT seemed to cause a 
shift in the use of health care resources as mental health care use was higher and 
hospital care lower in the MBCT condition. The shift in health care use might lead to 
more eff ective care for patients with persistent MUS. In future research diff erent 
comparators such as cognitive behavioural therapy should be added, and studies 
should measure costs and eff ects with a longer follow-up.
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ABSTRACT 
Background
Preliminary evidence has recently been provided for the effectiveness of mindfulness 
based cognitive therapy (MBCT) for the top 10% frequent attenders in primary care  
with persistent medically unexplained symptoms (MUS) by a randomized controlled 
trial. This qualitative study aims to explore working mechanisms and possible barriers 
of MBCT in this population. 
Methods
Twelve participants of the trial were interviewed about their experiences. This was 
done before and after the MBCT course, and 12 months later. Written evaluations of 
participants and notes of participant observers were used for data-triangulation. 
Qualitative results were compared with individual scores on current health status, 
physical functioning and mental functioning. 
Results
In total, 35 qualitative interviews were carried out. MBCT initiated a process of 
change, starting with awareness of the present moment, the associated sensory 
experiences, thoughts and emotions and accepting rather than resisting these. 
Participants started to recognize their own behavioral patterns and change them, 
thus improving self care. Self-compassion seemed to result from and facilitate this
process. Main barriers were concurrent social problems and the inability or 
unwillingness to accept symptoms. There were remarkable inconsistencies between 
quantitative and qualitative data.
Conclusions 
Whereas before MBCT patients with MUS focused on short term symptom relief, 
MBCT created an opportunity for many of them to accept symptoms as a part of life, 
while at the same time taking better care of themselves.
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INTRODUCTION 
Medically unexplained symptoms (MUS) are highly prevalent. In primary care 20-50% 
of the physical symptoms remain medically unexplained(1, 2). Often, these symptoms 
resolve over time. However,  in a minority of the patients these symptoms persist(2-4). 
Patients with persistent MUS suff er from psychological distress, functional 
impairment and social isolation(5). 
A promising intervention for MUS is Mindfulness-Based Cognitive Therapy (MBCT)(6- 8). 
MBCT combines insights from cognitive behavioural therapy with the Mindfulness-
Based Stress Reduction program as developed by Jon Kabat-Zinn(9). Previous studies 
have demonstrated the eff ectiveness of MBCT for patients with depressive and 
anxiety disorders(10), fi bromyalgia(11, 12) chronic pain(13, 14) and chronic fatigue 
syndrome(15). MBCT might be eff ective for patients with persistent MUS by increasing 
the acceptance of symptoms and tolerance of distress(16-18).
Recently, we have conducted a randomized controlled trial (RCT) (n=125) to examine 
the eff ectiveness of MBCT in frequently attending patients with persistent MUS 
(submitted for publication). Although the MBCT and usual care group did not diff er in 
current health status and physical functioning, the MBCT group reported a signifi cant 
better mental functioning at the end of the course. In addition, MBCT participants 
reported signifi cant improvements in vitality, social functioning and health anxiety 
at 3 months after baseline, whereas patients in the usual care group did not. This 
qualitative study aims to investigate the working mechanisms of MBCT in patients 
with persistent MUS. 
METHOD
Randomized controlled trial
This qualitative study was embedded in an RCT examining the eff ects of MBCT in 125 
patients with persistent medically unexplained symptoms. general practitioners were 
provided with a list of their 10% most frequently attending patients. The general 
practitioners selected patients from this list who had persistent medically 
unexplained syptoms. Having chronic medical conditions was not a reason for 
exclusion. The selected patients were invited for a research interview. If they met the 
DSM-IV criteria for undiff erentiated somatoform disorder, they were asked to 
participate in the RTC in witch they were randomized to MBCT or usual care. The 
MBCT course consisted of eight 2.5 hour sessions and a silent day, delivered by 
experienced mindfulness trainers. The program consisted of formal meditation 
exercises such as the body scan, sitting meditation, walking meditation and mindful 
movement. Participants were encouraged to cultivate awareness of everyday 
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activities, such as eating or taking a shower. Participants were provided with CDs to 
practice at home for 45 minutes a day, 6 days a week. group size varied between 7 to 
14 participants. Primary outcome measure was current health status at end of 
treatment (EQ-5D visual analogue scale, 0-100)(19). Secondary outcome measures 
were mental (SF-36 mental component summary, 0-100) and physical functioning 
(SF-36 physical component summary, 0-100) (20). Assessments took place at baseline, 
end of treatment and 9 months follow-up.
Qualitative study
Twelve patients randomized to the MBCT condition were selected by a purposive 
sampling strategy taking account of gender and age(21, 22).  To examine the working 
mechanism of MBCT over time, they were interviewed before and after the course 
and one year later. The first interview took place by telephone before the course and 
focused on the expectations about MBCT (Appendix 1). The second interview was 
done face-to-face within a month after completion of the course and focused on the 
experiences during the MBCT and the effects on symptoms (Appendix 2). The third, 
face-to-face, interview was conducted a year later and consisted of only two 
questions: 1)How are you now? and 2)What did you learn from the mindfulness training? 
The first interview lasted between 5 and 10 minutes, the second and third interviews 
lasted between 25 and 45 minutes. All interviews were recorded, transcribed verbatim 
and anonymized. A researcher and psychiatrist in training (HR) conducted the first and 
third interviews, a medical student (JL) conducted the second interviews under 
supervision of two researchers (PL and HR). 
In addition to the interview data, we used the written evaluations of 61 patients who 
had attended MBCT within the trial. During their last MBCT session they were asked to 
write down what they had learnt. As well, we had two sets of written observations by 
researchers who took part in a full MBCT training as participant observers (HR and EM). 
The Medical Ethical Committee of the region Arnhem Nijmegen approved the study 
and all participants gave informed consent. 
Analysis 
We used analytical induction from the grounded theory as strategy to build a 
theoretical framework(21, 23) and a scientific qualitative research software program (Atlas.
ti) to support the coding process. The starting point for the analysis of change related to 
MBCT were the interviews conducted a year after the training.  By reading and 
re-reading the transcripts of the interviews, we familiarized ourselves with the data and 
searched for relevant phenomena (HR, yS). We independently generated sensitizing 
concepts as a starting point for the analysis in order to produce a grounded theory(24, 25). 
We coded the interviews independently to link raw data to these sensitizing 
concepts. Subsequently, we jointly assembled, modified and categorized these themes 
in main themes and subthemes to build a theoretical framework of the process of 
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change, including facilitators and barriers.  Next, we recoded all  transcripts of the 
interviews paying particular attention to data diverging from the theoretical framework. 
No new themes or contradicting data were found. For verifi cation of our theoretical 
framework we used the remaining data: the earlier interviews, written evaluations and 
observational reports, a process also known as data triangulation. We used  
characteristic quotes to illustrate the acquired theoretical framework. 
Eventually, for each participant the qualitative fi ndings were compared with their 
quantitative results. We calculated the proportional increase or decrease of current 
health status (visual analogue scale of the EQ-5D), physical functioning and mental 
functioning (physical component summary and mental component summary of the 
SF-36) over the one year follow-up period, presented as: -- for a 10% or more 
decrease, - for a 0-9% decrease, + for a 1-9% increase, and ++ for a 10% or more 
increase. We examined whether the change which we had seen during the interviews 
matched with the results on the questionaires.
RESULTS 
In the randomized controlled trial (in press), current health status and physical 
functioning did not signifi cantly diff er between groups. However, participants in the 
Table 1. Participants characteristics at baseline
P1
P2
P3
P4
P5
P6
P7
P8
P9
P10
P11
P12B)
Age Education
level(A)
f 22 middle Abdominal pain 2 0
f 66 middle Dizziness 4 2
m 63 high Back pain 4 8
m 37 low Back pain 1 0
f 36 middle Fatigue 2 0
f 50 high Throat complaints 4 1
f 46 high Pelvic pain 3 3
f 40 high Fatigue 3 1
f 33 high Fatigue 8 1
m 30 middle Neck pain 1 2
m 51 middle Fatigue 4 3
f 47 low Pain in ankles 6 2
Main
symptomParticipant Gender
Number of
other
symptoms
Number of
physical
diseases
A) Education level was classifi ed as low (primary and lower secondary education), middle
(upper secondary education) and high (higher vocational training and university) 
B) This participant was interviewed twice, she withdrew from the study a year after the
mindfulness training due to religious considerations.
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Table 2. Themes frequently mentioned by participants 
     during and after the MBCT training
Being in the present
Awareness
Acceptance
Recognizing patterns
Changing patterns
Self-compassion
Themes Subthemes Examples
Sense of calmness
Body-awareness
Awareness of thoughts
De-identification
Acceptance of symptoms
Mind-body-relation
Not setting limits
Setting limits
Healthier lifestyle
Kindness
“It gave me rest, inner rest”
“I became more aware of my body 
and my bodily limitations”
“Sick of  all the thoughts in my mind”
“A bit more distance: I’m not my 
symptoms”
“It is as it is, just take it as it is”
“When I don’t feel well  it affects my 
body”
“I was always tremendously crossing 
my boundaries”
“You learn to stand up for yourself, 
listen to yourself and say ‘no’ in time”
“I take a break more often”
“I may just be there”
MBCT group reported a significantly greater improvement in mental functioning at 
the end of treatment (adjusted mean difference 3.9, 95%CI 0.24 to 7.6), in particular 
with regard to vitality and social functioning. Within the MBCT group, almost half of 
the secondary outcome measures had significantly improved at end of treatment, 
whereas in the EUC group none had. 
For the qualtitative study in total 35 interviews were carried out with 12 participants 
(Table 1). One participant was interviewed only twice, she withdrew from the study 
due to religious considerations. One year after the MBCT, most participants were still 
practicing mindfulness although often in an informal way (paying attention to daily 
activities and breathing). Three participants reported hardly any change due to the 
MBCT, all others reported a decline of symptoms and changes in several life aspects. 
Based on the themes evolving from the data, we identified a common process by 
which the mindfulness training appeared to affect the participants: ‘being in the 
present’, ‘being aware’, ‘acceptance’, ‘recognizing patterns’, ‘changing patterns’ and ‘self 
compassion’ (Table 2). Facilitators of this process were the nonjudgmental and calm 
presence of the trainer, being acknowledged by the group and recognizing processes 
in others.
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Figure 1. Process of change
Illustration of steps in the process of change based on the descriptions of 
experiences of patients with persistent medically unexplained symptoms who 
followed an MBCT course.
Being in the 
present(A)
Self-
compassion(F) Acceptance
(C)
Changing
patterns(E)
Insight in
patterns(D)
Awareness(B)
The process seemed to be circular and iterative rather than a linear one, as illustrated 
in Figure 1.  Participants moved back and forth through the diff erent stages, or 
followed a diff erent pace for diff erent problems. Some participants only made a start 
in the process, some encountered signifi cant barriers which withheld them from 
further change (Table 3). 
A. Being in the present 
By participation in the mindfulness training, the participants had to come to a 
standstill for 2.5 hours, at least once a week. The exercises invited them to be present 
in the here and now. Participants described how they experienced a state of 
tranquility and calmness during the MBCT sessions.
 I have the idea that the mindfulness helped me because every Wednesday I just had  
 (…) a sort of fi xed point in the week, I just went there and I really came to a sense of  
 relaxation. (P10)
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Not all participants were able to fully participate during the mindfulness training. 
An important barrier was having social problems, such as death of a husband, an ill 
family member or broken relationship. 
 Deceased relatives, the end of my relationship and many financial problems (…) all  
 happened so fast, I tumbled from one thing into the other (…) I mean, there was so  
 much to worry about, no time for nothing, I had to get my problems under control. (P4)
B. Awareness
By doing the mindfulness exercises, participants mentioned an increased awareness 
of their sensory experiences, for example being more aware of the environment 
during walking or cycling, or being more aware of the taste of the food. 
 The idea that you have to be more aware of the present (…) like really tasting your  
 food. I think that’s something I have gained from mindfulness training. (P6)
Several participants described that they became more aware of bodily sensations. 
Participants experienced that their symptoms were not constantly bothering them 
with the same intensity. For some, awareness of bodily sensations made it possible to 
‘de-identify’ with their symptoms.
 In the training we approached a problem in a way in which you noticed that you were  
 not that problem. You are not a chronic neck pain patient, you just have a lot of pain  
 there at this moment. (P10)
Also the awareness of the relationship between physical sensations and thoughts 
and emotions increased. They started to regard bodily symptoms as a warning sign 
and they reflected upon what had happened in the days before the symptoms came 
up. 
 What happens is that my life affects my body. Now, whenever I feel something coming  
 up, I first think: what has happened this week? Oh, wait, I have felt pressurized, or, I  
 have been very busy, well look, my body reacts to that. (…) I think that this really got  
 through to me: if I do not feel well, this will also affect my body. (P1)
 Most of all, I am more aware (…) For example, if I sit in a certain way [sits with arms  
 crossed in a tense posture] then something is going on, otherwise I wouldn’t sit like that  
 (…) I do something with my body and suddenly I notice that I do it and then I 
 immediately wonder: what is it that is bothering me? (P5)
There were two participants who described that becoming more aware of bodily 
sensations was very uncomfortable. In the end, they preferred distraction over 
awareness. 
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It focused really at the body, so the body troubled me more [laughing] and I thought: 
I actually do not even want to think about the body. (P7)
C. Acceptance 
Instead of avoiding or fi ghting against these experiences, some participants felt that 
by becoming more aware of physical sensations, emotions and thoughts they could 
accept them more.
During the training the most important thing which I learned, has become my motto:  
‘It is the way it is and that is it’. If anything [a symptom] comes up, I say: ‘it is the way it  
is, you can’t change it, it must fi rst run its course.’ (P3)
Two participants described having great diffi  culty to accept their symptoms, or 
being unwilling to do so. P7 reported that she found it very diffi  cult to accept her 
symptoms because she was still angry at the person causing the accident that 
provoked her symptoms. P8 described how the possibility of having an underlying 
serious medical condition kept her from accepting the symptoms.
They actually presume that nothing is wrong, so I am not sick. But I think: it is not so  
simple, because if you can’t prove anything, it doesn’t mean that nothing is there. 
(P8)
Not being able to accept their symptoms was a major barrier for further change in 
these two participants. 
D. Recognizing patterns
Through enhanced awareness and acceptance participants could gain insight in their 
own automatic patterns. Some described recognizing a pattern of worrying about 
many diff erent issues, catastrophic thinking had become a habit. Some specifi cally 
worried about physical symptoms. Visiting the gP had become a way of fi nding 
reassurance for their fears.
In the past I would’ve worried about it, about certain symptoms, mainly because of the  
family history. The whole family has died from cancer (…) You start to worry, you start  
to ruminate. (P3)
Some became aware of their avoidance of negative emotions. P5 described how she 
came to understand that the suppression of her emotions was a family pattern.
In the past I put it all away, because I didn’t want to deal with it. Because then I would  
feel pain and sadness. (…) My father, mother and sisters, they do exactly the same.
One could say that we were spoon-fed with it. (P5)
Several participants described becoming aware of having diffi  culties with setting 
limits. Some became aware of the fact that they frequently crossed their own 
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boundaries, especially by not paying attention to their physical symptoms and by not 
daring to say ‘no’ to others.  
 I crossed my limits tremendously (…) every time when I felt a little bit better I took  
 up running again and started working extra hours and cycling everywhere and simply  
 doing so much and my body was simply extremely tired. I have ignored this time and  
 time again. (P8)
E. Changing patterns
With the newly gained insights about half of the participants were able to let go of 
old patterns. Participants noticed being able to observe worries and let them go, 
instead of identifying with them and slipping into rumination.
 It happens to be there, that in itself is not a problem. It all depends on how you deal  
 with it.(…) I feel calmer now because I can set things aside and leave it there, whereas  
 in the past I would get stuck in it and it would keep running in my head. (P5)
Some participants noticed that their way of coping with physical symptoms had 
changed, for example avoidance or reassurance seeking behaviours. Now they were 
able to wait and see for a while. Several participants mentioned that their health care 
use had changed.
 Astonishing, when I called the doctor’s assistant she said: Wow, Pete, I haven’t seen you  
 in a long time. (P3)
In addition to changing old patterns, participants gave examples of having 
developed new patterns which enhanced their self-care. Some gave examples of 
striving for a healthier lifestyle, for example by quitting smoking and nutritional 
changes. Participants became motivated to reduce stress in their lives and increase 
pleasant activities, or changed jobs in order to take better care of themselves.
 I’ve changed jobs. I used to work in a bar and now I have a nine to five job. So I have a  
 much better daily pattern, which makes me feel much better. (P9)
Others learned to set priorities and became more assertive. 
 It is easier for me now to be frank (…) I just say: ‘I don’t appreciate it, or I don’t like it.  
 (…) I am allowed to say that you know. (…) My mom thinks that I changed completely  
 [laughing], I react really differently now. (P5)
Several participants described that their physical symptoms had diminished during  
and after the mindfulness training. Some felt less tired, others experienced less pain.  
Mostly this was described as a gradual process, however there were a couple of 
participants who described purposefully using meditation to directly reduce the pain. 
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 I am able to relax the specifi c spot (…) I do not tighten a single muscle (…) I call that  
 ‘getting beneath the pain’. I just go to the spot and I fully relax. (P3)
Two participants, P7 and P8, were aware that they frequently crossed their own 
physical limits, but they did not want to change this. They expected that their quality 
of life would be diminished if they would listen to their symptoms.  These two 
participants were  also unwilling to experience their bodily sensations and could not 
accept their symptoms. Strikingly, they both specifi cally asked for a longer duration 
of the mindfulness training.  
 I do way too much in a given week (…) and immediately I get those symptoms. (…)  
 But I really feel that I otherwise would not have a satisfying life, as it would consist  
 solely out of working and sitting at home suff ering from pain. So I decided to just keep  
 on doing things. (P7)
F. Self-compassion 
A third of all participants gave examples which demonstrated an increase in 
self-compassion. By recognizing their self-criticism, they experienced that they could 
be kinder towards themselves. Some described that they were now able to allow 
themselves to just be there. Self-compassion seemed to enhance participants 
motivation to take good care of themselves. 
 I really felt that I was allowed to be there: everything is okay, whatever I feel. (P6)
 I’ve learned that I am important too. If I’m not doing well, then it’s hard for me to take  
 care of someone else. (P5) 
P3 described how he also felt more compassionate to others since the MBCT training.
 The judgment which I had about him [colleague] was actually undeserved. (…) I have  
 clearly become  more forgiving. (P3)
In some participants an increase in self-compassion seemed to result from the 
process of change. At the same time self-compassion also seemed to facilitate other 
steps in the process (e.g. awareness and acceptance). 
Comparison of qualitative and quantitative results
In Table 3,  we show the qualitative information of each individual patient in relation 
to the degree of change in current health status, physical functioning and mental 
functioning. Overall, mental functioning seemed to be more related to the changes 
reported in the interviews than physical functioning or current health status. 
In some participants there was strong correspondence between the changes 
mentioned in the interviews and the outcome measures (P2, 3, 7, 10, 12), but in 
others (P1, 4, 5, 9) there were remarkable inconsistencies between the qualitative and 
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quantitative data.  For example, P4 showed major improvements in current health 
status and physical functioning while according to the interview he did not seem to 
have made steps towards better self care. The improvements in physical health might 
be due to a reduction of stressors or by spontaneous recovery.  On the other hand, P5 
described having experienced major changes by accepting her symptoms and 
becoming aware of automatically suppressing her negative emotions. She had 
become more assertive and reported feeling less pain, fatigue and restlessness. 
However, she showed a major decrease in current health status and mental 
functioning, possibly explained by denial of her symptoms at baseline.
Table 3. Levels of change after MBCT
P1
P2
P3
P4
P5
P6
P7
P8
P9
P10
P11
P12*
Steps in the 
proces of 
change(1)
Participant Barriers
Change based on questionnaires(2)
A,B,C,D,E
A,B,C,D
A,B,C,D,E,F
A
A,B,C,D,E,F
A,B,C,D
A,B
A,B
A,B,C,D,E,F
A,B,C,D,E,F
A,B,C,D,E
A,B,C,D
death of spouse
social and 
financial 
problems
anger about 
accident
fear for serious 
disease
Current 
health status
Physical 
functioning
Mental 
functioning
++
+
++
++
- -
- -
- -
- -
-
++
++
+
++
-
+
++
+
-
+
-
+
++
-
+
- -
+
++
-
-
++
- -
++
+
++
+
+
1) A= Being in the present, B=Awareness, C=Acceptance, D=Recognizing patterns,   
 E=Changing patterns, F= Self-compassion
2)  Difference in scores on questionnaires at baseline versus 12 months after start MBCT
- -  10% or more decrease
- 0-9% decrease
+  1-9% increase
++ 10% or more increase 
* Based on the second interview and questionnaires at end of MBCT
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Discussion 
Main Findings
Based on the longitudinal interviews of patients with MUS, we were able to identify 
a process of change due to the MBCT which seemed to be characterized by diff erent 
stages: paying attention to the present moment, becoming aware of bodily 
sensations, emotions and thoughts and their inter-relatedness, acceptance of these 
experiences, recognizing their own ineff ective patterns and changing them to take 
better care of themselves. In the end, some participants expressed a more self-
compassionate attitude. The main barriers were concurrent social problems and 
the inability to accept the symptoms. The nonjudgmental and calm presence of the 
trainer, being acknowledged by the group and recognizing processes in others were 
mentioned as facilitators of this process. 
The results of our qualitative study shed a new light upon the results of the 
randomized controlled trial examining the eff ects of MBCT in patients with persistent 
MUS (submitted for publication). In the RCT, patients in the MBCT group reported a 
better mental functioning than those in usual care group particularly in terms of 
vitality and social functioning. This is in line with the changes in awareness, 
acceptance, insight and change of unhelpful behavioural patterns, reported in the 
interviews. However, not for all participants did this result in improvement of 
physical symptoms and functioning. For some, this might simply take more time.  
Others reported to have become more aware and better able to tolerate their 
physical symptoms, which might even have resulted in a decrease of their scores on 
physical functioning and current health status.   
Comparison with literature 
Recently a theoretical framework based upon conceptual and neuroscientifi c fi ndings 
has been proposed for the working mechanisms of mindfulness meditation(26). 
Four mechanisms of action are described: attention regulation, body awareness, 
emotion regulation and change in perspective on the self. Our model (Figure 1) 
shows substantial overlap with the elements of this framework. A striking diff erence 
is the rather limited role of emotions in our study. This might be due to our particular 
population. Patients with persistent MUS have been described as ‘alexithymic’, which 
means having diffi  culty with recognizing and describing emotions(27, 28). Emotion 
regulation as described by Hölzel(26) was described as “exposing oneself to whatever 
is present in the fi eld of awareness; letting oneself be aff ected by it; refraining from 
internal reactivity”(26). This process was also present in our participants, but possibly 
focusing more on physical sensations than on emotions. Being able to expose oneself 
to aversive phenomena (e.g. physical symptoms), paying attention to them and not 
automatically reacting but ‘being with the symptoms’ seem to be quintessential 
aspects of the process of change in our participants. And this attitude might not only 
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be helpful to them, but possibly also to the health care professionals attending to 
them. 
Our model of change as seen in patients with persistent MUS who attended MBCT, 
shows some similarities to the ‘stages of change’ model as developed by Prochaska 
and DiClemente in 1984(29). They developed the ‘stages of change’ model which 
consists of 6 steps: pre-contemplation, contemplation, preparation, action, 
maintenance and  termination. Contemplation is described as getting ready for 
change by recognizing problems, which might be related to Awareness as identified 
in our model. Preparation and Action show similarities to Recognizing and Changing 
Patterns, respectively. However, the ‘stages of change’ model emphasizes cognitive 
processes underlying change, whereas mindfulness addresses change in a broader, 
experiential sense. 
Participants started their learning process by experiencing what was present, and by 
reflecting upon these experiences, they gained insight in their ineffective patterns 
and started to change their behaviour. This might relate more to the Experiential 
Learning Theory of experiencing, reflecting, thinking and acting as developed by 
Kolb(30). Recently, yeganeh and Kolb examined how mindfulness training could be 
used to assist learners in unlocking their full learning potential(31). They concluded 
that self-monitoring when coupled with practicing acceptance creates new 
opportunities to think and act. Acceptance disallows the mind and body to suffer 
from things beyond one’s control. This can paradoxically enable one to attain goals 
that may have otherwise been self-sabotaged by stress and attempts at over-
controlling.  In patients with MUS, MBCT indeed seemed to stimulate change through 
self-monitoring and increasing acceptance, which opened up possibilities to change.
Strengths and Limitations 
The longitudinal qualitative design of our study enabled us to formulate a model 
for the change processes patients with MUS experienced during and after MBCT. By 
making use of different qualitative data sources for data-triangulation, the internal 
validity and reliability were enhanced(32). By comparing our qualitative and 
quantitative results we were able to gain further insight in the individual processes of 
the participants. Another strength of our study was making use of a heterogeneous 
group of participants with considerable variety in age, gender and symptoms. As 
all participants belonged to the 10% most frequently attending patients of gPs, our 
population is representative of patients who are severely impaired by their symptoms 
and who lay a high burden on our health care system.
There are some limitations to the study which should also be taken into account. To 
begin with, the study had a relatively small sample size. Due to both the longitudinal 
nature of this study and time constraints, we were unable to keep selecting patients 
until data saturation occurred(33). However, by making use of additional data sources 
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we have validated our fi ndings by comparison with the observational reports of two 
full MBCT courses and with the notes of in total 61 patients with persistent MUS at 
the end of a MBCT course.  We are quite confi dent that our results refl ect the most 
important aspects of the process of change taking place. Another limitation is that 
the interviews were conducted by two researchers. For the quality of the interviews 
it might have been better if all serial interviews were conducted by the same person, 
as the relationship between researcher and participant develops over time(34). Due 
to personal circumstances, this was unfortunately not possible.  By carefully reading 
transcripts of the previous interviews and by referring to these interviews during the 
follow up interviews we have tried to compensate for this.
Recommendations
There are some clinical recommendations which could be derived from our fi ndings.  
In the fi rst place, patients with signifi cant social problems might be advised to 
postpone participation in MBCT until their problems have more or less resolved. The 
same might apply for patients with a relatively low ‘readiness for change’. These 
patients might need individual support to  increase their willingness to experience 
and face their symptoms, before they are ready to fully benefi t from MBCT. 
In addition, MBCT training for patients with persistent MUS might need further 
adaptations. Acceptance might need more emphasis during the training as the 
non-acceptance of symptoms, or the intolerance of distress, was an important barrier 
for some participants. Some patients might be in need of a longer training or more 
booster sessions to support their process of change. 
From a research point of view, further research is needed to examine whether our 
proposed model is valid for other patients attending MBCT. New instruments should 
be developed to specifi cally measure processes of change. Measures regarding 
behavioural change in problem situations, resilience and self-compassion might be 
included in study designs(35). We also recommend the integration of qualitative 
evaluations in future RCT’s as more dimensions of the eff ects of the intervention can 
be discovered in this way.
Appendix A.
Topic list fi rst semi-structured interview
	 •	 Expectations	about	MBCT;	“what	do	you	expect	from	mindfulness	training?”
	 •	 Infl	uence	on	physical	symptoms;	“which	infl	uence	do	you	expect	on	your			
    symptoms?”
	 •	 Mindfulness	trainer;	“what	do	you	expect	from	the	mindfulness	trainer?”
	 •	 Group	sessions;	“what	do	you	expect	from	being	in	a	mindfulness	group?”
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Appendix B.
Topic list second semi-structured interview
	 •	 Expectations	about	MBCT;	“were	your	expectations	about		mindfulness	training		
  met?”
	 •	 Physical	symptoms;	“did	you	notice	any	changes	in	your	physical	symptoms		
  related to the mindfulness training?”
	 •	 Structure	of	training;	“what	do	you	think	about	the	duration	of	the	training?”
	 •	 Elements	of	training;	“which	elements	were	most	beneficial,	which	least?”
	 •	 Homework;	“how	did	you	practice	at	home?”	
	 •	 Group;	“how	was	your	experience	with	participation	in	the	group?”
	 •	 Trainer;	“what	did	you	think	of	the	mindfulness	trainer?”
	 •	 Influences	on	everyday	life;”did	you	notice	influences	of	the	mindfulness	
  training on daily life?” 
	 •	 Ongoing	practice;	“are	there	any	techniques	you	continue	to	use?”
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SUMMARY
Medically unexplained symptoms are symptoms for which no clear biomedical cause 
has been identified. In general, doctors have great difficulty dealing with patients 
with persistent medically unexplained symptoms. These patients often feel strongly 
impaired by their symptoms and they have a relatively high health care use, they 
receive many medical investigations and interventions. This leads to a high risk for 
adverse effects. The high healthcare use also leads to considerable healthcare costs. 
An intervention directed at this specific group of patients has the potential to have 
large societal and individual impact. 
In this thesis we have studied ways of identifying patients with persistent medically 
unexplained symptoms, we have explored the views of these patients upon health 
care and we have examined the effectiveness of diagnostic tests as a way of 
reassuring patients. In addition, we have examined a new intervention for patients 
with medically unexplained symptoms: mindfulness-based cognitive therapy (MBCT). 
The main aim of this thesis was to study the feasibility, effectiveness and the cost 
effectiveness of mindfulness training for patients with persistent medically 
unexplained symptoms. Furthermore, we wanted to gain a deeper understanding of 
the working mechanisms of MBCT for patients with persistent medically unexplained 
symptoms (MUS).
It is a challenge for physicians to improve their competence in recognizing and 
managing patients with somatoform disorders, and a screening questionnaire for 
somatoform disorders might be helpful. In chapter 2 we present our study examining 
whether the PHQ-15 is a suitable questionnaire for the detection of somatoform 
disorders in a high-risk primary care population. The study shows that the PHQ-15 is a 
valid and moderately reliable questionnaire for the screening of patients in a primary 
care setting at risk for somatoform disorders. The positive predictive value of the 
PHQ-15 for a somatoform disorder was 21%. 
With little evidence available on the experiences of patients with persistent MUS, 
we interviewed 17 patients with a long history of presenting MUS in chapter 3. The 
patients wanted to be taken seriously by their gP, they wanted to be partners in 
decision making and expected ongoing guidance from their gP. In addition, they 
wanted prevention of further suffering and a clear explanation for what was going 
on. The participants showed a relatively high level of health anxiety. They expected 
their gP to react quickly to their symptoms and, if necessary, to use diagnostic tests. 
These patients seem to have a high level of distress intolerance. New interventions 
for persistent MUS might focus on improving the doctor-patient relationship and on 
increasing the patient’s acceptance of symptoms.
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In chapter 4, we examined whether diagnostic tests lead to increased reassurance of 
patients by performing a systematic review. In total, fi ve randomized controlled trials 
examined the reassuring value of a diagnostic test. The trials used diff erent 
diagnostic tests for diff erent frequently presented physical symptoms. Four out of 
fi ve trials did not fi nd a signifi cant reassuring value of the diagnostic tests. One study 
reported a reassuring eff ect at three months, but this had disappeared after one year. 
The results point in the direction of diagnostic tests making hardly any contribution 
to the level of reassurance of patients. Diagnostic tests are easily available and might 
seem to be a good instrument to reassure patients, but the reassuring eff ect of 
diagnostic tests is limited. 
Patients with persistent MUS make heavy demands on the health care system. 
Cognitive behavioral therapy (CBT) has been proven to be eff ective, but an off er for 
psychological treatment is often declined because these patients do not expect an 
improvement from psychological treatment. Thus, there is a need for acceptable and 
eff ective treatments for persistent MUS. Mindfulness-based cognitive therapy (MBCT) 
is a relatively new development within the fi eld of medicine. It consists of 
meditation, yoga exercises and psycho-education during eight weekly group 
sessions and daily homework exercises. MBCT facilitates participants in developing 
the ability to tolerate symptoms while at the same time not letting the symptoms 
dictate behavior. MBCT is a group based skills training program intended to enable 
participants to become more aware of their bodily sensations, thoughts, and feelings. 
It has a body focused and experiential approach, which is diff erent from CBT. MBCT 
might be acceptable to patients with MUS because it is off ered as a group training 
that is directed towards the body to enhance self-care rather than as a psychological 
treatment. Previous studies have demonstrated the eff ectiveness of MBCT for 
patients with depressive and anxiety disorders, fi bromyalgia, chronic pain and 
chronic fatigue syndrome. MBCT might also be eff ective for patients with persistent 
medically unexplained symptoms.
Chapter 5 describes the primary results of our randomized controlled trial (RCT). 
We performed a randomized controlled trial investigating the feasibility and 
effectiveness of mindfulness-based cognitive therapy (MBCT) on patients with 
persistent MUS. Nineteen gPs in the area of Nijmegen participated. They selected 
patients with MUS from their 10% most frequent attenders. These patients were 
invited to participate in the trial. Patients who were interested, were seen for a 
research interview. 125 Patients were randomized over two conditions: receiving 
MBCT or receiving enhanced usual care (EUC). Participants receiving MBCT had a 
significant greater improvement in mental functioning at the end of the training, 
specifically vitality and social functioning improved. Physical functioning and general 
health status did not diff er between groups. We conclude that MBCT was feasible for 
these frequently attending patients with persistent MUS. MBCT led to clinically relevant 
improvements in mental functioning. 
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In chapter 6, we present the results of the economic analysis performed alongside the 
RCT. We performed a cost-effectiveness analysis with a time horizon of one year from 
a societal perspective. MBCT led to a small increase in quality adjusted life years 
(QALy) and slightly higher societal costs. Participants in the MBCT condition used re-
latively more mental health care and less hospital care than participants in the control 
condition. The shift in health care use might lead to more effective care for patients 
with persistent MUS. At a willingness to pay of € 80,000 per QALy, the probability that 
MBCT was cost-effective is 57%. MBCT is a relatively cheap intervention, in our study 
MBCT was more cost-effective than usual care within one year.
To reach a deeper understanding of the findings of the RCT we performed a 
qualitative study examining how mindfulness training works in patients with 
persistent MUS. In chapter 7 we present a theoretical model which was derived from 
the analysis of different sources: longitudinal interviews with participants and 
observational reports of two researchers who attended a full MBCT course. In total, 
35 qualitative interviews were carried out. MBCT initiated a process of change, 
starting with awareness of the present moment, the associated sensory 
experiences, thoughts and emotions, and accepting rather than resisting these. 
Participants started to recognize their own behavioral patterns and change them, 
thus improving self care.  In some participants we noticed an increase in self-
compassion. Main barriers were concurrent social problems and the inability or 
unwillingness to accept symptoms. Whereas before MBCT patients with MUS 
focused on short term symptom relief, MBCT created an opportunity for many of 
them to accept symptoms as a part of life. At the same time these patients took 
better care of themselves. 
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SAMENVATING
Onverklaarde lichamelijke klachten zijn klachten waarvoor geen biomedische 
oorzaak is gevonden. Artsen hebben vaak veel moeite met het omgaan met 
patiënten met persisterende onverklaarde lichamelijke klachten. Deze patiënten 
voelen zich sterk gehinderd door hun klachten en maken over het algemeen veel 
gebruik van de gezondheidszorg, ze ondergaan vele medische onderzoeken en 
ingrepen. Hierdoor worden ze blootgesteld aan een hoog risico op bijwerkingen. 
Het hoge zorggebruik leidt ook tot forse gezondheidszorg kosten. Een behandeling 
gericht op deze specifi eke groep patiënten heeft daarom de potentie om grote 
individuele en maatschappelijke impact te hebben.
In dit proefschrift hebben we manieren bestudeerd om patiënten met onverklaarde 
lichamelijke klachten te identifi ceren, we hebben de opvattingen van deze patiënten 
over de gezondheidszorg onderzocht en we hebben onderzocht wat  de eff ectiviteit 
is van het gebruik van diagnostische testen om patiënten gerust te stellen. Daarnaast 
hebben we onderzoek gedaan naar een nieuwe behandeling voor patiënten met 
onverklaarde lichamelijke klachten: mindfulness-based cognitieve therapie (MBCT). 
Het hoofddoel van dit proefschrift was om de haalbaarheid, eff ectiviteit en 
kosteneff ectiviteit van MBCT voor patiënten met onverklaarde lichamelijke klachten 
te onderzoeken. Daarnaast wilden we meer inzicht krijgen in de werkings-
mechanismen van MBCT bij deze patiënten.
Het is een uitdaging voor artsen om hun deskundigheid in het herkennen en 
behandelen van patiënten met onverklaarde lichamelijke klachten te vergroten. Een 
vragenlijst ter screening op deze klachten zou behulpzaam kunnen zijn. In hoofdstuk 2 
presenteren we de studie waarin we onderzocht hebben of de PHQ-15 een geschikte 
vragenlijst is voor het opsporen van patiënten met persisterende onverklaarde 
lichamelijke klachten in een populatie met een hoog risico. Het artikel toont aan dat 
de PHQ-15 een valide en redelijk betrouwbaar instrument is voor het screenen van 
deze patiënten in een eerstelijns setting. 
Omdat er nog maar weinig wetenschappelijke studies verricht waren naar de 
ervaringen van patiënten met onverklaarde lichamelijke klachten, hebben we voor 
hoofdstuk 3 patiënten geïnterviewd met een lange voorgeschiedenis van 
onverklaarde lichamelijke klachten. De patiënten vertelden dat ze serieus genomen 
willen worden door hun huisarts, ze willen als partners betrokken zijn bij het maken 
van beslissingen en ze verwachten continuïteit in de begeleiding door de huisarts. 
Daarnaast willen ze een heldere uitleg over wat er aan de hand is. Deze patiënten 
hadden relatief veel last van angsten rondom hun gezondheid. Ze verwachtten dat 
hun huisarts snel zou reageren op hun klachten en, indien nodig, diagnostische 
testen zou gebruiken. Ze hadden veel moeite met het omgaan met hun klachten en 
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leken niet te aanvaarden dat ze door de klachten gehinderd werden. We concludeer-
den dat een nieuwe behandeling voor onverklaarde lichamelijke klachten zou zich 
kunnen richten op het verbeteren van de arts-patiënt relatie en op de acceptatie van 
klachten.
In hoofdstuk  4 hebben we onderzocht of diagnostische testen leiden tot een 
toename van de geruststelling van patiënten. Dit hebben we met een systematisch 
literatuur onderzoek gedaan. In totaal waren er vijf gerandomiseerde en gecontro-
leerde trials die de geruststellende waarde van diagnostische testen onderzochten. 
De trials onderzochten verschillende diagnostische testen voor verschillende veel-
voorkomende lichamelijke symptomen. Vier van de vijf trials vonden geen significant 
geruststellend effect van de diagnostische testen. Een trial vond een geruststellend 
effect drie maanden na de test, maar een jaar later was het effect verdwenen. De 
resultaten wijzen erop dat diagnostische testen meestal vrijwel geen bijdrage leveren 
aan het niveau van geruststelling van patiënten. Diagnostische testen zijn eenvoudig 
beschikbaar en lijken soms een goede manier om patiënten gerust te stellen, maar 
het geruststellende effect  lijkt zeer beperkt te zijn.
Cognitieve gedragstherapie (CgT) is bewezen effectief voor deze patiëntengroep. 
Echter, het aanbod van de huisarts om te verwijzen naar een psycholoog wordt door 
deze patiënten vaak afgewezen, omdat zij niet verwachten baat te hebben bij een 
psychologische behandeling. Er is daarom behoefte aan een andere behandeling 
die zowel acceptabel als effectief is.  Mindfulness-based cognitieve therapie (MBCT) 
is een relatief nieuwe ontwikkeling in de geneeskunde. Het bestaat uit meditatie, 
bewegingsoefeningen en psycho-educatie, dit vindt plaats tijdens acht wekelijkse 
groepsbijeenkomsten en tijdens dagelijkse huiswerk oefeningen. MBCT maakt 
deelnemers meer bewust van hun lichamelijke sensaties, gedachten en gevoelens. 
Het is een experiëntiële benadering met veel aandacht voor het lichaam. Eerdere 
studies hebben de effectiviteit van MBCT aangetoond voor patiënten met depressies 
en angststoornissen, fibromyalgie, chronische pijn en het chronisch vermoeidheids-
syndroom. MBCT zou ook effectief kunnen zijn voor patiënten met onverklaarde 
lichamelijke klachten. 
Hoofdstuk 5 beschrijft de belangrijkste resultaten van ons onderzoek. We hebben 
een gerandomiseerde gecontroleerde trial uitgevoerd waarin we de haalbaarheid en 
effectiviteit van mindfulness-based cognitieve therapie (MBCT) voor patiënten 
onverklaarde lichamelijke klachten hebben onderzocht. Negentien huisartsen in 
de regio Nijmegen hebben deelgenomen aan het onderzoek. Van hun 10 procent 
meest frequente bezoekers hebben zij de patiënten geselecteerd met onverklaarde 
lichamelijke klachten. Deze patiënten werden uitgenodigd om deel te nemen aan 
het onderzoek. Patiënten die geïnteresseerd waren, kregen een onderzoeksinterview. 
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125 Patiënten werden gerandomiseerd over twee groepen: de interventiegroep 
kreeg MBCT, de controlegroep kreeg gebruikelijke zorg. Patiënten die MBCT kregen, 
hadden een signifi cant grotere verbetering van hun mentaal functioneren aan het 
einde van de training, vooral de vitaliteit en het sociaal functioneren verbeterden. 
Het fysiek functioneren en de algemene gezondheidstoestand verschilden niet 
wezenlijk tussen de groepen. Wij concluderen dat MBCT haalbaar was voor deze 
groep frequente huisartsbezoekers met persisterende onverklaarde lichamelijke 
klachten. MBCT leidde tot een klinisch relevante verbetering van het mentale 
functioneren.
In hoofdstuk 6 presenteren we de resultaten van de economische analyse die we 
binnen de gerandomiseerde en gecontroleerde trial hebben uitgevoerd. We hebben 
een kosteneff ectiviteitanalyse uitgevoerd met een tijdsbestek van een jaar vanuit een 
maatschappelijk perspectief. MBCT leidde tot een kleine toename in ‘quality adjusted 
life years’ (QALy) (kwaliteit van leven) en tot iets hogere maatschappelijke kosten. 
Deelnemers in de MBCT groep maakten meer gebruik van de geestelijke gezondheids-
zorg en minder gebruik van ziekenhuiszorg dan de deelnemers in de controle groep. 
Deze verschuiving in gezondheidszorg gebruik zou ertoe kunnen leiden dat deze 
patiënten eff ectievere behandeling kregen voor hun persisterende onverklaarde 
lichamelijke klachten. Bij een bereidheid tot het betalen van € 80,000 per QALy, is 
de kans dat MBCT kosteneff ectief was 57%. MBCT is een relatief goedkope groeps-
training, in onze studie bleek MBCT binnen een jaar kosteneff ectiever te zijn dan de 
gebruikelijke zorg.
Om beter te begrijpen wat de resultaten van ons onderzoek betekenen, hebben we 
een kwalitatieve studie gedaan waarin we onderzocht hebben hoe mindfulness trai-
ning werkt bij patiënten met onverklaarde lichamelijke klachten. In hoofdstuk 7 
presenteren we een theoretisch model dat we ontwikkeld hebben aan de hand van 
verschillende bronnen: longitudinale interviews met deelnemers en observatie 
verslagen van twee onderzoekers die deelnamen aan MBCT. In totaal werden er 35 
interviews afgenomen. Bij de meeste deelnemers startte MBCT een proces van 
verandering. Dit begon met bewustzijn van het huidige moment met de daarbij 
horende zintuiglijke ervaringen, gedachten en emoties. Deelnemers leerden om deze 
ervaringen te accepteren in plaats van er weerstand tegen te bieden. 
Ze begonnen hun eigen gedragspatronen te herkennen en sommigen konden deze 
patronen ook veranderen, waarmee de zelfzorg verbeterde. Bij een deel van de 
deelnemers zagen we een toename van zelfcompassie. De belangrijkste barrières in 
het proces waren sociale problemen en onvermogen of onwil om de klachten te 
accepteren. Terwijl de deelnemers voor de MBCT vooral focusten op het laten 
verdwijnen van de klachten op de korte termijn, gaf MBCT de meesten van hen de 
mogelijkheid om de klachten als een onderdeel van het leven te accepteren. 
Tegelijkertijd gingen deze patiënten beter voor zichzelf zorgen.
8
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GENERAL DISCUSSION
The studies presented in this thesis were performed to gain a deeper understanding 
of medically unexplained symptoms and of interventions for these symptoms. The 
primary results are presented in the summary of this thesis. Specific strengths and 
limitations are addressed in chapters 2-7. In this general discussion we will discuss 
the overall methodological and clinical considerations of our studies. We will consider 
how the effects occurred and in what way the intervention could be improved for  
successful implementation in clinical care. In addition we will discuss remaining 
questions for future research.
Selection of patients with persistent medically unexplained symptoms for MBCT
Our aim was to identify a study population which was representative for clinical 
practice. We would like to include patients in our study who suffered from medically 
unexplained symptoms, who frequently attended their gP for these symptoms and 
were a heavy burden to the health care system. For that reason we closely co-
operated with gPs in our region to identify patients who might be suitable for our 
study. For each participating gP, we extracted lists with the top 10% of the most 
frequently attending patients in the past year. As male patients visit their gP less than 
female, the extraction process was controlled for gender. gPs were asked to exclude 
patients from the list who did not fulfill the DSM-IV criteria of undifferentiated 
somatoform disorder, pain disorder or somatization disorder. With the exception of 
psychosis, bipolar disorder, cognitive impairments and current alcohol or drug abuse, 
co-morbid physical or psychiatric disorders were not a reason for exclusion. Next, 
patients who were eligible for participation were informed about the study by a letter 
which was signed by their own gP. Patients who were interested were contacted by 
the research team. 
Consequently, in contrast with most studies examining the effects of mindfulness 
training, participants were not self-referred but systematically recruited from the 
lists of the general practices. Due to the diversity in neighborhoods in which the 
participating general practices were located, our study population consisted of low, 
middle and highly educated groups. Other study populations examining the effects 
of mindfulness are often characterized by an overrepresentation of highly educated 
patients(1-3). The co-morbidity rates were high in our study population. Eighty-two 
percent had at least one chronic somatic disease and 29% had three or more chronic 
somatic conditions, 35% had a co-morbid depressive or anxiety disorder. Based on 
the scores on the SF-36, the functional impairment of our participants was similar 
to that of patients with serious somatic conditions, such as COPD with hypertension 
or diabetes(4, 5). Although the inclusion of patients with co-morbid disorders has 
increased the ecological validity of our study, it may also have contributed to slightly 
disappointing results on our primary outcome measures. Due to the multi-morbidity 
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and serious functional impairment of these patients, our expectation to improve the 
general health status, our primary outcome measure,  to the extent we hoped for, 
was probably over-optimistic. The general health status and physical functioning 
(PCS) might be aff ected more strongly by co-morbid somatic conditions than by 
possible changes due to the MBCT training.
Eff ects of enhanced usual care
Participation in a scientifi c study by itself may have eff ects on patients. Irrespective 
of the experimental condition, patients receive specifi c attention from the research 
team. Especially in behavioral trials, the eff ects of participating in a study and 
receiving extrinsic health care services, also known as non-study care, are important 
and under-recognized(6). The fact that in our RCT both MBCT and control groups 
showed improvements over time (e.g. physical symptoms and mental functioning) 
might be partially due to regression to the mean or to a natural reduction of 
symptoms over time. This could partly be due to the eff ects of the ‘usual care’ which 
all patients received regardless of their randomization. Health care use was similar in 
both groups and pretty high, with a median of about 25 contacts (e.g. with 
physiotherapist, gP, medical specialist, psychologist) per person per year. These 
contacts have probably aff ected the health status of the participants in both the 
MBCT and the control condition. 
In addition, health improvements could also be attributable to the attention patients 
received during the trial. To begin with, these patients were personally invited by 
their gP. Patients reported being positively surprised that their gP had thought of 
them. Those who were willing to participate, implicitly showed ‘a readiness for 
change’. Next, a thorough interview was done, in which the patient received the full 
attention of the researcher. In some patients the assessment by itself might have 
been therapeutic as it might have led to new insights. Also, gPs received a letter 
about the assessment, which included a new psychiatric diagnosis in 30% of the 
patients. This might have led to a more eff ective treatment of psychiatric symptoms 
by the gP. Moreover, the patients in the EUC group, just like those in the MBCT group, 
fi lled out many questionnaires over the year which might have made them more 
aware of their coping style. Controlling for the eff ects of (enhanced) usual care is 
diffi  cult, especially in behaviorally oriented trials. Nonetheless, this topic deserves 
further attention in future studies. 
MBCT for patients with medically unexplained symptoms
given the fact that patients with medically unexplained symptoms are reluctant to 
accept psychological treatment(7), we were pleasantly surprised by the fact that more 
than a quarter of the invited frequently attending patients was willing to take part. 
In addition, MBCT was feasible for patients with persistent medically unexplained 
symptoms. Ninety-two percent of patients who started the MBCT fi nished the 9
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training. In our trial, there was no significant difference in general health status and 
physical functioning between the MBCT and the control group. This was 
disappointing because we anticipated a larger effect. However, MBCT did lead to 
significant improvements in mental functioning in patients with persistent medically 
unexplained symptoms. Specifically  vitality and social functioning had significantly 
improved after MBCT. In addition, several outcomes significantly improved over the 
year of follow up within the MBCT group, but not in the control group such as health 
anxiety, and the mindfulness skills of observing, describing and non-reactivity to 
inner-experience. MBCT appears to mostly affect the mental and social aspects of 
health in patients with persistent medically unexplained symptoms. MBCT might 
therefore be a useful addition to other interventions for patients with medically 
unexplained symptoms. 
In our longitudinal qualitative study, we identified a process of change many of the 
participants in the MBCT groups experienced. This process was defined by six stages: 
being in the present, awareness, acceptance, insight in patterns, changing patterns 
and self-compassion. Patients seemed to be able to change their focus from 
short-term symptom relief to acceptance of their symptoms as a part of life. Some 
even seemed to ‘befriend’ their symptoms and use them as a guide in better self care. 
We identified some barriers that could interfere with the process of change: 
concurrent social problems and being totally unable to accept symptoms due to 
anger or fear. These barriers might have clinical implications. For patients with severe 
concurrent social problems, it might be advisable to postpone participation in MBCT 
until later. In patients who have great difficulty accepting their current symptoms, 
CBT might be suitable as a first step. They might benefit from the more psycho-
educational, active and didactic approach which characterizes CBT.  
Several patients indicated that they would have liked the MBCT training to be of 
longer duration. Some had just started to glimpse the meaning and possible impact 
of mindfulness training by the time the training ended. It might be that this particular 
population would benefit from a longer training. This finding is supported by the fact 
that the changes in mindfulness skills appeared to take place at 9 months follow-up 
rather than at the end of the MBCT training. Another possibility is that patients with 
unexplained symptoms might benefit from more behavioral activation as in CBT or 
from stimulation of activities related to their values as in Acceptance and Commitment 
Therapy (ACT).  Interestingly, a recent RCT examining the effects of group CBT 
training for patients with somatoform disorders was effective in improving physical 
functioning, but not in improving mental functioning(8). More research is needed 
to develop the optimal intervention or combination of interventions for patients 
with medically unexplained symptoms. In clinical care, the advised therapy should 
of course not simply be based on the presence of symptoms, but above all on the 
personal needs of the patient.
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How to assess the eff ectiveness of mindfulness?
The main outcome measures which we had chosen for our RCT were the visual 
analogue scale (VAS) of the EQ-5D and the SF-36.  These measures have a focus on 
symptom reduction and complete wellbeing. With hindsight, they might not have 
been the most appropriate. MBCT focuses on acceptance of symptoms and learning 
to relate to them in a wiser way, instead of fi ghting against symptoms. This might not 
show up in more biomedically oriented outcome measures such as symptom levels 
or functional impairment (e.g. being able to carry groceries, not experiencing pain, 
absence of sadness). One might even say that we chose our instruments based on 
the biomedical paradigm of health, a paradigm that might be applicable for acute 
and treatable diseases, but less so for chronic conditions. 
Recently, 38 international experts discussed the defi nition of health during an 
invitational conference(9). Just as environmental scientists describe the health of the 
earth as the capacity of a complex system to maintain a stable environment within 
a relatively narrow range, they proposed the formulation of health as the ability to 
adapt and to self manage. This change in emphasis might help doctors to focus on 
empowerment of the patient (for example by discussing the lifestyle in relation to the 
symptom) instead of just reducing or removing symptoms (for example by 
medication). 
In the disease model, a possible diagnosis for unexplained symptoms stands center-
stage in the encounter between the patient and physician. In person centered care it 
is the person with the symptoms that deserves full attention. Mindfulness training 
can help both patients, therapists and physicians to stay out of the discussion 
whether a persistent symptom has a medical explanation or not. During the MBCT 
no diff erence is made between medically explained and unexplained symptoms. The 
symptom is simply there. The patient has probably already tried to reach short-term 
symptom relief; and this probably did not work. Mindfulness training can teach the 
patient to experience the symptom without resistance, to pay attention to the 
symptom and to adapt to it. 
New ways of measuring health are needed to incorporate this new paradigm of 
health into the fi eld of research. Assessment measures could represent this 
conceptualization of health as the ability to adapt and to self manage in the face of 
social, physical, and emotional challenges. Instruments should focus on the ability to 
cope with the adversities of life rather than the level of symptoms. It is impossible to 
avoid pain and sadness in life, but the way one relates to these experiences might be 
sensitive to change. Measuring how ‘mindful’ people are, is notoriously diffi  cult, and 
maybe even impossible(10). However, it might be possible to use more precise 
instruments to measure changes due to mindfulness practice. 9
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 In our longitudinal qualitative study patients described being present in the current 
moment. They also described being more aware of bodily sensations, emotions and 
thoughts, combined with reaching an understanding of the connection between 
them. Patients started to recognize unhelpful reactions and behavioral patterns and 
sometimes made a start at changing them. It would be very interesting to measure 
these aspects of change. We are therefore currently developing new assessment 
measures by making use of the results of qualitative studies. One of the possibilities 
is to let people identify three important problem situations in daily life (e.g. physical, 
emotional or social problems). They are then asked to rate their cognitive, emotional 
and behavioral reactions to these situations. In this way, one could measure their co-
ping in specific ‘problem situations’ before the start of MBCT and at the end of MBCT. 
We hypothesize that MBCT might lead to a more aware and accepting way of dealing 
with life’s adversities. 
A promising method in behavioral research is the experience sampling method (ESM)(11). 
This is a method in which patients are asked to rate their situation and reactions 
several times during the day. This provides the researcher with real time data, which 
might be very appropriate for the assessment of coping. In a recent study, 
geschwind et al. used the ESM in depressed patients. MBCT was associated with 
increased experience of momentary positive emotions as well as greater appreciation 
of, and enhanced responsiveness to, pleasant daily-life activities(12). A similar study 
could be done with the ESM in patients with medically unexplained symptoms. By 
using the ESM, one could measure the direct physical, emotional and cognitive 
reactions to symptoms, to other adversities and also to pleasant moments in life. 
Implications for future research
Defining the study population is of great importance in scientific research. We have 
chosen to define a study population that is clinically relevant with a high ecological 
validity. However, this resulted in high co-morbidity rates, making it more difficult to 
reach statistically significant differences between the intervention and control 
condition on symptom-related outcome measures. Therefore, the outcome measures 
in future studies of MBCT for patients with medically unexplained symptoms, should 
be chosen with great care. Taking into account the high rates of co-morbid somatic 
and psychiatric disorders, outcome measures should focus more on the ability to 
adapt to adversities in life than on reduction of mental and physical symptoms. By 
using new instruments, such as a problem-situation-oriented questionnaire or by 
using the ESM, we will probably gain more insight into the effectiveness of MBCT for 
patients with medically unexplained symptoms.
Our trial showed positive effects of MBCT for patients with medically unexplained 
symptoms in the domains of mental and social functioning. MBCT therefore seems to 
be a valuable contribution to the existing therapies for patients with medically 
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unexplained symptoms. However, the intervention can probably be improved in 
order to meet the specifi c needs of these patients. Future research should examine 
whether an MBCT training of longer duration, or with booster sessions is more 
eff ective. Also, MBCT could be combined with CBT or ACT in either a stepped care 
model or, probably more challenging, in a new intervention combining elements 
of the diff erent treatment approaches. This could lead to an integrative therapy for 
patients with medically unexplained symptoms which might lead to a longer lasting 
ability to adapt to adversities in life.
Finally, mindfulness training might not only be benefi cial to patients with medically 
unexplained symptoms but also be of value in the training of physicians and 
psychotherapists. In a study with 70 gPs, mindfulness training reduced the risk for 
burnout and improved their adaptability(13). gP’s who attended mindfulness training 
reported that sharing personal experiences from medical practice with colleagues 
reduced professional isolation(14). In addition, mindfulness skills improved their ability 
to be attentive and listen deeply to patients’ concerns and to respond to patients 
more eff ectively. This could particularly improve the care for their patients with 
medically unexplained symptoms, who often experience diffi  culties in being taken 
seriously. In fact, a recent RCT showed that psychotherapists who practiced 
mindfulness had signifi cantly better results with their patients than those who 
did not. For example, their patients reported greater symptom reduction on the 
somatization and anxiety scales of the SCL-90(15). Mindfulness training might help 
health care workers to switch more easily from a disease oriented model to a person 
centered model. In the person centered model physicians can focus on the impact of 
symptoms on daily life. This means paying attention to the symptom itself, the 
experience of having the symptom, the cognitions about the symptom and the 
ability to perform daily life activities with the symptom. In addition, more attention is 
paid to the patient’s reactions to the symptom and the reactions of signifi cant others.
Consequently, it would be very interesting to examine the impact of mindfulness 
training for health care workers in improving the care of patients with medically 
unexplained symptoms.
9
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Dank
Net klaar met de opleiding geneeskunde en vastbesloten om psychiater te worden, 
was ik op zoek naar een opleidingsplek. Toen ik de kans kreeg om de opleiding te 
combineren met onderzoek naar onverklaarde lichamelijke klachten, twijfelde ik. 
Promoveren, was dat wel wat ik wilde? Het zou ertoe leiden dat ik vele jaren langer 
over mijn opleiding zou doen. Aan de andere kant, onverklaarde lichamelijke 
klachten was ik tijdens mij coschappen vaak tegengekomen. Zowel bij patiënten als 
bij artsen had ik de onmacht gezien die deze klachten teweeg kunnen brengen. De 
beperkingen van het biomedische model waren duidelijk zichtbaar. Het frustreerde 
me dat ik het zag en er tegelijkertijd zo weinig aan kon doen. Ik besloot daarom de 
uitdaging van het onderzoeken aan te gaan. gelukkig, want het werd een mooie reis. 
Tijdens eerdere reizen ontdekte ik dat het niet zozeer de bezienswaardigheden 
waren die me bij blijven, maar vooral de mensen die ik ontmoet heb.  Dat was ook bij 
deze reis zo. De patiënten die deelgenomen hebben aan het onderzoek wil ik heel 
hartelijk bedanken. Door jullie persoonlijke ervaringen met mij te delen, heb ik eens 
temeer geleerd dat de gemiddelde patiënt met het gemiddelde behandeleffect niet 
bestaat. Dank voor jullie vertrouwen. 
Het was heerlijk om een gids te hebben die weet welke kant op te gaan. 
Anne Speckens, heel hartelijk dank voor je begeleiding. Van het bedenken van de 
opzet van de trial, het aanvragen van het AgIKO stipendium tot en met het schrijven 
van de artikelen; bij alles was je nauw betrokken. Je hebt je taak als promotor heel 
ruim opgevat. Je scherpe blik en vrije geest bewonder ik. Ik heb veel van je geleerd. 
Een dierbare reisgenoot was Peter Lucassen, mijn copromotor. Een onderzoeksdag 
was net even leuker als ik wist dat jij er die dag ook zou zijn. Naast dat je me op het 
wetenschappelijke pad erg goed begeleid hebt als copromotor, ben je ook op andere 
gebieden een voorbeeld. Half 11 stipt: tijd voor koffie. Je ervaring als huisarts in Bakel 
bracht je regelmatig in, prachtig nuchter en zo bescheiden. Al lopend hebben we 
de afstand tussen de Eerstelijnsgeneeskunde en Psychiatrie regelmatig overbrugd. 
Ik voelde me gesterkt door jouw visie op het artsenvak, waarbij humaniteit altijd 
voorop staat. 
Zonder Lea Peters zou mijn reis stukken stressvoller verlopen zijn. Jij zorgde ervoor 
dat ik precies de juiste spullen in mijn rugzak had. Nog voor ik kon bedenken dat ik 
iets vergeten was, had jij het er al ingestopt. En als ik door zwangerschapsverlof of 
klinisch werk het onderzoek tijdelijk moest verlaten, dan kon ik er volledig op 
vertrouwen dat jij de boel zou bewaken. Zo vriendelijk als jij eenieder te woord stond, 
en zo geduldig en gedegen als jij werkt: prachtig. Heel erg bedankt voor alles wat je 
voor de patiënten, huisartsen en voor mij gedaan hebt.
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Ik had het geluk nog een tweede gids te mogen raadplegen, Chris van Weel. Een 
moment dat me nog helder voor ogen staat is een refereeravond waarop ik de review 
naar de geruststellende waarde van diagnostische testen presenteerde. Mijn collega’s 
reageerden niet bijster enthousiast, maar jij wel, en dat gaf mij vertrouwen. Ik 
waardeer je immer snelle reacties. Als ik een stuk geschreven had, kon ik ervan 
uitgaan dat ik van jou zeer waardevol commentaar zou krijgen. Ik ben dit jaar de 
tiende die bij jou promoveert. Prachtig.
Er waren reisgenoten die me bijna het hele pad vergezeld hebben. We deden samen 
onderzoek en schreven gezamenlijk de uiteindelijke artikelen. Inge van Dijk, jij weet 
de dingen zo mooi helder te verwoorden. Ik hoop nog lang en vaak met jou over de 
inhoud van ons vak te mogen sparren. Tim olde Hartman, hooggewaardeerde kamer-
genoot en harde werker, bij jou kon ik erop vertrouwen dat je je er nooit gemakkelijk 
van af zou maken. Waar het de financiële kant van mijn reis betrof, kreeg ik van jou de 
beste tips. Hans Bor, hoe druk je het ook had, je vond altijd wel weer ergens tijd om 
mij in al je kalmte door het woud van de statistiek te loodsen. 
Andere reisgenoten hebben me gedurende een kortere periode vergezeld. Fred 
Wester, hoogleraar sociologie,  met een enkele rake vraag hielp je me weer een eind 
op weg in de velden van het kwalitatieve onderzoek, dank. Jasmijn Langbroek en 
yvonne Suijkerbuijk, beiden waren jullie tijdens jullie wetenschappelijke stages drie 
maanden lang mijn reisgenoten, dank voor jullie werk. Janneke grutters, je hebt me 
ingewijd in de wondere wereld van het bootstrappen en daar heb ik van genoten. 
Twee van mijn vrienden werden plots ook even reisgenoot. Matthijs, dank voor je 
adviezen bij de analyse van de trial resultaten. Toen ik moe was en blaren begon te 
krijgen, wist jij me moed in te spreken. Hedwig, dank voor je vertalingen van de cita-
ten. Jouw spreektaal-Engels leest stukken beter dan het mijne.
Onderweg kreeg ik gedegen advies van ervaren reizigers. Henriëtte van der Horst, 
Ingrid Arnold en Nettie Blankenstein dank voor jullie adviezen. Op veel plaatsen was 
ik niet gekomen zonder de hulp van anderen. Het artikel over de PHQ-15 heb ik 
kunnen schrijven met dank aan het Apollo project, een samenwerking tussen het 
UMC St Radboud en het AMC. Hiervoor wil ik Machteld Borghuis, Karin Wittkampf, 
Kim Baas, Henk van den Hoogen, Jan Mulder, Henk van Weert, Jochanan Huijser en 
Aart Schene bedanken. Ook wil ik graag alle andere coauteurs bedanken: 
David Darmon (Merci beaucoup!), gert-Jan van der Wilt, Waling Tiersma, 
Juke Nijenhuis, Esther Muskens en Floris van der Laar. 
Dankzij de mensen die hun deuren voor mij openden kon ik mijn reis voortzetten. 
Huisartsen en assistenten, graag wil ik jullie danken voor jullie tijd en energie: 
Paul giesen, Eric van den Berg, Elianne Snoeren, Nadja Joosen, Marie-José Metz, 
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Mark van der Wel, Mirjam Meijer, Juliëtte Mooren, Herman Levelink, Merijn Kemper, 
Olaf Ouwendijk, ysbrand van der Vleugel, Jos van den Hoogen, Bernard van Drenth, 
guido Adriaansens, Annet Matser, Cunera Cottaar en yvo goffin. 
Mijn favoriete verblijfsplek gedurende deze reis was de afdeling Eerstelijnsgenees-
kunde, waar ik terecht kon voor een warm bad. Lieke Hassink, zeer gewaardeerde 
voormalig kamergenoot, ik heb genoten van je adviezen en reflecties over het te 
volgen pad. Dank daarvoor.  Toine Lagro, dank voor je adviezen. Een advies heb ik al 
opgevolgd: ik ben intussen copromotor geworden. Ook wil ik Kees van Boven, Eloy 
van de Lisdonk, Wil van den Bosch, Twanny Jeijsman, Annelies Daanen, Debby ger-
ritsen, Tjard Schermer, Erik van Rijswijk en alle andere collega’s van de Eerstelijnsge-
neeskunde hartelijk bedanken voor de samenwerking.
Reizen kan erg eenzaam zijn, maar mede dankzij de (voormalig) promovendi en AIO-
THO’s was deze reis een alles behalve eenzame tocht. Lotte, Carolien, Erik B., Floris, 
Mark, Annemarie, Erwin, Franca W., Rhona, Claudia, Hilde, Wouter, Karin, Els, Sten, 
Esther, Jaap, Sabine, Willemijn, Evelien, Stephanie, Elza, Vincent, Erik T., Antoinette, 
Franca R., geertje en Maartje, heel hartelijk dank. In het bijzonder wil ik ook Marloes, 
Melanie en Joël bedanken, mijn ‘mindfulness maten’. Allen, dank voor jullie inspiratie, 
kritische vragen en welgemeende aanmoediging. 
Een van de geneugten van het reizen is het delen van foto’s en verhalen. Collega’s 
van de afdeling psychiatrie, bij jullie mocht ik regelmatig verslag doen van mijn reis, 
dank voor jullie interesse. Indira Tendolkar, als opleider heb je mij de afgelopen jaren 
de ruimte geboden om naast het klinische werk ook onderzoek te doen. Dat stel ik 
erg op prijs. Mijn jaargenoten Niels, Inge, Take, Karlijn en Dirk wil ik in het bijzonder 
bedanken. Ik heb me enorm gesteund gevoeld door jullie en ben er trots op dat geen 
van ons vroegtijds met de opleiding gestopt is. 
Deze reis was anders verlopen als ik niet eerst had mogen oefenen tijdens kortere 
trips. Mijn eerste wetenschappelijke schreden heb ik in Maastricht gezet door 
onderzoek te doen naar het gebruik van gynaecologische onderzoeksmedewerkers. 
Jan-Joost Rethans, bedankt dat je me deze kans gaf. De volgende trip was ‘Project 
6’, een onderzoeksproject rondom eenzaamheid. Elise, Cathelijn, Jonne, Evelien en 
Hanna, ik ben er nog steeds trots op dat we ons eigen onderzoek hebben uitgestip-
peld en uitgevoerd. Op de afdeling Eerstelijnsgeneeskunde in Nijmegen wordt nog 
steeds wel eens met bewondering over onze eindpresentatie gesproken.
Het is goed om tijdens een lange reis een plek te hebben waar je je batterij op kan 
laden. Collega’s van het Radboud Universitair Medisch Centrum voor Mindfulness ik 
geniet ervan met jullie samen te werken. Renee Metzemaekers het was mij een waar 
genoegen om samen met jou de werkmap voor de training te maken. Ik wil jou en 
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Hetty Janssen heel hartelijk danken voor het geven van de trainingen. Ton en Nicole, 
dank voor jullie mooie lessen in de postacademische opleiding tot mindfulness 
trainer van het Radboud. Opleidingsgenoten, tijdens het laatste stuk van mijn reis 
hebben jullie mij van voedsel voorzien, dank.
Wat reizen onderscheidt van zwerven, is het hebben van een thuis. Deze weten-
schappelijke prestatie had ik niet kunnen leveren zonder de steun van vele lieve 
mensen. Vrienden, familie, buren, dank voor jullie betrokkenheid en aanmoedigin-
gen. Er zijn een paar mensen aan het thuisfront die mijn bijzondere dank verdienen. 
Mijn broer Maurits, dank voor het ontwerp van de boom, ik ben een grote fan van 
jouw werk. Mijn zus Jette, dank voor je luisterend oor en voor je inspirerende verha-
len. Ik prijs me gelukkig met jou als paranimf. Lieve Cathelijn, wat een geluk dat we 
zoveel kunnen delen en dat je mijn paranimf wil zijn. Mijn schoonouders, Douwe (Sr) 
en Elly, dank dat jullie bij konden springen als oppas tijdens congressen. Ik vind het 
bijzonder dat jullie ondanks de zware tijden toch altijd interesse hadden in mijn werk. 
Douwe (Sr), prachtig dat jij dit boekje hebt vormgegeven. Heel veel dank daarvoor. 
Mijn ouders, lieve papa en mama, ik ben jullie dankbaar. Dank voor jullie vertrouwen, 
jullie liefde en jullie hulp. Terwijl ik dit schrijf, passen jullie op yke en gijs, en dat doen 
jullie regelmatig. Mede doordat jullie zo voor ons klaar staan, weten Douwe en ik ons 
prachtige gezin met ons werk te combineren.
Lieve Douwe, met jou aan mijn zij kan ik heel veel aan. Fantastisch hoe je onlangs let-
terlijk een medereiziger werd. Op het Voorjaarscongres van de psychiatrie zat je met 
onze vier weken oude gijs achter in de zaal zodat ik hem kon voeden vlak voordat ik 
een presentatie gaf. Je geeft me de ruimte en helpt me om datgene te doen wat ik 
belangrijk vind. Daar ben ik je erg dankbaar voor. 
En dan tot slot, lieve yke, jouw komst heeft me zoveel kracht gegeven. Als ik zoiets 
prachtigs op de wereld kan zetten, nou, dan kan ik bijna alles. Lieve gijs, met jou in 
mijn buik heb ik de laatste hoofdstukken geschreven. Je hebt me gemotiveerd om 
een beetje haast te maken. Deze reis moest maar eens afgerond worden, want het 
wordt tijd voor nieuwe reizen, nieuwe avonturen.
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